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ABSTRACT
An increasing number of systematic reviews summarize results from cluster randomization
trials. Applying existing meta-analysis methods to such trials is problematic because
responses of subjects within clusters are likely correlated. The aim of this thesis is to eval-
uate heterogeneity in the context of fixed effects models providing guidance for conducting
a meta-analysis of such trials. The approaches include the adjusted Q statistic, adjusted
heterogeneity variance (τ 2c ) estimators and their corresponding confidence intervals and
adjusted measures of heterogeneity (H2a , R
2
a, I
2
a) and their corresponding confidence
intervals. Attention is limited to meta-analyses of completely randomized trials having
a binary outcome. An analytic expression for power of Q test is derived, which may be
useful in planning a meta-analysis. The Type I error and power for the Q statistic, bias
and mean square errors for the estimators and the coverage, tail errors and interval width
for the confidence interval methods are investigated using Monte Carlo simulation.
Simulation results show that the adjusted Q statistic has a Type I error close to the
nominal level of 0.05 as compared to the unadjusted Q statistic which has a highly inflated
Type I error. Power estimated using the algebraic formula had similar results to empirical
power. For τ 2c estimators, the iterative REML estimator consistently had little bias.
However, the noniterative MVVC and DLVC estimators with relatively low bias may also
be recommended for small and large heterogeneity, respectively. The Q profile confidence
interval approach for τ 2c had generally nominal coverage for large heterogeneity. The
measures of heterogeneity had generally low bias for large number of trials. For confidence
interval approaches, the MOVER consistently maintained nominal coverage for ‘low’ to
‘moderate’ heterogeneity. For the absence of heterogeneity, the approach based on the Q
statistic is preferred. Data from four cluster randomization trials are used to illustrate
methods of analysis.
Keywords: cluster randomization; meta-analysis; heterogeneity; binary outcome; Q
statistic; power; confidence intervals
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1Chapter 1
Introduction
1.1 Cluster randomization trials
Randomized controlled trials are often deemed the gold standard to assess the effectiveness
of an intervention in health research (Wade, 1999). A key benefit of randomization is
the potential for elimination of bias due to confounding. The units of randomization in
randomized trials are usually the individual.
Over the past two decades, randomized trials in which the unit of randomization is at the
cluster level have been more frequently adopted in the evaluation of health care interven-
tions, screening and educational programs (Bland, 2004). Such trials are characterized
by random assignment of intact social units (e.g., worksites, clinical practices, schools or
entire communities) instead of individual study subjects (Donner and Klar, 2000).
For example, a study evaluating the effect of vitamin A supplementation on childhood
mortality (Sommer et al., 1986) adopted cluster randomization because it was not po-
litically feasible to randomize individuals. Hence, the units of randomization for this
study were villages instead of individuals within a village. Contamination could have
arisen using individual random assignment. For instance, contamination would occur if
2individuals from the same village who were assigned to different interventions shared their
vitamin A supplement. Cluster randomization trials are preferred in situations where
the ethical issues, the desire to control costs or the attempt to minimize experimental
contamination are major concerns.
However, the cluster randomization design is statistically less efficient compared to in-
dividual randomization because responses of individuals in a cluster tend to be more
similar to each other than to responses of individuals in different clusters. The degree of
similarity is measured using the intracluster correlation coefficient denoted by ρ (Donner
and Klar, 2000, p2) which takes a value between 0 and 1. In order to adjust for clustering,
the variance of the estimated intervention effect is multiplied by a variance inflation factor
(or design effect), IF = 1 + (m¯ + 1)ρ where m¯ is the average cluster size. Intracluster
correlation coefficients may be quite small particularly for community intervention trials
where they rarely take on values above 0.1 (Murray et al., 2000). However even then
design effects may be quite large since such trials typically recruit hundreds of subjects
per cluster. Subsequently, ignoring clustering effects could result in spurious statistical
significance where the variance estimators will tend to be underestimated.
1.2 Meta-analysis of individually randomized trials
Since the 1980s there have been a growing number of published systematic reviews sum-
marizing results from clinical trials (Whitehead, 2002, page xiii). At the same time, there
has also been increasing methodological research dealing with meta-analytic methods.
A key challenge in combining study results is possible heterogeneity in the estimated
intervention effect. Heterogeneity may reflect systematic differences in study design or
in characteristics of participating subjects or may be a consequence of random variation
(Whitehead, 2002).
31.2.1 Fixed versus random effects modeling of heterogeneity
Fixed effects and random effects models depend on different assumptions about hetero-
geneity of the intervention effect. The fixed effects model assumes that there is a common
fixed effect (at least for interval estimation) and a random component (sampling error)
that is responsible for differences among trial results. Often, however, there may be some
heterogeneity of intervention effects across trials. A test of heterogeneity is frequently
used to evaluate the assumption of a common fixed effect. On the other hand, the random
effects model assumes that the observed trials are a random sample from a hypothetical
population of trials. To account for the variation among trial results, an additional
random term is added to the model. This added term, recognized as the heterogeneity
variance parameter, is denoted by τ 2. Consequently, the random effects model generally
yields more conservative inferences about the intervention effect as compared to the fixed
effects model (Schulze, 2007; Villar et al., 2001).
1.2.2 Tests of heterogeneity: Q statistic
The Q statistic (Cochran, 1954) tests the null hypothesis: Ho : θ1 = θ2 = . . . = θk = θ
versus the alternative HA: at least one trial had a truly different intervention effect as com-
pared to the other trials, where θj denotes the intervention effect for trial j, j = 1, . . . , k.
Mathematically, the Q statistic is defined as a weighted sum of squares of the deviations
of individual study estimates θˆj, from the overall estimate θˆ. The Q statistic when Ho is
true, is approximately a chi-square random variable with k − 1 degrees of freedom. If
the null hypothesis Ho is rejected, one concludes that there is at least one study which
truly differs from other studies in terms of the intervention effect. Further analyses are
then usually recommended to identify covariates that stratify studies into homogeneous
populations.
4Several other test statistics are available to test for heterogeneity (e.g. likelihood ratio
test, score test). In a simulation study generating continuous outcome data, Viechtbauer
(2007b) showed that the Q statistic as compared to other test statistics kept the tightest
control of the Type I error rate for meta-analyses based on studies having at least moder-
ately large sample size, such that the number of trials is from 5 to 80 and the average
sample size per trial is 20 to 640. He also suggested that if the amount of heterogeneity
was small, sample sizes exceeding 100 observations within each study would be required
to detect it. As for binary outcome data in large sample sizes, the Q statistic based on
the Woolf estimator is conservative in general and least powerful for severely unbalanced
and within-strata unbalanced designs (Paul and Donner, 1989). However, for balanced
and mildly unbalanced designs, the Q statistic, which is easy to calculate, is recommended.
According to Hardy and Thompson (1998), the Q statistic may detect clinically unim-
portant heterogeneity when there are many studies but is unable to detect clinically
significant heterogeneity when there are few studies. Therefore, power calculations for the
Q statistic prior to conducting a meta-analysis may prove helpful in assessing statistical
power (Hedges and Pigott, 2001; Valentine et al., 2010). Power for the Q statistic is a
function of the selected effect measure, the specified Type I error, number of trials and
sample size per trial.
1.2.3 Heterogeneity variance estimators τ 2
Point estimation
Heterogeneity variance estimators are also useful in assessing heterogeneity in meta-
analysis. Their advantage is that they do not depend on the number, or size of trials
in a meta-analysis like the Q statistic. A disadvantage they share with the Q statistic
is that comparisons across meta-analyses must be limited to trials with the same effect
5measures (e.g. odds ratio, risk ratio and hazard ratio) (Ru¨cker et al., 2008). Seven
methods of estimating the parameter τ 2 were compared in terms of bias and mean square
error under a random effects model for a binary outcome in a simulation study Sidik and
Jonkman (2007). Four of these estimators are simple to compute while the remaining
three approaches require relatively extensive computation.
Hedges (1983) originally developed a method of moments estimator obtained by setting
the usual sample variance equal to its expected value and solving for τ 2, known as the
variance component type estimator. Another method of moments estimator proposed by
DerSimonian and Laird (1986) using the expectation of the Q statistic (Cochran, 1954) is
commonly used in random effects meta-analysis (Brockwell and Gordon, 2001; Thompson
and Sharp, 1999). Furthermore, given that the DerSimonian and Laird estimator often
underestimates the true value (e.g., Bohning et al., 2002; DerSimonian and Kacker, 2007;
DerSimonian and Laird, 1986; Sidik and Jonkman, 2007), DerSimonian and Kacker (2007)
proposed a two-step method to avoid using iterative methods (e.g. likelihood approaches).
Besides the method of moments estimators, Sidik and Jonkman (2005) proposed an
estimator based on the unbiased estimation of the error variance in a linear model, called
a model error variance type estimator. The model error variance type of estimator requires
an initial estimate of τ 2. The simplest is to use the empirical variance estimate as an
initial estimator for τ 2. Later, Sidik and Jonkman (2007) suggested an improved version
of this approach by using the variance component type estimate as an initial estimate of
τ 2. The common iterative approaches to estimating τ 2 are maximum likelihood estimation
and restricted maximum likelihood estimation (Hardy and Thompson, 1996; Harville,
1977; Raudenbush and Bryk, 1985). Another iterative approach is obtaining by using the
empirical Bayes estimator (Morris, 1983).
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Sidik and Jonkman’s (2007) simulation results showed that the improved variance com-
6Table 1.1: Summary of the heterogeneity variance estimators
Method Description
Non-Iterative
Variance Component (VC) Method of moments
DerSimonian and Laird (DL) Method of moments
Two-step DL (DLVC) Empirical variance as an initial estimator
Two-step DL (DL2) Variance component as an initial estimator
Model Error Variance (MV) Empirical variance as an initial estimator
Improved (MVVC) Variance component as an initial estimator
Iterative
Maximum Likelihood (ML) Likelihood
Restricted (REML) Likelihood
Bayes Bayesian
ponent type estimator and the empirical Bayes estimator provide the most accurate
estimation when the heterogeneity is moderate to large (i.e. τ 2 ≥ 0.5). The variance
component estimator and the model error variance both tend to overestimate the true
heterogeneity variance except for meta-analyses with large number of trials and unless
the heterogeneity variance is large, respectively. However, the likelihood estimators and
DerSimonian and Laird’s estimator tend in general to underestimate the true heterogeneity
variance. Schlattmann (2009, Chapter 7) found similar results. Table 1.1 provides a
summary of the heterogeneity variance estimators mentioned above.
Interval estimation
It is often useful to report a confidence interval in addition to a point estimator of
τ 2. Viechtbauer (2007a) proposed a new method called the Q profile to construct such
intervals and evaluated its performance in terms of nominal coverage as compared with
other existing approaches, including Biggerstaff-Tweedie (Biggerstaff and Tweedie, 1997),
profile likelihood, Wald-type, Sidik-Jonkman (Sidik and Jonkman, 2005), parametric
bootstrap and non-parametric bootstrap using Monte-Carlo simulation.
The Q statistic approximately follows a chi-square distribution with k − 1 degrees of free-
7dom under the null hypothesis. Alternatively, the 95 percent confidence interval obtained
from the Q profile method is constructed based on the 2.5th and 97.5th percentile of this
distribution. Based on a similar idea, the Biggerstaff-Tweedie confidence interval can be
obtained by approximating the distribution of Q with a gamma distribution (Biggerstaff
and Tweedie, 1997). For the profile likelihood method, the confidence intervals can
be obtained by profiling the likelihood ratio statistic with the maximum likelihood or
restricted maximum likelihood estimates. Then, the inverse of the Fisher information
matrix is used to calculate the asymptotic sampling variances of the maximum likelihood
and restricted maximum likelihood estimates of the heterogeneity estimator in order to
construct Wald-type confidence intervals. The confidence interval for the model error
variance is based on the assumption that its estimator approximately follows a chi-square
distribution with k − 1 degrees of freedom (Sidik and Jonkman, 2005). Last is the boot-
strap confidence interval constructed by taking the 2.5th and 97.5th empirical percentiles
of the heterogeneity estimate based on the bootstrap sample after repeating the same
process up to 1000 times.
According to simulation results (Viechtbauer, 2007a), the profile likelihood method with
the Q statistic yields the most accurate coverage, closely followed by Biggerstaff and
Tweedie’s method. The performance of other methods was poor in general with a coverage
probability either too low or too high.
1.2.4 Measures of heterogeneity
Higgins and Thompson (2002) proposed three statistics which measure the impact of
heterogeneity on a meta-analysis: H, R, and I2. The advantage of these measures as
compared to the heterogeneity variance is that they allow heterogeneity of the intervention
effect to be compared across meta-analyses including different numbers of studies and
different outcome measures.
8The H statistic is given by the square root of the Q statistic divided by its degrees of
freedom. Since the expectation of Q is equal to k − 1 under Ho, H = 1 indicates that the
intervention effects are homogeneous across trials. Values of H exceeding 1.5 may suggest
heterogeneity complicating interpretation of the summary estimates of the intervention
effect. The R statistic is the ratio of the standard error of a random effects meta-analytic
summary estimate to the standard error of a fixed effects meta-analytic summary estimate.
It describes the inflation in the confidence interval for a summary intervention effect
estimate under a random effects model compared with a fixed effects model. When the
value is 1, it indicates that the two models yield identical inferences and the fixed effects
model is sufficient. The I2 statistic is interpreted as the proportion of total variation
in the estimate of an intervention effect that is due to heterogeneity between studies.
When the I2 statistic is 0 percent, the variation is considered only due to sampling error
and not due to heterogeneity. Similarly, an I2 statistic of 20 percent indicates that 20
percent of variability in the trials may be attributed to between-study variation. Several
investigators (e.g. Higgins and Green, 2008; Higgins and Thompson, 2002; Higgins et al.,
2002a) recommend including the H or I2 statistics when reporting meta-analyses.
Several simulation studies (Huedo-Medina et al., 2006; Mittlbo¨ck and Heinzl, 2006) exam-
ined the properties of H and I2 as a function of the ratio of between and within study
variances. They concluded that I2 but not H may depend on the number of trials when
that number is small (i.e. k ≤ 10). In addition, the values of I2 may be affected by the
ratio of between and within study variances rather than the between study variance alone.
Possible approaches for constructing confidence intervals for each measure were also
summarized in the appendix of the Higgins and Thompson’s article (2002): i) based on
the distribution of Q, ii) based on the statistical significance of Q (test-based method),
iii) based on the estimation of a heterogeneity estimator, and iv) using a non-parametric
9bootstrap procedure. In addition, the confidence interval approach known as the method
of variance estimates recovery (MOVER) originally proposed by Zou (2008) may be used
to construct a confidence interval for H by treating it as a ratio of within study and
between study variances (Donner and Zou, 2010).
According to the simulation results presented in Table A1 for the H statistic (Higgins
and Thompson, 2002), it appears that a confidence interval constructed based on the
distribution of Q has coverage close to 100 per cent even with large number of trials k (i.e.
k = 30) except for large heterogeneity. The maximum likelihood, restricted likelihood
and bootstrap confidence intervals have inadequate coverage above nominal for small
heterogeneity and below nominal for large heterogeneity. The coverage of the test-based
confidence interval appears to be conservative in most of the situations except when
significant heterogeneity is present or the number of studies is large. The Pearson type
III confidence interval constructed for the heterogeneity estimator provides good coverage
in all situations, but is complicated to calculate. Finally, the accuracy of MOVER will
depend heavily on the performance of confidence intervals for numerator and denominator
of the given ratio (Schuster and Metzger, 2010, Chapter 11).
In summary, despite the different assumptions and methods regarding the assessment
of heterogeneity among studies, the fixed and random effects approaches in principle
both use weighted averages with only a change in the weights to calculate the overall
mean effect size. When the two modeling approaches yield similar results, the conclusions
based on these results gain credibility. When the intervention effects are considered
homogeneous, the results from both models are identical with the heterogeneity variance
equal to zero.
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1.3 Meta-analysis of cluster randomization trials
In response to the frequent use of cluster randomization designs in the health research
field, the need to conduct meta-analyses for such trials becomes increasingly evident and
necessary. The challenge in planning and conducting such a meta-analysis involves the
need for accounting for clustering effects. Not recognizing that the unit of randomization
for cluster randomization trials is at the cluster level with outcome measures collected
and analyzed at the individual level will generally lead to underestimating the variance
due to lack of independence between individuals.
Heterogeneity is recognized as another important analytic issue in performing a meta-
analysis by investigators who have performed separate meta-analyses on trials that involve
very different randomization units. For example, a study was conducted by Fawzi et al.
(1993) to investigate the effect of vitamin A supplementation on child mortality. The
participants of this study were taken from studies of hospitalized children with measles,
as well as other studies involving healthy children participating in community-based
trials. Individual children were assigned to intervention in the four hospital-based trials,
while allocation was by village, district or household in the eight community-based trials.
Therefore, the meta-analysis was performed separately for the hospital-based trials and
the community studies. When the results agree, an important advantage is the confidence
gained that the intervention tested is effective (or ineffective) in more than one setting.
Otherwise, the investigator can further study the impact of different choices of random-
ization unit as part of a sensitivity analysis.
One approach to testing heterogeneity in the meta-analysis of cluster randomized trials is
to use the Q statistic adjusted for clustering discussed in Donner et al. (2001). In principle,
the idea is similar to the Q statistic used to test for heterogeneity in meta-analysis of
individually randomized trials, except its weights are modified to account for clustering to
ensure test validity. A similar method of adjusting tests of heterogeneity for clustering was
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described independently by Song (2004), suggesting that the adjusted tests maintained
the nominal significance level in a stimulation study.
Methodological researches on meta-analytic methods involving cluster randomized trials
have mainly focused on fixed effects models. By assuming there is no variation between
studies, there are several statistical approaches that can be applied to a meta-analysis
of cluster randomization trials with a binary endpoint. Statistical methods include the
adjusted Mantel-Haenszel procedures, the ratio estimator approach, the general inverse
variance approach, Woolf procedures and generalized estimating equations (GEE) using
robust variance estimation (Donner et al., 2001).
The adjusted Mantel-Haenszel test statistic (Donner and Klar, 2000) is slightly modified
from the standard Mantel-Haenszel test statistic to account for clustering effects. The null
hypothesis is that the overall odds ratio of all 2x2 tables is equal to one and the test statis-
tic follows approximately a chi-squared distribution with one degree of freedom. The ratio
estimator approach is based on an adjustment of the Mantel-Haenszel chi-square statistic
in which the event rate is regarded as a ratio rather than as a proportion. It was developed
by Rao and Scott (1992) and involves dividing the observed sample frequencies (counts) in
a given study by the estimated design effect. The general inverse variance approach (GIV)
is obtained by combining study estimates in a meta-analysis using a weighted average
of estimated effect measures that are calculated separately for each trial. This approach
is recommended in the guidance provided by the Cochrane Collaboration. The Woolf
procedure, which is best applied with a small number of clusters each of fairly large size,
transforms the intervention odds ratio of each trial to the logarithmic scale in order to
obtain a distribution which is more likely to be normally distributed. Then, the average of
the transformed odds ratios is computed using a weighting scheme originally described by
Woolf (1955) and modified for cluster randomization trials by Donner and Donald (1987a).
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Furthermore, a simulation study (Darlington and Donner, 2007) was performed to compare
the unadjusted Mantel-Haenszel method, the adjusted Mantel-Haenszel methods, the
ratio procedure, the general inverse variance, and the Woolf procedure. This simulation
study had two important results. First, the simulation results clearly showed that it is
inappropriate to use the unadjusted Mantel-Haenszel method due to elevated Type I error
rate. Second, the adjusted Mantel-Haenszel method had the greatest power and slightly
outperformed the general inverse variance method since it uses information on the cluster
sizes and intracluster coefficient ρ for each trial, while the general inverse method is a
generic procedure.
1.4 Scope of thesis
Most meta-analytic methods focus on combining study results of individually randomized
trials where observations are independent. Meta-analytic methods for cluster randomiza-
tion trials are largely extensions of meta-analytic methods for individually randomized
trials. However, applying existing meta-analytic methods to handle heterogeneity of
cluster randomized trials is problematic with correlated observations. The rationale for
limiting attention to heterogeneity among studies is that this is a substantial issue for
meta-analysis, since when present it complicates discussion of an overall intervention effect.
This research focuses mainly on binary outcomes because such outcomes have been most
frequently used in cluster randomization trials (Laopaiboon, 2003). There are three fre-
quently used designs in cluster randomization trials: completely randomized, matched-pair
and stratified. The completely randomized design is best suited to trials that have a fairly
large numbers of clusters, whereas matching or stratification is more effective in small
studies (Donner and Klar, 2000). The challenge of extending all methods to stratified and
pair-matched designs is an area for future research and will not be further discussed. For
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simplicity, the discussion will thus be focused on designs where there is a single binary,
cluster-level covariate, i.e., trials where there is one experimental group and one control
group.
In summary, my thesis will focus on exploring and evaluating heterogeneity in the context
of fixed effects models with the aim of providing general guidance in conducting a meta-
analysis of cluster randomization trials. Attention will also be limited to meta-analyses
of community intervention trials which typically enroll a small number of large clusters.
This focus reflects the relatively greater methodological challenge of statistical inferences
when estimates of variance inflation are less precisely estimated. Intervention effects for
binary outcomes will be measured using odds ratio estimators comparing an experimental
group to a control intervention.
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1.5 Thesis objectives
The primary objectives of this research are:
1. Analytics
(a) To extend the Q statistic, as commonly applied to test for heterogeneity in
meta-analyses of individually randomized trials, to the meta-analysis of cluster
randomization trials by specifying a weight accounting for clustering.
(b) To obtain an analytic expression for the power curve of the adjusted Q statistic.
(c) To derive heterogeneity variance estimators and their confidence intervals
accounting for clustering.
(d) To derive measures of heterogeneity and their confidence intervals accounting
for clustering.
2. Simulation
(a) To evaluate the performance of the adjusted Q statistic in terms of Type I error
and statistical power and to compare its power with the proposed formula.
(b) To assess the bias and mean square error for the adjusted heterogeneity variance
estimators and to evaluate the coverage, tail errors and interval width of the
proposed confidence interval methods.
(c) To assess the bias and mean square error for the adjusted measures of het-
erogeneity and to evaluate the coverage, tail errors and interval width of the
proposed confidence interval methods.
3. Example
(a) To illustrate the application of results, both in fixed and random effects models,
using data from four cluster randomization trials.
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1.6 Organization of the thesis
This thesis includes eight chapters. Chapter 2 extends the Q statistic, as commonly
applied to test for heterogeneity in meta-analyses of individually randomized trials, to the
meta-analysis of cluster randomization trials. An analytic expression for the power of the
Q statistic is derived. The effect on the power of cluster size, number of clusters, degree of
heterogeneity, and magnitude of intracluster correlation is explored. Chapter 3 presents
analytic expressions for the heterogeneity variance estimators adjusted for clustering and
describes approaches for constructing confidence intervals. Chapter 4 presents analytic
expressions for the measures of heterogeneity adjusted for clustering and approaches for
constructing confidence intervals.
Chapter 5 describes the design of a simulation study used to assess the procedures and
to validate analytical findings. Performance is evaluated in terms of Type I error and
statistical power for the Q statistic, bias and mean square error for both heterogeneity
variance estimators and measures of heterogeneity, and coverage for the confidence inter-
vals approaches. Results of the simulation study are described in Chapter 6. Chapter 7
presents a meta-analysis of 4 cluster randomization trials to illustrate the application of the
proposed methods. Finally, Chapter 8 summarizes the main results, the recommendations
based on the main results, the limitations of this thesis, and directions for future research.
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Chapter 2
Approximate power of the adjusted
Q statistic
2.1 Introduction
The Q statistic was introduced in Chapter 1 for meta-analysis of individually randomized
trials. An extension of this statistic was also described for cluster randomization trials.
Applying the Q statistic to a meta-analysis of cluster randomized trials without adjusting
for clustering is problematic because the unadjusted Q statistic tends to have inflated
Type I error rates. Therefore, we will derive the adjusted Q statistic to account for
clustering as well as derive a formula for its power that may be useful in planning a
meta-analysis of such trials. It can be quite time consuming to review randomized trials
and combine their results for meta-analyses. Thus, performing power calculations prior to
conducting a meta-analysis may prevent wasting time, money and energy in the searching
and collection of representative trials when there is scant likelihood of detecting clinically
relevant amounts of heterogeneity (Donner et al., 2003).
Approaches to computing the power of the Q statistic as applied to the meta-analyses
of individually randomized trials have been frequently discussed (e.g. Biggerstaff and
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Jackson (2008); Hardy and Thompson (1998); Hedges and Pigott (2001); Jackson (2006);
Valentine et al. (2010)). However, relatively little attention has been given to considering
the power of the Q statistic in planning a meta-analysis of cluster randomized trials.
Therefore, the aim of this chapter is to extend existing approaches to approximating power
of the adjusted Q statistic (i.e. adjusted for clustering). Specifically, interest focuses
on investigating the power of the adjusted Q statistic as a function of number of trials,
number of clusters, cluster size, disease risk rates, intracluster correlation coefficient and
degree of odds ratio heterogeneity across trials.
Section 2.2 provides the notation used throughout this thesis. An analytic expression
for the adjusted Q statistic is derived in Section 2.3.1, followed by a power formula
approximating the power of the adjusted Q statistic in Section 2.3.2. Summary comments
are provided in Section 2.4.
2.2 Notation
The data layout for a meta-analysis of k cluster randomized trials is provided in Table
2.1, where the notation used is defined in Table 2.2.
Suppose θ1, . . . , θk are the intervention effects of k trials, each measured as a log odds
ratio. Then the estimated intervention effect of θj of trial j is denoted
θˆj = ln
[
Pˆ1j(1− Pˆ2j)
Pˆ2j(1− Pˆ1j)
]
.
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Table 2.1: Data layout for a meta-analysis of k cluster randomized trials.
Trial Intervention Number Number Subjects Number
of clusters of events per cluster of subjects
1 Experimental n11 A11 m11l M11
Control n21 A21 m21l M21
Total N1 A1 M1
2 Experimental n12 A12 m12l M12
Control n22 A22 m22l M22
Total N2 A2 M2
...
...
...
...
...
...
k Experimental n1k A1k m1kl M1k
Control n2k A2k m2kl M2k
Total Nk Ak Mk
Table 2.2: Notation used in Table 2.1 given that intervention groups i = 1, 2, cluster
l = 1, . . . , nij and trial j = 1, . . . , k.
Symbol Description
mijl size of the i
th group in cluster l of trial j
nij total number of clusters in group i of trial j
Nj =
∑2
i=1 nij total number of clusters in trial j
Mij =
∑nij
l=1mijl total number of subjects in group i of trial j
Mj =
∑2
i=1Mij total number of subjects in trial j
Aijl number of events of the i
th group in cluster l of trial j
Aij =
∑nij
l=1Aijl number of events in group i of trial j
Aj =
∑2
i=1Aij total number of events in trial j
Pˆijl = Aijl/mijl proportion of events of the i
th group in cluster l of trial j
Pˆij = Aij/Mij total event rate in group i of trial j
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2.3 Fixed effects model
A fixed effects model assumes that there is a common effect measure and a random
component (within study sampling error), which is responsible for observed between study
heterogeneity in a meta-analysis. The fixed effects model for the observed study-specific
intervention effect θˆj is given (Whitehead, 2002) by
θˆj = θ + j, (2.1)
where the sampling error j is assumed to be approximately independently and normally
distributed with mean 0 and within study variance σ2j and with overall mean effect size θ,
respectively, for trial j, j = 1, . . . , k.
2.3.1 Adjusted Q statistic
Individually randomized trials
The null hypothesis Ho for the Q statistic is given by θ1 = θ2 = . . . = θk = θ and the
alternative hypothesis HA is θi 6= θj for some i 6= j. The mathematical expression for the
Q statistic is defined as a weighted sum of squares of the deviations of individual study
estimates from the overall mean effect size, given by
Q =
k∑
j=1
wˆj(θˆj − θˆ)2 (2.2)
where the estimated overall mean effect size is given by
θˆ =
∑k
j=1 wˆj θˆj∑k
j=1 wˆj
.
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The estimated weights are the reciprocals of the estimated within study variances, given
by wˆj = 1/σˆ
2
j . These particular weights are chosen to provide the most precise estimate
of θ by minimizing the variance of θ (Hardy and Thompson, 1996). Under Ho, the Q
statistic is distributed as a chi square random variable with k − 1 degrees of freedom.
The derivation of the Q statistic is provided in Appendix A.
In practice, the within study variance σ2j is estimated using data from jth trial, j = 1, . . . , k.
Given the responses for the jth trial in Table 2.3,
Table 2.3: Responses for the jth trial
Positive Negative Total P(positive)
Experimental A1j M1j − A1j M1j P1j = A1j/M1j
Control A2j M2j − A2j M2j P2j = A2j/M2j
and applying Woolf (1955)’s approach to estimate the within study variance for the
estimated log odds ratio, denoted as θˆj:
wˆj = (σˆ
2
j )
−1 =
[
1
A1j
+
1
M1j − A1j +
1
A2j
+
1
M2j − A2j
]−1
=
[
1
M1jPˆ1j(1− Pˆ1j)
+
1
M2jPˆ2j(1− Pˆ2j)
]−1
.
Cluster randomized trials
In the case of cluster randomization trials where individuals of the same cluster are
correlated with a positive intracluster correlation coefficient ρ, Donner and Donald (1987b)
suggested an adjustment using the variance inflation factor for each intervention group
i = 1, 2 defined as
Cij =
nij∑
l=1
mijl[1 + (mijl − 1)ρˆj]/Mij. (2.3)
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The intracluster correlation coefficient ρj may be obtained by using the ‘analysis of
variance’ (ANOVA) estimator proposed by Snedecor and Cochran (1980) (see Appendix
B for details). Consequently, the weights adjusting for clustering wjc become
wˆjc = (σˆ
2
jc)
−1 =
[
C1j
M1jPˆ1j(1− Pˆ1j)
+
C2j
M2jPˆ2j(1− Pˆ2j)
]−1
. (2.4)
Accordingly, replacing wˆj in (2.2) by wˆjc, the adjusted Q statistic is obtained by
Qa =
k∑
j=1
wˆjc(θˆj − θˆc)2, (2.5)
where the estimated adjusted overall mean effect size is given by
θˆc =
∑k
j=1 wˆjcθˆj∑k
j=1 wˆjc
. (2.6)
The adjusted Q statistic asymptotically follows a chi square distribution with k − 1
degrees of freedom under Ho (Song, 2004). Note that if ρˆj = 0 or Cij = 1 for i = 1, 2 and
j = 1, . . . , k, indicating there is no clustering, wˆjc reduces to wˆj and Qa equals Q.
Now, the adjusted Q statistic from equation (2.5) may be rewritten as
Qa =
k∑
j=1
wˆjc(θˆj − θ)2 −
k∑
j=1
wˆjc(θˆc − θ)2 (2.7)
and the variance of the overall mean effect size is computed as
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var(θˆc) =
∑k
j=1 wˆ
2
jcvar(θˆj)(∑k
j=1 wˆjc
)2 =
∑k
j=1 wˆ
2
jcwˆ
−1
jc(∑k
j=1 wˆjc
)2 = 1∑k
j=1 wˆjc
. (2.8)
Assuming within study variances are known, the expectation of the adjusted Q statistic
under the null hypothesis based on equations (2.7) and (2.8) is given by
E[Qa|Ho] =
k∑
j=1
wjcE(θˆj − θ)2 −
k∑
j=1
wjcE(θˆc − θ)2
=
k∑
j=1
wjcvar(θˆj)−
k∑
j=1
wjcvar(θˆc)
=
k∑
j=1
wjcw
−1
jc −
k∑
j=1
wjc
 k∑
j=1
wjc
−1 = k − 1.
2.3.2 Approximate power
Let δj denote the deviation of the intervention effect θj from the overall mean effect size
θ for trial j, j = 1, . . . , k, under the alternative hypothesis such that θi 6= θj for at least
one pair (i, j) or equivalently δj 6= 0 for at least one j (Montgomery, 2000, p.64). This
implies that the model in equation (2.1) for the observed intervention effect θˆj becomes
θˆj = θ + δj + j (2.9)
= θj + j,
since δj = θj − θ, where θ is the overall mean effect size. The sampling error j is
approximately normally distributed with mean 0 and within study variance σ2jc for trial j,
j = 1, . . . , k. The fixed effects δj has a constraint such that the sum of weighted δj equals
zero to satisfy the condition that θˆc remains an unbiased estimator of θ with variance
of 1/
∑k
j=1wjc. Moreover, the expectations of all cross-products with j are set to zero
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because the expectation of j is equal to zero (i.e. E(j) = 0).
Next, replacing θˆj defined in (2.7) by (2.9), the expectation of the adjusted Q under the
alternative hypothesis assuming the within study variance being known is given by
E[Qa|HA] =
k∑
j=1
wjcE(θ + δj + j − θ)2 −
k∑
j=1
wjcvar(θˆc)
=
k∑
j=1
wjcE(δ
2
j ) +
k∑
j=1
wjcE(
2
j)− 1
=
k∑
j=1
wjc(θj − θ)2 + k − 1,
where the adjusted Q statistic is distributed as a noncentral chi square distribution with
k − 1 degrees of freedom and noncentrality parameter NC defined as
NC =
k∑
j=1
wjc(θj − θ)2. (2.10)
The overall mean effect size θ may be estimated using θˆc in equation (2.6). It follows that
the power of the adjusted Q statistic at significance level α is defined as
power = 1− P (Accept Ho|HA)
= 1− P (Qa ≤ χ2k−1|HA)
= 1− F (cα|k − 1, NC), (2.11)
where F (cα|k−1;NC) is the cumulative distribution function of the noncentral chi-square
with k − 1 degrees of freedom and noncentrality parameter NC given in equation (2.10)
and cα is the 100(1− α) percent point of the chi-square distribution (Hedges and Pigott,
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2001).
In practice, parameters used for calculating statistical power are rarely available; therefore,
it is common to make some a priori assumptions. Based on these assumptions, we
investigate the approximate power of the adjusted Q statistic as a function of the number
of clusters, cluster size, disease risk rates, intracluster correlation coefficient and degree of
heterogeneity.
First, we focus on the case of an equal number of clusters n per intervention group,
where each cluster has a constant cluster size of m. Equal allocation is considered to be
statistically efficient as compared to unequal allocation, which requires more clusters to
obtain the same statistical power. In the case of unequal cluster sizes, we may replace m
by average cluster size m¯. The slight underestimation of the actual sample size can be
negligible, providing that the variation in cluster size is not substantial. If m is replaced
by mmax, the statistical power calculated will be more conservative (Donner and Klar,
2000, p.57).
Second, for simplicity, we assume a constant within study variance across trials (i.e.
σ2jc = σ
2
c for j = 1, . . . , k). However, in the case where the within study variance varies,
the noncentrality parameter assuming a constant within study variance tends to be
overestimated. Thus, the statistical power of the test obtained based on a constant within
study variance will be overestimated.
Third, Donner and Klar (2000, p.56) noted that the study design has an impact on the es-
timates of intracluster correlation coefficient. Since each of the trials in the meta-analysis
is assumed to be completely randomized, we will assume the intracluster correlation
coefficient ρ is constant across trials.
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Following these assumptions, the variance inflation factors defined in equation (2.3) are
reduced to 1 + (m− 1)ρ and the within study variance in (2.4) is simplified to a common
variance denoted by σ2c , given by
σ2c =
1 + (m− 1)ρ
nmP1(1− P1) +
1 + (m− 1)ρ
nmP2(1− P2) . (2.12)
Furthermore, the between study variance denoted by τ 2c (also referred to as the heterogene-
ity variance) can be estimated using the sample variance, given by
∑k
j=1(θj − θ¯)2/(k − 1),
where θ¯ =
∑k
j=1 θj/k. When the weights are assumed constant across trials, θ¯ is equivalent
to the overall mean effect size θc. Subsequently,
∑k
j=1(θj − θc)2 may be approximated by
(k − 1)τ 2c (Hedges and Pigott, 2001). Therefore, the noncentrality parameter in equation
(2.10) is approximated by
NC = (k − 1)τ 2c /σ2c . (2.13)
Note that the ratio τ 2c /σ
2
c is a measure of the degree of heterogeneity (see section
5.3). However, for plotting purposes, τ 2c and σ
2
c are considered as two separate quan-
tities. Therefore, without loss of generality, let the effect size (ES) be defined as
d = 2|arcsin(P1)(1/2) − arcsin(P2)(1/2)| (Cohen, 1992), the values of disease rates (P1, P2)
corresponding to d = 0.20 (small effect size) and 0.50 (medium effect size) are (0.1, 0.168)
and (0.1, 0.293), respectively. The effect sizes are defined in term of the disease rates
in order to plot the power of the adjusted Q statistic in function of the between study
variance τ 2c or the intracluster correlation coefficient ρ. Given the number of trials k,
number of clusters n, cluster size m, disease rates (P1, P2), between study variance τ
2
c , and
intracluster correlation coefficient ρ, the power of the adjusted Q statistic was calculated
for the following parameter values:
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(P1, P2) = (0.1, 0.168), (0.1, 0.293)
(n,m) = (5, 50), (5, 100), (10, 50)
k = 5, 10, 20
τ 2c = 0 to 0.5 in steps of 0.1
ρ = 0 to 0.05 in steps of 0.01
The values for the number of trials k and between study variance τ 2c , are taken from Hardy
and Thompson (1998). Also, the values of the effect sizes and intracluster coefficients
in community intervention trials are frequently small (Donner and Klar, 1996). For
example, the intracluster correlation coefficients for four cluster randomization trials
(Jolly et al., 1999; Moher et al., 2001; Montgomery et al., 2000; Woodcock et al., 1999)
performed to compare two or more interventions in primary care for cardiovascular heart
disease (CHD), which will be used as an example for this research, were in the range
of 0 to 0.0125. Also, when the approximate power of the adjusted Q statistic plotted
against the between study variance τ 2c , the intracluster correlation coefficient ρ was set
to 0.01. But when the approximate power of the adjusted Q statistic plotted against
the intracluster correlation coefficient ρ, the between study variance τ 2c was then set to 0.1.
Figure 2.1(a)-(b) shows that the approximate power of the adjusted Q statistic increases
as the number of trials increases, while holding other variables constant. Similarly, in
Figure 2.1(c)-(d), the approximate power of the adjusted Q statistic increases as the total
sample size increases while holding other variables constant. In addition, for a given
total sample size (nm = 500), the adjusted Q statistic with n = 10 has greater power
than with n = 5. In Figure 2.1(e)-(f), the approximate power increases as the effect
size becomes larger while holding other variables constant because larger effect size with
larger P2(1−P2) in equation (2.12) given P1 fixed results in smaller constant within study
variance. From the plots of power against τ 2c (first column), it is seen that the approximate
power increases as τ 2c increases. For instance, in Figure 2.1(a), the approximate power of
the adjusted Q statistic is approximately 60% for τ 2c = 0.2 and 80% for τ
2
c = 0.4 while
fixing k = 5, (n,m) = (5, 50), ρ = 0.01, and ES = small. On the contrary, for the plots
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of power against ρ (second column), it is seen that the approximate power decreases
as ρ increases. For instance, in Figure 2.1(b), the approximate power of the adjusted
Q statistic is approximately 80% for ρ = 0 and 40% for ρ = 0.02 while fixing k = 10,
(n,m) = (5, 50), τ 2c = 0.1, and ES = small.
2.4 Summary
In summary, since the validity of the unadjusted Q statistic in the presence of clustering
becomes questionable with inflated Type I error rates, the adjusted Q statistic has been
introduced. In addition, the approximate power of the adjusted Q statistic was derived
from a noncentral chi square distribution with k − 1 degrees of freedom and a specified
noncentrality parameter.
We have also investigated the power in terms of parameters including the number of
trials, number of clusters, cluster size, disease rates between intervention groups (i.e.
effect size), between study variance and intracluster correlation coefficient. It appears
that the power of the adjusted Q statistic increases by increasing any of the following
parameters: number of trials, overall sample size per trial (i.e. n×m), effect size (disease
rates between intervention groups) and between study variance. In contrast, the power
decreases as the intracluster correlation coefficient increases. Moreover, for a fixed sample
size, it is seen that the power of the adjusted Q statistic is greater for a large number of
small clusters than for a small number of large clusters.
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Figure 2.1: Approximate power of Qa plotted against τ
2
c (first column) and ρ (second
column). (a)-(b) varying numbers of trials k (k = 5, 10, 20); (c)-(d) varying number of
clusters per trial n and cluster size m ((n,m) = (5, 50), (5, 100), (10, 50)); (e)-(f) varying
effect size ES ((P1, P2) = (0.1, 0.168), (0.1, 0.293)).
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Chapter 3
Heterogeneity variance estimation
3.1 Introduction
The fixed effects model described in Chapter 2 assumes homogeneity of intervention effects
across the k trials. In contrast, the random effects model assumes that the observed
trials are a random sample from a hypothetical population of trials. In order to account
for the variation among trials, a random term known as heterogeneity variance is added
to compute the weights in the random effects model; this tends to equalize the weights
assigned to small and large trials. Subsequently, the random effects model may lead to
wider confidence intervals for the overall intervention effect.
Heterogeneity variance is also used as a measure of heterogeneity in meta-analysis. Al-
though heterogeneity variance may be solely limited to trials with the same effect measures
(e.g. odds ratio, risk ratio and hazard ratio), its value does not depend on the number, or
size of trials in a meta-analysis unlike the other measures such as the Q statistic (Ru¨cker
et al., 2008).
The aim of this chapter is to extend existing approaches for estimating the heterogeneity
variance of meta-analysis of individually randomized trials to meta-analysis of cluster
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randomization trials. We begin by considering eight methods for estimating the hetero-
geneity variance. In addition to a point estimate, confidence intervals for the heterogeneity
variance estimate may be useful, as they indicate its precision while also conveying all the
information contained in the corresponding test of heterogeneity (Hardy and Thompson,
1996; Viechtbauer, 2007a). Moreover, such confidence intervals may be also used to
construct confidence intervals for measures of heterogeneity (Higgins and Thompson,
2002), which will be discussed in Chapter 4.
The random effects model for cluster randomization trials is briefly described in Section
3.2. The eight approaches for estimating the heterogeneity variance adjusted for clustering
and the six methods for constructing confidence intervals, which are introduced in Section
1.2.3, are discussed with corresponding mathematical expressions presented in Section 3.3
and 3.4, respectively. Furthermore, a simulation study conducted in order to assess the
bias and mean square error of the adjusted heterogeneity estimators and the coverage
probabilities of the confidence intervals appears in Chapter 5.
3.2 Random effects model
Let θˆj denote the estimated intervention effect (experimental vs. control) on the log
odds ratio of the study outcome for the jth trial, j = 1, . . . , k. The random effects
meta-analysis model (Whitehead, 2002, p.88) is given by
θˆj = θ + νj + j,
where θ is the true overall mean effect size. Also, two independent random effects in-
cluded in the model are the random study effects and the error terms, denoted by νj and
j, respectively. Random study effects are assumed to be independently and normally
distributed with mean 0 and variance τ 2c (i.e. νj ∼ N(0, τ 2c )) and similarly, the error terms
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are assumed to be independently and normally distributed with mean 0 and variance σ2jc,
(i.e. j ∼ N(0, σ2jc)), where τ 2c is the between study component of variance also known as
the heterogeneity variance and σ2jc is the within study component.
In practice, the within study variance is estimated using equation (2.4) for cluster ran-
domization trials ignoring the sampling errors within the trial. This practice is often used
because the within study variance tends to be relatively small as compared to the between
study variance. Therefore, the errors can be negligible. However, caution must be taken
using the estimated within study variance as the true variance for trials with small overall
sizes, where the large sample approximation may be questionable (Bohning et al., 2002;
Brockwell and Gordon, 2001; Sidik and Jonkman, 2006). In this chapter, the focus will
be restricted to estimating heterogeneity variance τ 2c , with σ
2
jc being assumed known.
3.3 Adjusted heterogeneity variance estimators τ 2c
3.3.1 Variance component estimator (VC)
Hedges and Olkin (1985) proposed a simple approach to estimate the heterogeneity
variance using a method similar to that for estimating the variance components in a
random effects analysis of variance. Given the unweighted mean θ¯ =
∑k
j=1 θˆj/k, the usual
sample variance of θˆj may be expressed as
S2θ =
1
k − 1
k∑
j=1
(θˆj − θ¯)2.
Then the expected value of S2θ in terms of variance components is
E[S2θ ] = τ
2
c +
1
k
k∑
j=1
σˆ2jc,
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since as noted in Section 3.2, σ2jc is assumed known. The variance component estimate of
τ 2c is obtained as
τˆ 2c.V C =
1
k − 1
k∑
j=1
(θˆj − θ¯)2 − 1
k
k∑
j=1
σˆ2jc. (3.1)
Negative values of τˆ 2c.V C will be truncated (i.e. max{0, τˆ 2c.V C}). The variance component
estimator is a method of moments estimator.
3.3.2 DerSimonian and Laird estimator (DL)
Another method of moments estimator is the DerSimonian and Laird type estimator.
This estimator is also implemented in RevMan (DerSimonian and Laird, 1986) software,
which is the software recommended by The Cochrane Collaboration. Let wjc denote the
adjusted weights. The expectation of the adjusted Q statistic in equation (2.7) is then
calculated (the derivation is given by Whitehead (2002, p.90)) as
E[Qa] = τ
2
c
 k∑
j=1
wjc −
∑k
j=1w
2
jc∑k
j=1wjc
+
 k∑
j=1
wjcσ
2
jc −
∑k
j=1w
2
jcσ
2
jc∑k
j=1wjc
 . (3.2)
By equating the expression
∑k
j=1wjc(θˆj − θˆc)2 to its expected value given by equation
(3.2), solving for τ 2c and then substituting σˆjc for σjc, j = 1, . . . , k, a general method
of moment estimator for τ 2c without any particular weights assigned to the trials is as
follows:
τˆ 2c =
∑k
j=1 wˆjc(θˆj − θˆc)2 −
(∑k
j=1 wˆjcσˆ
2
jc −
∑k
j=1 wˆ
2
jcσˆ
2
jc/
∑k
j=1 wˆjc
)
∑k
j=1 wˆjc −
∑k
j=1 wˆ
2
jc/
∑k
j=1 wˆjc
. (3.3)
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A negative estimate of τˆ 2c is set to zero.
It is noted that the variance component estimator described in Section 3.3.1 and the
DerSimonian and Laird estimator for τ 2c are special cases of the general method of moments
estimator presented in equation (3.3) differing only in the choices of wˆjc (DerSimonian
and Kacker, 2007). For the variance component estimator, wˆjc = 1/k where k is the
number of trials. In this case, equation (3.3) is simply equal to τˆ 2c.V C of equation (3.1).
On the other hand, the DerSimonian and Laird estimator may be obtained by assigning
wˆjc = 1/σˆ
2
jc to equation (3.3), given by
τˆ 2c.DL =
Qa − (k − 1)∑k
j=1 wˆjc −
∑k
j=1 wˆ
2
jc/
∑k
j=1 wˆjc
. (3.4)
Furthermore, to improve performance, two two-step estimators to the one-step non-
iterative procedures may be derived based on the variance component estimate τˆ 2c.V C in
equation (3.1) and the DerSimonian and Laird estimate τˆ 2c.DL in equation (3.4) (DerSimo-
nian and Kacker, 2007). Specifically, the first two-step estimate (DLVC) is obtained by
assigning wˆjc.V C = 1/(σˆ
2
jc + τˆ
2
c.V C) to wˆjc in equation (3.3), given by
τˆ 2c.DLV C =
∑k
j=1 wˆjc.V C(θˆj − θˆc.V C)2∑k
j=1 wˆjc.V C −
∑k
j=1 wˆ
2
jc.V C/
∑k
j=1 wˆjc.V C
−
∑k
j=1 wˆjc.V C σˆ
2
jc −
∑k
j=1 wˆ
2
jc.V C σˆ
2
jc/
∑k
j=1 wˆjc.V C∑k
j=1 wˆjc.V C −
∑k
j=1 wˆ
2
jc.V C/
∑k
j=1 wˆjc.V C
, (3.5)
where θˆc.V C =
∑k
j=1 wˆjc.V C θˆj/
∑k
j=1 wˆjc.V C . Alternatively, the second two-step estimate
(DL2) is obtained by assigning wˆjc.DL = 1/(σˆ
2
jc + τˆ
2
c.DL) to wjc in equation (3.3), given by
τˆ 2c.DL2 =
∑k
j=1 wˆjc.DL(θˆj − θˆc.DL)2∑k
j=1 wˆjc.DL −
∑k
j=1 wˆ
2
jc.DL/
∑k
j=1 wˆjc.DL
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−
∑k
j=1 wˆjc.DLσˆ
2
jc −
∑k
j=1 wˆ
2
jc.DLσˆ
2
jc/
∑k
j=1 wˆjc.DL∑k
j=1 wˆjc.DL −
∑k
j=1 wˆ
2
jc.DL/
∑k
j=1 wˆjc.DL
, (3.6)
where θˆc.DL =
∑k
j=1 wˆjc.DLθˆj/
∑k
j=1 wˆjc.DL.
3.3.3 Model error variance estimator (MV)
Consider the random effects meta-analysis model presented in Section 3.2 as a linear
regression model with no covariates. To obtain the model error variance estimator of τ 2c ,
we reparameterize the total variance of θˆj (Sidik and Jonkman, 2005), such that the to-
tal variance σˆ2jc+τ
2
c becomes τ
2
c (rˆjc+1), where rˆjc denotes the ratio of σˆ
2
jc to τ
2
c with τ
2
c 6= 0.
Now, letting θˆ be a vector of the elements θˆ1, . . . , θˆk, the expectation and the variance of θˆ
are expressed in terms of matrices as E(θˆ) = Xθ and V ar(θˆ) = τ 2c V, respectively, where
X is a vector of all ones and V is a diagonal matrix with rˆ1c + 1, . . . , rˆkc + 1. Therefore,
the best linear unbiased estimator for the overall mean effect size θ is the weighted least
squares estimator
θˆυc = (X
TV−1X)−1XTV−1θˆ =
k∑
j=1
υˆ−1jc θˆj/
k∑
j=1
υˆ−1jc , (3.7)
where υˆjc = rˆjc + 1. The estimated variance of θˆυc is given by
̂
var(θˆυc) = (X
TV−1X)−1τˆ 2c = τˆ
2
c /
k∑
j=1
υˆ−1jc . (3.8)
Analogous to the usual weighted least squares estimator (Dobson, 2002), an estimate of
τ 2c may be obtained as
35
τˆ 2c.MV =
(θˆ −Xθˆυc)TV−1(θˆ −Xθˆυc)
k − 1 =
1
k − 1
k∑
j=1
υˆ−1jc (θˆj − θˆυc)2. (3.9)
In order to compute rˆjc, an initial estimate of τ
2
c is required, denoted by τˆ
2
o . The commonly
used one is the empirical variance estimate given by τˆ 2o =
∑k
j=1(θˆj − θ¯)2/k, where the
unweighted overall mean effect size is θ¯ =
∑k
j=1 θˆj/k. According to Sidik and Jonkman
(2005), this initial estimate works reasonably well for estimating moderate and large
values of the heterogeneity variance. Unlike the other estimators, τˆ 2c.MV will always yield
a nonnegative value.
In addition, Sidik and Jonkman (2007) proposed an improved version of the model error
variance estimator obtained by replacing τˆ 2o with τˆ
2
c.V C in (3.1). This improved model
error variance estimate (MVVC) of τ 2c is referred to as τˆ
2
c.MV V C .
3.3.4 Maximum likelihood estimator (ML)
The maximum likelihood approach requiring an iterative numerical solution may also
be used to estimate the adjusted heterogeneity variance (DerSimonian and Laird, 1986;
Hardy and Thompson, 1996; Harville, 1977). Given that the marginal distribution of θˆj is
assumed to be normally distributed with mean θ and variance σˆ2jc + τ
2
c , the log likelihood
function is given by
lnL(θ, τ 2c ) = −
k
2
ln2pi +
1
2
k∑
j=1
ln(wˆ∗jc)−
1
2
k∑
j=1
wˆ∗jc(θˆj − θ)2, (3.10)
where wˆ∗jc = 1/(σˆ
2
jc + τ
2
c ). By setting the first derivative of lnL(θ, τ
2
c ) with respect to
τ 2c equal to zero, the maximum likelihood estimate of τ
2
c (for details see Appendix D) is
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given by
τˆ 2c.ML =
∑k
j=1 wˆ
2
jc.ML{(θˆj − θˆc.ML)2 − σˆ2jc}∑k
j=1 wˆ
2
jc.ML
, (3.11)
where wˆjc.ML = 1/(σˆ
2
jc + τˆ
2
c.ML) and θˆc.ML =
∑k
j=1 wˆjc.MLθˆj/
∑k
j=1 wˆjc.ML. In equation
(3.11), τˆ 2c.ML may be obtained iteratively with an initial value of τˆ
2
c.ML = 0. At each
iteration, a positive value of τˆ 2c.ML is assured by setting the negative values to zero until
convergence is reached.
3.3.5 Restricted maximum likelihood estimator (REML)
The restricted maximum likelihood estimator is often recommended over the maximum
likelihood estimator, which tends to underestimate the variances (Harville, 1977). By
modifying the log likelihood function for the ML estimator in (3.10), the log likelihood
function for the REML estimator becomes
lnLR(θ) = −k
2
ln2pi +
1
2
k∑
j=1
ln(wˆ∗jc)−
1
2
k∑
j=1
wˆ∗jc(θˆj − θ)2 −
1
2
ln
k∑
j=1
wˆ∗jc, (3.12)
where wˆ∗jc = 1/(σˆ
2
jc + τ
2
c ). Similar to the ML estimator, by setting the first derivative
of lnLR(θ) with respect to τ
2
c equal to zero, the REML estimate of τ
2
c (for details see
Appendix E) is
τˆ 2c.RE =
∑k
j=1 wˆ
2
jc.RE{(θˆj − θˆc.RE)2 + (1/
∑k
j=1 wˆjc.RE)− σˆ2jc}∑k
j=1 wˆ
2
jc.RE
, (3.13)
where wˆjc.RE = 1/(σˆ
2
jc + τˆ
2
c.RE) and θˆc.RE =
∑k
j=1 wˆjc.RE θˆj/
∑k
j=1 wˆjc.RE. Similarly, with
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an initial value of τˆ 2c.RE = 0, τˆ
2
c.RE in (3.13) may be obtained iteratively. For each iteration,
negative values are truncated until convergence.
3.4 Confidence intervals for τ 2c
3.4.1 Q profile confidence intervals
Q profile confidence intervals for τ 2c are constructed based on the distribution of the
adjusted Q statistic, followed by P (χ2k−1,0.025 ≤ Q(τ 2c ) ≤ χ2k−1,0.975) where χ2k−1,0.025 and
χ2k−1,0.975 denote the 2.5th and 97.5th percentiles of a χ
2 distribution with k − 1 degrees
of freedom, respectively. Thus, the lower and upper bounds of a 95 percent confidence
interval for τˆ 2c is determined by solving for τ˜
2
c from
(
Q(τ˜ 2c ) = χ
2
k−1,0.975, Q(τ˜
2
c ) = χ
2
k−1,0.025
)
. (3.14)
The iterative procedure is used by repeatedly computing Q(τ˜ 2c ) with increasing values of
τˆ 2c until the critical values of χ
2 distribution are reached. A lower bound with negative
values, which is outside of the parameter space, is truncated to zero in order to ensure a
positive confidence interval. When Q(τ 2c = 0) ≤ χ2k−1,0.025, the upper bound is set equal
to the null set.
3.4.2 Biggerstaff-Tweedie confidence intervals
The Biggerstaff-Tweedie confidence intervals are constructed based on an approximation
of the distribution of the adjusted Q statistic, the gamma distribution with shape γ
and scale parameter φ. More specifically, the shape and scale parameters are defined as
γ(τ 2c ) = E(Qa)
2/var(Qa) and φ(τ
2
c ) = var(Qa)/E(Qa), respectively as functions of the
38
expected value and variance of the adjusted Q statistic, which are expressed as
E(Qa) = (k − 1) +
(
s1 − s2
s1
)
τ 2c , (3.15)
and
var(Qa) = 2(k − 1) + 4
(
s1 − s2
s1
)
τ 2c + 2
(
s2 − 2s3
s1
+
s22
s21
)
τ 4c , (3.16)
respectively, where st =
∑k
j=1w
t
jc (the proof is given by Biggerstaff and Tweedie (1997)).
The lower and upper bounds of a 95 percent confidence interval for τ 2c can be obtained by
finding those two values of τ˜ 2c such that
∫ ∞
Q/φ(τ˜2c )
f(x/γ(τ˜ 2c ))dx = 0.025 (3.17)
and
∫ Q/φ(τ˜2c )
0
f(x/γ(τ˜ 2c ))dx = 0.025, (3.18)
where f(x/γ(τ˜ 2c )) denotes the density function of a gamma distribution with shape pa-
rameter γ(τˆ 2c ) and scale parameter 1. This approach yields non-negative values. Similar
to the Q profile approach, it requires iteratively inputting monotonic increasing values
of τ 2c until conditions (3.17) and (3.18) are satisfied for the lower and upper bounds,
respectively. Also, when the negative upper bound is obtained, where the second integral
(3.18) is smaller than 0.025, the interval is set to be null. However, the accuracy of this
approach relies on the approximation of the gamma distribution to the true distribution
of the Qa statistic which follows a chi square with k − 1 degrees of freedom when τ 2c = 0
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but a noncentral chi square with k − 1 degrees of freedom when τ 2c 6= 0.
3.4.3 Profile likelihood confidence intervals
The profile likelihood approach is mainly used for constructing confidence intervals for
the ML estimator in (3.11) and the REML estimator in equation (3.13). Given the
log-likelihood function of θ and τ 2c , lnL(θ, τ
2
c ) in equation (3.10), and the restricted log-
likelihood function of τ 2c , lnLR(θ) in equation (3.12), the 95 percent confidence intervals
for τˆ 2c.ML in equation (3.11) and τˆ
2
c.RE in equation (3.13) are given by a set of τˆc
2 values
satisfying the following conditions
lnL(θ, τ 2c ) ≥ lnL(θˆc.ML, τˆ 2c.ML)− 3.84/2 (3.19)
lnLR(τ
2
c ) ≥ lnLR(τˆ 2c.RE)− 3.84/2 (3.20)
The value of 3.84 is the 5% point of the chi-square distribution with one degree of freedom.
The lower and upper bounds for τ 2c.ML and τ
2
c.RE may be found iteratively by substituting
values into equations (3.19) and (3.20), respectively, until convergence is reached. Since
τ 2c.ML and τ
2
c.RE always yield nonnegative values with truncation, the lower bound of
the profile likelihood confidence intervals remains nonnegative, followed by the positive
upper bound. Unlike the likelihood functions, the profile likelihood function takes into
consideration that τ 2c is estimated while varying values of the overall mean θˆc.
3.4.4 Wald-type confidence intervals
Wald-type confidence intervals are another option for the maximum likelihood estimators.
Such confidence intervals are constructed by taking inverse elements of the Fisher infor-
mation matrix as the asymptotic sampling variances of the ML and REML estimates.
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The 95 percent Wald-type confidence intervals for τˆ 2c.ML in equation (3.11) and τˆ
2
c.RE in
equation (3.13) are then given by
τˆ 2c.ML ± 1.96
√
ˆvar(τˆ 2c.ML)
τˆ 2c.RE ± 1.96
√
ˆvar(τˆ 2c.RE)
where
ˆvar(τˆ 2c.ML) = 2
 k∑
j=1
wˆ2jc.ML
−1
ˆvar(τˆ 2c.RE) = 2
 k∑
j=1
wˆ2jc.RE − 2
∑k
j=1 wˆ
3
jc.RE∑k
j=1 wˆjc.RE
+
(∑k
j=1 wˆ
2
jc.RE∑k
j=1 wˆjc.RE
)2−1
with wˆjc.ML = 1/(σˆ
2
jc + τˆ
2
c.ML) and wˆjc.RE = 1/(σˆ
2
jc + τˆ
2
c.RE), respectively. Details on
how the sampling variances are obtained can be found in Appendix A and Appendix
B, respectively. The negative lower bound are suggested not be truncated to zero to
preserve the precision of the τ 2c estimate. The upper bound will always be positive for
the confidence interval are constructed around a non-negative τ 2c .
3.4.5 Sidik-Jonkman confidence intervals
Sidik-Jonkman confidence intervals may be constructed for the model error variance
heterogeneity estimator. Given that (k−1)τˆ 2c.MV /(
∑k
j=1(θj− θ¯)2/k) approximately follows
a χ2 distribution with k− 1 degrees of freedom, a 95 percent confidence interval for τˆ 2c.MV
in equation (3.9) can be obtained as
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(
(k − 1)τˆ 2c.MV
χ2k−1,0.975
,
(k − 1)τˆ 2c.MV
χ2k−1,0.025
)
This approach is straightforward and does not require iterative solutions. Moreover, the
estimates of τ 2c obtained by using Sidik-Jonkman are always greater than zero. Thus,
the lower and upper bound of Sidik-Jonkman confidence intervals are also greater than zero.
3.4.6 Nonparametric bootstraps confidence intervals
The advantage of the nonparametric bootstraps approach is that it does not require
any distributional assumptions for the estimators. In addition, it is relatively simple to
implement. A set of 1000 nonparametric bootstraps samples can be obtained by sampling
with replacement the same number of observations as in the original dataset consisting of
θj and the corresponding σˆ
2
jc. For each bootstraps sample, τ
2
c can be estimated using the
DerSimonian and Laird method, where we denote the resulting estimate as τˆ 2b . Repeating
this process 1000 times, a 95 percent confidence interval for τ 2c is then given by the 2.5th
and 97.5th empirical percentiles of the 1000 τˆ 2b values. Since the DerSimonian and Laird
method is applied, which has the negative values truncated to zero, the confidence interval
will be positive.
3.5 Summary
The approaches for point and interval estimation of τ 2c are summarized in Table 3.1.
Overall, eight heterogeneity variance estimators have been described, including the four
noniterative estimators VC, DL, MV and MVVC, the two two-step estimators DLVC and
DL2 and finally the two iterative estimators ML and REML. Most of the estimators will
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yield nonnegative estimates with truncation at zero, while the adjusted MV and improved
MV will always give positive τ 2c estimates without truncation.
In addition to the point estimation, a total of six approaches for constructing confidence
intervals are provided including the Q profile, Biggerstaff-Tweedie, profile likelihood,
Wald-type, Sidik and Jonkman and nonparametric bootstraps confidence intervals. The
iterative approaches are Q profile, Biggerstaff-Tweedie, profile likelihood, and nonpara-
metric, while the rest of confidence interval approaches are noniterative. The Q profile
and Biggerstaff-Tweedie approaches are mainly used to construct confidence intervals for
the method of moments estimators. The profile likelihood and Wald-type approaches are
used to constructed confidence intervals for the ML and REML estimators. Finally, the
Sidik-Jonkman approach is uniquely designed to construct confidence intervals for the
Sidik-Jonkman estimator. Most of the confidence intervals require truncation at zero,
except that the Wald-type confidence interval allows a negative lower bound to enhance
the precision of the τ 2c estimate and the Sidik and Jonkman confidence interval always
has a lower bound greater than zero.
The performance of the proposed methods has not yet been compared for meta-analysis
of cluster randomized trials. Therefore, we will conduct a simulation study evaluating the
adjusted heterogeneity variance estimators in terms of bias and mean square errors and
the confidence interval approaches in terms of coverage, tail errors and interval width in
Chapter 5.
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Table 3.1: Summary of the adjusted heterogeneity variance estimators with the methods
of constructing confidence intervals
Estimator Confidence Intervals
Non-Iterative
Variance Component (VC) τˆ 2c.V C (3.1) Q Profile, Biggerstaff-Tweedie
DerSimonian and Laird (DL) τˆ 2c.DL (3.4) Q Profile, Biggerstaff-Tweedie
Two-step DL based on VC (DLVC) τˆ 2c.DLV C (3.5) Q Profile, Biggerstaff-Tweedie
Two-step DL based on DL (DL2) τˆ 2c.DL2 (3.6) Q Profile, Biggerstaff-Tweedie
Model Error Variance (MV) τˆ 2c.MV (3.9) Sidik-Jonkman
Improved based on VC (MVVC) τˆ 2c.MV V C (3.9) Sidik-Jonkman
Iterative
Maximum Likelihood (ML) τˆ 2c.ML (3.11) Profile likelihood, Wald-type
Restricted (REML) τˆ 2c.RE (3.13) Profile likelihood, Wald-type
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Chapter 4
Measures of heterogeneity
4.1 Introduction
Heterogeneity of the intervention effect in a meta-analysis of cluster randomized trials
may be assessed using the adjusted Q statistic or by estimating the adjusted heterogeneity
variance. However, the power of the adjusted Q statistic depends on the number of trials
included in the meta-analysis, while estimation of the heterogeneity variance is limited to
trials using the same intervention effect measures.
Higgins and Thompson (2002) developed three statistics (i.e. H, R and I2), known as
measures of heterogeneity, that avoid these two above-mentioned shortcomings. These
three statistics, described earlier in Section 1.2.4, provide intuitive interpretations al-
lowing comparisons across meta-analyses regardless of the number of trials, the type
of outcome data (e.g. dichotomous, quantitative, or time to event) and the choice of
intervention effect measure (e.g. odds ratio or hazard ratio). Consequently, these three
statistics have been adopted by many researchers for quantifying heterogeneity across
trials. Due to this wide usage, the I2 statistic is now recommended in the guidelines
for conducting meta-analysis provided by The Cochrane Collaboration, an international
network for maintaining and ensuring the accessibility of systematic reviews in health care.
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In addition to the estimated statistics, the confidence intervals are informative in summa-
rizing precision by providing a range of values that reflect the degree of uncertainty in
the estimation procedure. Moreover, the use of confidence intervals in presenting research
results is usually recommended in reporting guidelines (e.g. the CONSORT statement
(Altman et al., 2001)).
The objectives of this chapter are to adapt H, R and I2 to the meta-analysis of cluster ran-
domization trials and to modify existing approaches for constructing confidence intervals
for the adjusted statistics. Specifically, the formula, interpretation and properties of the
adjusted H, R and I2 statistics are explicitly described in Section 4.2. Confidence intervals
for the adjusted statistics are presented in Section 4.3. Key results are summarized in
Section 4.4.
Small sample properties and confidence intervals for adjusted H, R and I2 will be evaluated
by simulation in Chapter 5.
4.2 Measures of Heterogeneity
4.2.1 Quantifying Heterogeneity
The measures of heterogeneity developed for individual randomized trials were derived
based on three criteria (Higgins and Thompson, 2002). The first criterion is that the
measure depends on the extent of heterogeneity (i.e. τ 2c ). The second criterion requires
the measure to be scale invariant, allowing comparisons across meta-analyses involving
different outcome data (e.g. lbs vs. kg or odds ratio vs. hazard ratio). The third criterion
requires the measure to be invariant to the number of trials.
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The first and second criteria suggest that the measures should be monotonically increasing
with the between study variance τ 2c and depend on the within study variance σ
2
c , but not
depend on the choice of intervention effect and the number of trials (according to the
second and third criteria, respectively). Therefore, the measures proposed by Higgins and
Thompson (2002) must be a monotonic increasing function of γ = τ 2c /σ
2
c .
The assumption of equal within study variances across trials is often applied to obtain
a common within study variance. However, this assumption may not hold when binary
outcomes are considered. The assumption of equal within study variances, equivalent to
assuming the same disease risk, may not be realistic because the trials with the same
disease risk are mostly likely to be replicates (i.e. the disease rates are for each trial).
Alternatively, the individual within study variances may be summarized to obtain an
overall within study variance referred to as a typical within study variance σˆ2wc by Higgins
and Thompson (2002). There have been two suggestions for estimating a typical within
study variance.
One is to estimate a typical within study variance using the harmonic mean, i.e., the
reciprocal of the arithmetic mean weight (Takkouche et al., 1999), given by
σˆ2wc,1 = k/
k∑
i=1
wˆjc. (4.1)
where wˆjc = 1/σˆ
2
jc. The within study variance σ
2
jc may be estimated using equation (2.4).
A second possibility discussed by Higgins and Thompson (2002) is given by
σˆ2wc,2 =
(k − 1)∑ki=1 wˆjc(∑k
i=1 wˆjc
)2 −∑ki=1 wˆ2jc . (4.2)
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According to Mittlbo¨ck and Heinzl’s (2006) simulation results for individual randomized
trials, σˆ2wc,2 is preferable because it is derived from the expectation of Qa. However, σˆ
2
wc,2
is approximately equal to σˆ2wc,1 when there is little variation in the within study variances.
4.2.2 Adjusted H statistic
One approach that meets the three proposed criteria is to calculate the adjusted H
statistic, given by
Ha =
√√√√ τˆ 2c + σˆ2wc
σˆ2wc
(4.3)
When the DerSimonian and Laird estimator τˆ 2c.DL in equation (3.4) and the typical within
study variance σˆ2wc,2 in equation (4.2) are used to estimate τˆ
2
c and σ
2
wc in equation (4.3),
respectively, the adjusted H is expressed as
Ha =
√√√√ τˆ 2c.DL + σˆ2wc.2
σˆ2wc.2
=
√
Qa
k − 1 (4.4)
The adjusted H statistic describes the square root of the relative excess in Qa over its
degrees of freedom. Specifically, the Ha values reflect the relation of between to within
study variance. For instance, when the between study variance is equal zero or in the
case of homogeneity, Ha has a value of 1. A rough guideline will be that values exceeding
1.5 may suggest heterogeneity among trials and values below 1.2 may suggest little het-
erogeneity.
The next step is to investigate the values of Ha as a function of parameters including
the number of trials, number of clusters per group, cluster size, intracluster correlation
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coefficient and degree of heterogeneity. For simplicity, the focus will be restricted to the
case of an equal number of clusters per group (i.e. Nj = N1j = N2j) having constant
cluster size m. The measure of degree of heterogeneity is defined in Section 5.3.
The simulation results are illustrated in Figure 4.1 where values of Ha are plotted against
the degree of heterogeneity, while varying the intracluster correlation coefficient, number
of trials, number of clusters per trial, and cluster size. The plotted lines indicate the
values of Ha = 1.2 and Ha = 1.5 corresponding to the boundaries for ‘low’ to ‘moderate’,
and ‘moderate’ to ‘high’ heterogeneity, respectively. Unlike the adjusted Q statistic, the
value of Ha does not intrinsically depend on the number of trials and increases with the
degree of heterogeneity. However, the variability of Ha across different values of ρ is large
when the number of trials is small and the suggested guideline may not be applicable.
Consequently, it becomes difficult to distinguish ‘moderate’ heterogeneity from chance.
The variability of Ha across different ρ is slightly reduced in the case of a large number of
small clusters (e.g. (Nj,m) = (40, 100)) compared to a small number of large clusters
(e.g. (Nj,m) = (20, 200)) for a fixed sample size per trial and significantly reduced when
the number of trials increases (e.g. to k = 20 or k = 40).
4.2.3 Adjusted R statistic
The adjusted R statistic is an alternative to equation (4.3). Let the ML estimate in
equation (3.4) be used to estimating the heterogeneity variance. It uses the estimated
variances of the estimated intervention effect under the fixed and random effects model
denoted by υˆF and υˆR, respectively (Higgins and Thompson, 2002), and given by
Ra =
√
υˆF
υˆR
=
√√√√∑kj=1 wˆjc∑k
j=1 wˆ
∗
jc
, (4.5)
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a) k=4, (n,m)=(20,100)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
b) k=4, (n,m)=(20, 200)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
c) k=4, (n,m)=(40,100)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
d) k=20, (n,m)=(20,100)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
e) k=20, (n,m)=(20, 200)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
f) k=20, (n,m)=(40,100)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
g) k=40, (n,m)=(20,100)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
h) k=40, (n,m)=(20, 200)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
i) k=40, (n,m)=(40,100)
degree of heterogeneity
H
a
1.0
1.2
1.4
1.6
1.8
No Low Moderate High
Figure 4.1: Estimated Ha plotted against degree of heterogeneity (‘no’, ‘low’, ‘moderate’,
‘high’) varying numbers of trials k (k = 4, 20, 40), number of clusters per group Nj
and cluster size m ((Nj,m) = (20, 100), (20, 200), (40, 100)) and intracluster correlation
coefficient ρ (ρ = 0, 0.01, 0.05). Plotted lines indicate the values of Ha = 1.2 and Ha = 1.5.
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where wˆjc = 1/σˆ
2
jc and wˆ
∗
jc = 1/(τˆ
2
c.DL + σˆ
2
jc). The adjusted R statistic describes the infla-
tion in the confidence interval for a single summary estimate under a random effects model
compared with a fixed effects model. A value of 1 indicates identical inferences under the
two models in which the intervention effects are homogeneous. The properties for Ra are
similar to those for Ha since they estimate the same measure (i.e. γ+1) using different ap-
proaches. When both estimates have equal precision, values of Ha are equal to values of Ra.
4.2.4 Adjusted I 2 statistic
The adjusted I2 statistic may be expressed as
I2a =
τˆ 2c.DL
τˆ 2c.DL + σˆ
2
wc.2
=
H2a − 1
H2a
=
Qa − (k − 1)
Qa
(4.6)
in terms of either Ha or Qa and k. The adjusted I
2 statistic describes the total vari-
ation across trials due to heterogeneity. It may also be considered as a measure of
inconsistency, since it depends on the extent of overlap in confidence intervals across
studies (Higgins, 2008). Values of I2a are normally expressed as a percentage with a range
from 0 to 100, where a value of zero percent indicates no observed heterogeneity. A
general guideline for ‘low’, ‘moderate’ and ‘high’ heterogeneity correspond to 25%, 50%
and 75% values of I2a , respectively. Alternatively, a value of I
2
a greater than 50% may
be considered as substantial heterogeneity (Higgins and Green, 2008; Higgins et al., 2002a).
Note that values of I2a should be interpreted with caution when the number of subjects
in the trials and the number of trials in the meta-analysis are low (Huedo-Medina et al.,
2006; Mittlbo¨ck and Heinzl, 2006; Ru¨cker et al., 2008).
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4.3 Confidence intervals
Methods of constructing confidence intervals for the proposed measures include the method
of variance estimates recovery (MOVER), using the distribution of the adjusted Q statistic,
statistical significance of the adjusted Q statistic, estimation of an adjusted heterogeneity
variance estimator, and a nonparametric bootstraps procedure. Following the approach
of several previous investigations (Higgins and Thompson, 2002), all approaches except
MOVER proceed as if the within study variance is known and the between study variance
is unknown. Although the discussion is restricted to constructing a confidence interval
for Ha, a confidence interval for I
2
a can be easily computed using equation (4.6). Note
that the approaches based the adjusted Q statistic may not be applicable to construct
confidence intervals for the adjusted R statistic.
Assuming the adjusted weights are known, Ra is considered to be a function of τ
2
c ; thus, it
may be calculated based on the estimators listed in Chapter 3. As a result, the confidence
intervals for Ra may be constructed using approaches similar to that of constructing a
confidence interval for τ 2c , as described in Section 3.4.
4.3.1 Intervals based on MOVER
The confidence intervals may be constructed for Ha using the method of variance estimates
recovery (MOVER) (Zou, 2008) for a ratio. By rearranging equation (4.3), the adjusted
Ha may be considered as a ratio as
H2a − 1 =
τˆ 2c.DL
σˆ2wc
The equations for constructing the confidence intervals (Rl, Ru) for a ratio (Donner and
Zou, 2010) are given by
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Rl =
θˆ1θˆ2 −
√
(θˆ1θˆ2)2 − l1u2(2θˆ1 − l1)(2θˆ2 − u2)
u2(2θˆ2 − u2)
(4.7)
Ru =
θˆ1θˆ2 +
√
(θˆ1θˆ2)2 − u1l2(2θˆ1 − u1)(2θˆ2 − l2)
l2(2θˆ2 − l2)
. (4.8)
Let θˆ1 = τˆ
2
c.DL of equation (3.11) and θˆ2 = σˆ
2
wc.1 of equation (4.2). Assuming there is
relatively little variation in the within study variances, the typical within study variance
σˆ2wc.1 is used instead of σˆ
2
wc.2 to avoid complex computations.
The confidence interval [l1, u1] for τˆ
2
c.DL may be obtained using the Q profile confidence
intervals described in section 3.4.1. As for the confidence interval [l2, u2] for σˆ
2
wc.1, we will
first define the large sample confidence interval for wˆjc = 1/σˆjc as
l2jc = wjcχα/2,Mj−1/(Mj − 1), u2jc = wjcχ1−α/2,Mj−1/(Mj − 1),
where Mj is the total number of subjects in trial j. Next, the confidence interval for∑k
j=1 wˆjc (Zou et al., 2009) is obtained as
l′2 =
k∑
j=1
wˆjc −
√√√√√ k∑
j=1
[wˆjc − l2jc]2, u′2 =
k∑
j=1
wˆjc −
√√√√√ k∑
j=1
[wˆjc − u2jc]2.
Finally, the confidence interval for σˆ2wc.1 is simply given by
l2 = k/u
′
2, u2 = k/l
′
2.
The confidence interval for Ha− 1 may be obtained by applying equations (4.7) and (4.8).
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4.3.2 Intervals based on the distribution of Qa
In Chapter 2, the adjusted Q statistic was shown to follow a noncentral chi square
distribution under the alternative hypothesis that not all intervention effects are the same,
with the variance of Qa given by 2(k − 1 + 2NC). The noncentrality parameter NC may
be calculated using equation (2.10). As a result, a 95 percent confidence interval for Ha
may be obtained as
√
1
k − 1
(
Qa ± 1.96
√
ˆvar(Qa)
)
, (4.9)
which also can be recognized as a symmetric Wald-type confidence interval (Higgins and
Thompson, 2002). Alternatively, the distribution of the adjusted Q statistic may be
approximated by a gamma distribution where the variance of Qa in equation (3.16) is
used instead (Biggerstaff and Tweedie, 1997). This approach involves the estimation of
quantiles from the cumulative distribution function of the gamma distribution, which
requires more complex computation than the one based on a noncentral chi square distri-
bution.
4.3.3 Intervals based on the statistical significance of Qa
A simple method of constructing a confidence interval for Ha is derived from a test-based
standard error for ln(Ha) involving Qa and k (Abramowitz and Stegun, 1965, formula
26.4.13). Intervals are of the form exp(lnHa±Zα× SE(lnHa)) where Zα is the (1− α/2)
quantile of the standard normal distribution and a test-based standard error for ln(Ha) is
SE(lnHa) =
1
2
ln(Qa)− ln(k − 1)√
2Qa −
√
2k − 3
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Whenever Ha = 1 or Qa ≤ (k− 1), the test-based standard error for Ha may be estimated
(Abramowitz and Stegun, 1965, formula 26.4.13) by
SEo(lnH) =
√√√√ 1
2(k − 2)
(
1− 1
3(k − 2)2
)
.
4.3.4 Intervals based on the estimation of τ 2c
A confidence interval for Ha may be easily calculated using the approaches of constructing
a confidence interval for τ 2c illustrated in Chapter 3 by considering Ha as an estimate of
ηa =
√√√√(∑kj=1 wˆjc −∑kj=1 wˆ2jc/∑kj=1 wˆjc) τˆ 2c
k − 1 + 1 (4.10)
where wˆjc = 1/σˆ
2
jc. For instance, if τˆ
2
c.DL is used to replace τˆ
2
c of equation (4.10), the
Q profile approach described in section 3.4.1 may be applied to construct a confidence
interval for ηa. The same analogy may be used for constructing a confidence interval for
the adjusted R statistic as a function of τ 2c .
4.3.5 Bootstraps confidence intervals
A nonparametric bootstraps confidence interval for Ha may be obtained by taking samples
of size k with replacement from the pairs (θj, σ
2
jc) and calculating quantiles for the Ha
statistic 1000 times. A nonparametric bootstraps approach is selected because it does not
require any distributional assumptions and also because it is relatively simple to implement.
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4.4 Summary
The adjusted H, R and I2 statistics may be used to assess the presence of heterogeneity
in the meta-analysis of cluster randomization trials in place of the test of heterogeneity.
The disadvantage of the latter approach is that it may have low power because of a small
number of studies and inappropriately high power with many studies. These measures
of heterogeneity are usually recommended in guidelines for conducting meta-analyses
because they do not intrinsically depend on the number of trials, at least for relatively
large k, and also allow comparisons across meta-analyses with different outcomes. Table
4.4 summarizes the rough guideline for each statistic that corresponds to ‘low’, ‘moderate’
and ‘high’ heterogeneity. Moreover, the confidence intervals for the estimated statistics are
more informative since they provide a range of values that reflects the degree of uncertainty
in the estimation procedure. The confidence intervals for the estimated statistics may be
constructed based on the method of variance estimates recovery (MOVER), the distribu-
tion of the adjusted Q statistic, the statistical significance of the adjusted Q statistic, the
estimation of an adjusted heterogeneity variance estimator, or a nonparametric bootstraps
procedure.
Chapter 5 will also present the evaluation of the performance of the estimated hetero-
geneity statistics in terms of bias and mean square error and the performance of the
corresponding confidence interval approaches in terms of coverage, tail errors and interval
width.
Table 4.1: Degree of Heterogeneity
Statistic Low Moderate High
Ha or Ra < 1.2 1.2− 1.5 > 1.5
I2a < 25% 25− 50% > 50%
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Chapter 5
Simulation study design
5.1 Introduction
The adjusted Q statistic was derived in Chapter 2 while the adjusted heterogeneity
variance estimators and the adjusted measures of heterogeneity were described in Chapter
3 & 4, respectively. The purpose of this chapter is to report on the design of a simulation
study evaluating the performances of these statistics.
Objectives for the simulation study are described in Section 5.2. Parameters to be
considered are discussed and justified in Section 5.3, while procedures for generating
clustered binary data are described in Section 5.4. Finally, the criteria for evaluating
the performance of statistical approaches for selected scenarios are provided in Section
5.5. The design of the simulation study follows the guidelines proposed by Burton et al.
(2006).
57
5.2 Objectives
A list of the methods being compared for each type of heterogeneity assessment is provided
in Table 5.1. The specific objectives for the simulation study are
1. To evaluate the performance of the adjusted Q statistic in terms of Type I error
and statistical power and to compare its power with the proposed formula.
2. To assess the bias and mean square error of the adjusted heterogeneity variance
estimators and to evaluate the coverage, tail errors and interval width of the proposed
confidence interval methods.
3. To assess the bias and mean square error of the adjusted measures of heterogeneity
and to evaluate the coverage, tail errors and interval width of the proposed confidence
interval methods.
5.3 Selection of parameters
Given that a fixed effects design is used, the performance of the statistical methods may
depend on several factors, including the number of trials, number of clusters, cluster size
(mean, variability), disease rates for the control group, intracluster correlation coefficient
and degree of heterogeneity in the intervention effects. This section is devoted to justifying
the choices of the parameters used in generating the correlated binary data by showing that
they reflect practical scenarios encountered in the meta-analysis of cluster randomization
trials. The focus is limited to completely randomized designs with a binary outcome.
The focus is further restricted to a meta-analysis of k = 4, 12, 20, 40 cluster randomiza-
tion trials, each with two intervention groups, assuming an equal number of clusters
(Nj = n1j = n2j) with constant cluster size (m) in each intervention group for each trial.
The intervention effect was measured using the log odds ratio which is frequently used
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Table 5.1: List of methods being compared for each type of heterogeneity assessment.
Heterogeneity assessment Method
Heterogeneity variance (τ 2c ) Variance component (VC)
DerSimonian and Laird (DL)
Two-step DL (DLVC)
Two-step DL (DL2)
Model error variance (MV)
Improved model error variance (MVVC)
Maximum likelihood (ML)
Restricted maximum likelihood (REML)
Confidence intervals for τ 2c Q profile for DL
Biggerstaff-Tweedie for DL
Sidik-Jonkman for MV
Nonparametric bootstraps for DL
Profile likelihood for ML
Profile likelihood for REML
Wald-type for ML
Wald-type for REML
Measures of heterogeneity Ha
Ra
I2a
Confidence intervals for Ha MOVER
Based on distribution of Qa
Test-based
Based on τ 2c
Nonparametric bootstraps
in medical studies as compared to other types of measures (e.g. relative risks or risk
difference) (Bland and Altman, 2000).
Two log odds ratios values were chosen, −0.36 and 0, equivalent to 0.7 and 1 in terms
of the odds ratio (ψ), respectively. The results to ψ = 0.7 for an experimental group
reducing risk are expected to be the same for an experimental group increasing risk with
ψ = 1.4. Values for the parameters considered in the simulation study are summarized in
Table 5.2.
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Number of clusters, cluster size
In general, most cluster randomization trials tend to either have a large number of small
clusters (e.g. family randomized trials) or a small number of large clusters (e.g. community
intervention trials). In this study, we will focus on the latter case. Thus, the selected
values for the number of clusters per group and mean cluster size (Nj,m) were (20, 100),
(20, 200) and (40, 100) based on the previous simulation studies (Darlington and Donner,
2007; Donner et al., 1990; Donner and Klar, 1996; Eldridge et al., 2004).
Disease rates for the control group
We used two possible sets of disease rates for the control group (r1j) for each k. For
instance, the two sets at k = 4 were (0.35, 0.45, 0.50, 0.55) and (0.04, 0.07, 0.10, 0.13),
which corresponded approximately to the disease rates for the control group used in the
simulation study by Darlington and Donner (2007). The sets of disease rates for the
control group at k = 12, 20 and 40 were the 3-, 5- and 10-fold versions of the two proposed
sets of disease rates at k = 4, respectively.
Intracluster correlation coefficient
The intracluster correlation coefficient ρ, a measure of the similarity among individuals
within the same cluster, tends to be small for larger clusters (e.g. community intervention
trials). For example, 220 estimates of ANOVA-based intracluster correlation coefficients
from 21 implementation trials limited to hospital and physician randomized trials had
a median of 0.048 with a range from 0 to 0.415 (Campbell et al., 2005). In particular,
the values of ρ were around 0.05 for primary care trials and were even smaller for binary
outcomes (e.g. less than 0.01 for blood pressure ≥ 90 mm Hg in a study of hypertension
screening and management (Bass et al., 1986)). Based on these findings, the values of ρ
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were set to 0, 0.01 and 0.05, similar to those considered by Donner and Klar (1996).
Table 5.2: Simulation parameters for cluster randomization simulation study
Parameter Values
Number of Studies (k) 4, 12, 20, 40
Odds Ratio (θj = log(Ψj)) 0.7, 1.0
Number of clusters per group, cluster size (Nj,m) (20,100), (20,200), (40,100)
Disease rates for the control group at k = 4 (r1j) (0.04,0.07,0.10,0.13)
(0.35,0.45,0.50,0.55)
Intracluster correlation coefficient (ρ) 0, 0.01, 0.05
Degree of heterogeneity (w) 0, 0.33, 0.67, 1
Correspond to No, Low, Moderate, High
Degree of heterogeneity
The noncentrality parameter NC may be approximated by (k − 1) times the ratio of
between study variance to the within study variance, given in equation (2.13). In addition,
the above ratio denoted by w is typically 0.33 and rarely exceeds one (Schmidt, 1992).
Therefore, Hedges and Pigott (2001) suggested to use the convention that the values
w =0, 0.33, 0.67 and 1, equivalent to 0%, 25%, 40% and 50% in I2a (refer to Table 4.4),
corresponding to ‘no’, ‘low’, ‘moderate’ and ‘high’ heterogeneity, respectively.
Given the previously mentioned parameters, the odds ratios used to generate the clustered
binary data were selected such that the ratio of between study variance to the within
study variance corresponded to different degrees of heterogeneity and the deviation of the
intervention effect θj from the overall mean effect size were summed up to zero under the
alternative hypothesis (
∑k
j δj = 0). The list of these odds ratios is given in Table 5.3.
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Table 5.3: List of odds ratios to generate clustered binary datasets with odds ratio
ψ = 0.7, 1.0 as the common overall effect size, disease rates rA = (0.04, 0.07, 0.10, 0.13),
rB = (0.35, 0.45, 0.50, 0.55).
k Odds Ratio Disease rates Degree of heterogeneity OR
4 0.7 rA no 0.700 0.700 0.700 0.700
low 0.642 0.681 0.719 0.764
medium 0.617 0.672 0.727 0.795
large 0.599 0.666 0.733 0.819
rB no 0.700 0.700 0.700 0.700
low 0.670 0.690 0.709 0.730
medium 0.657 0.685 0.714 0.745
large 0.648 0.682 0.717 0.756
1.0 rA no 1.000 1.000 1.000 1.000
low 0.922 0.974 1.025 1.084
medium 0.890 0.963 1.036 1.124
large 0.867 0.955 1.044 1.155
rB no 1.000 1.000 1.000 1.000
low 0.958 0.986 1.013 1.043
medium 0.940 0.980 1.019 1.063
large 0.927 0.975 1.024 1.078
For k = 12, 20, 40, the odds ratios are 3-, 5- and 10-fold replicates of the odds ratios
for k = 4.
5.4 Generation of data
Clustered binary data were generated using the method proposed by Lunn and Davies
(1998) with an exchangeable correlation ρ. Thus, for cluster l in intervention group i
of trial j, m observations were generated as Xijkl = (1 − Uijkl)Yijkl + UijklZijkl where
i = 1, 2, j = 1, . . . , S, l = 1, . . . , Nj and k = 1, . . . ,m. Let Yijkl and Zijkl be generated
independently from the binomial distribution B(1, rij) where rij is the baseline disease rate
for intervention group i in trial j. Let Uijkl be generated from the binomial distribution
B(1,
√
ρ). Given that the disease rates r1j for the control group were fixed, the disease
rates r2j for the experimental group were then calculated using the following equation:
r2j = r1j exp (θj)/(1 − r1j + r1j exp θj) to maintain θj = logit(r2j)-logit(r1j), where θj
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denotes the intervention effect taken as a log odds ratio. The number of events for cluster
l in intervention group i of trial j is given by aijl =
∑m
k=1Xijkl. Based on a factorial
design, the selected values for the different parameters summarized in Table 5.2 were
simulated for 576 parameter combinations in total.
There were 1000 randomly generated datasets for each parameter combination. Given
that the standard error is calculated as
√
0.05× (1− 0.05)/1000 (Burton et al., 2006),
the approximate 95% confidence interval for a five percent rejection rate was (0.036, 0.064)
and the approximate 95% confidence interval for coverage probabilities with a 95 percent
nominal level was (93.6, 96.3). Therefore, statistical tests which had Type I error rates
less than 3.6% were overly conservative, and tests which had Type I error rates greater
than 6.4% were overly liberal (e.g. Bradley (1978); Klar and Darlington (2004)). For the
purpose of evaluating confidence interval coverage, coverage above 96.3% suggests that the
results are conservative. In contrast, coverage below 93.6% indicates that the results are
liberal. There are 144 parameter combinations for the case of ‘no’ heterogeneity (w = 0)
and 432 parameter combinations for the case of heterogeneity (w > 0).
5.5 Evaluation criteria
The evaluation measures used to compare the performance of the proposed approaches
include Type I error rate, statistical power, bias, mean square error, confidence interval
coverage, tail errors and interval width. The detailed descriptions for each measure are
provided as follows:
1. The Type I error rate is calculated as the proportion of simulation samples generated
under the null hypothesis which have p-values less than or equal to the nominal 5
percent significance level. Attention is restricted to the 144 parameter combinations
generated at w = 0.
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2. The statistical power is calculated as the proportion of simulation samples generated
under the alternative hypothesis which have p-values less than or equal to the
nominal 5 percent significance level, given that the corresponding test statistic
provides a valid Type I error rate. Attention is restricted to the 432 parameter
combinations generated at w > 0.
3. Bias is calculated as the difference between the average of 1000 estimates and the
true value (i.e. bias = ˆ¯τ
2
c − τ 2c ). The amount of bias considered troublesome varies
from 1
2
SE(τˆ 2c ) and 2SE(τˆ
2
c ).
4. The mean square error (MSE) is calculated as a function of bias and variability,
given by MSE = (ˆ¯τ
2
c − τ 2c )2 + SE(τˆ 2c )2.
5. The coverage of a confidence interval is calculated as the proportion of simulated
confidence intervals including the true estimate. The value for the coverage should
be approximately equal to nominal coverage rate, usually 95 percent, consistent
with a 5 percent Type I error rate.
6. The left and right tail errors are calculated as the proportion of simulated confi-
dence intervals missing the true estimate from the left and right, respectively. The
two-sided left and right tail errors should preferably be approximately 2.5 percent
in each tail with a nominal 95 percent confidence interval.
7. The interval width is calculated as the difference between the upper and lower limit
averaged over 1000 simulated confidence intervals. An interval estimate with less
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width is considered to be more precise.
In the process of calculating the suggested measures from the generated data, we es-
timated the intracluster correlation coefficients using the ANOVA estimator given in
Appendix B. Note that negative estimates of intracluster correlation were truncated at zero.
Furthermore, since the ML and REML heterogeneity variance estimators required iterative
solutions, an initial value was pre-specified and the number of simulations for convergence
was restricted to 20. For each iteration, a negative estimate was truncated at zero. The
convergence criterion adopted from Swallow and Monahan (1984) was given by
|τˆ 2j+1 − τˆ 2j |
1 + τˆ 2j
≤ 0.00001,
where the value 1 was added in the denominator to prevent singularity and to keep the
criterion stringent. When any of the two iterative methods did not reach convergence
within 20 iterations, the remaining heterogeneity estimates were estimated under the
same number of runs.
All of the computer programs for the simulation study were written in SAS V.9.2 and
run on a PC Workstation.
The design of our simulation study is summarized using a flowchart given in Figure 5.1.
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θj ∼ N(θ, σ2j ) (576)
Under Ho Under Ha
Correlated
binary data
Correlated
binary data
τ2c Ha Ra I
2
aQa τ
2
c Ha Ra I
2
aQa
Type I
Error
Bias, MSE,
CI Coverage,
Tail error &
interval width
Power
Bias, MSE,
CI Coverage,
Tail error &
interval width
(144)
(432)
Figure 5.1: Flowchart of the simulation study. Number of parameter combination is noted
in parentheses.
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Chapter 6
Simulation study results
6.1 Introduction
The results of the simulation study described in Chapter 5 are presented and tabulated in
the order of the three study objectives outlined in Section 5.3. In particular, the validity
and power of the adjusted Q statistic are summarized in Section 6.2. The performance
of the adjusted heterogeneity variance estimators in terms of their bias, mean square
error, confidence interval coverage, tail errors and interval width are discussed in Section
6.3. Finally, the performance of the adjusted measures of heterogeneity is summarized in
Section 6.4 using the same criteria as for the adjusted heterogeneity estimators.
6.2 Adjusted Q statistic
6.2.1 Type I error
Estimated type I error rates are given in Tables 6.1 and 6.2. The parameters of interest
include the number of trials k, number of clusters Nj, cluster size m, disease rates for
control group r1j (i.e. rA and rB), intracluster correlation coefficient ρ and odds ratio ψ.
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Each table displays the results for the unadjusted Q statistic, the adjusted Q statistic with
truncated ANOVA-based ρˆ and the adjusted Q statistic omitting truncation for each pa-
rameter combination. Type I error rates outside the desired range (3.6%-6.4%) are in bold.
The results in Table 6.1 and Table 6.2 are similar for all parameter combinations. Fur-
thermore, higher disease rates (rB) had tighter Type I error rates as compared to lower
disease rates (rA), particularly for small values of k.
In Table 6.1, Type I error rates for the unadjusted Q statistic were far greater than
nominal when ρ ≥ 0, with the inflated Type I error rate increasing with ρ. The highest
Type I error rate reached up to 100%.
On the other hand, Type I error rates for the adjusted Q statistic with truncated ANOVA-
based ρˆ consistently maintained the nominal level for almost all parameter combinations,
except at ρ = 0. Type I error rates were less than nominal with an average of 3.0% at
ρ = 0 for both rA and rB.
Type I error rates for the adjusted Q statistic omitting truncation fell into the desired
range 92% of the time.
6.2.2 Power
Empirical power estimated by simulation is displayed in Tables 6.3 to 6.6, where the
power of the unadjusted Q statistic is omitted due to its elevated Type I error rates.
Since a negative value of ρˆ is often set equal to zero in practice, the empirical power of
the adjusted Q statistic with truncated ANOVA-based ρˆ is given, although the deflated
Type I error rates may also be found occasionally when ρ = 0. The additional parameter
of interest aside from ones considered in evaluating Type I error rates is the degree of
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heterogeneity: ‘low’, ‘moderate’ and ‘high’. Each table displays the empirical power of
the adjusted Q statistic computed from data generated using either small disease rates
rA or large disease rates rB as compared to the power calculated using equation (2.11)
(same for both rA and rB) for each degree of heterogeneity.
In general, at ρ = 0, the empirical power for the adjusted Q statistic omitting truncation
was closer to the calculated power than the empirical power for the adjusted Q statistic
with truncated ANOVA-based ρˆ (Type I error rates less than nominal for the latter).
More specifically, the observed difference between them was approximately 7% on average
(Tables 6.5 vs. 6.3; Tables 6.6 vs. 6.4).
The empirical power for ψ = 1.0 was similar to that for ψ = 0.7 (Tables 6.3 vs. 6.4;
Tables 6.5 vs. 6.6). The empirical power generally agrees with the calculated power for all
parameter combinations, particularly for large degrees of heterogeneity. For instance, the
average differences between the calculated power and the empirical power were 2.3%, 2.2%
and 1.2% for ‘low’, ‘moderate’, and ‘high’ heterogeneity at rB, respectively, in Table 6.3.
Also, the empirical power obtained for large disease rates rB was relatively close to the
calculated power as compared to ones obtained for small disease rates rA. For instance,
the average differences between the calculated power and the empirical power at rA were
greater than at rB, given by 3.5%, 3.5% and 3.1% corresponding to ‘low’, ‘moderate’, and
‘high’ heterogeneity, respectively, in Table 6.3.
The power increases as the degree of heterogeneity increases but decreases as the intra-
cluster correlation coefficient increases. Moreover, the increase between the degrees of
heterogeneity becomes smaller as ρ increases. For (Nj,m) = (20, 100) at k ≤ 12, the
increase from ‘low’ to ‘moderate’ was approximately 20% for ρ = 0 as compared to 1%
for ρ = 0.05. The decrease is dramatic for a small increase in ρ, particularly with large
sample size. For (Nj,m) = (20, 100) at k ≤ 40, the calculated power to detect ‘high’
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heterogeneity was 84.2% for ρ = 0 as compared to 14.2% for ρ = 0.05.
The results show that, for a fixed number of subjects, the power is greater for a large
number of small clusters than for a small number of large clusters. For instance, at k = 40
and ρ = 0.01, the calculated power was 84.4% for (Nj,m) = (40, 100) as compared to
60.8% for (Nj,m) = (20, 200) to detect ‘high’ heterogeneity in Table 6.3.
Overall, at ρ = 0, a meta-analysis with at least 12 trials is sufficiently large to detect
‘high’ heterogeneity, while the detection of ‘moderate’ heterogeneity requires a meta-
analysis to have at least 20 trials in order to achieve a desired power of approximately
80%. For ρ = 0.01, a meta-analysis with 40 trials each with (Nj,m) = (40, 100) is
sufficiently large to detect ‘high’ heterogeneity. On the other hand, in Table 6.3, the
higher observed power for ρ = 0.05 was only 28.4% for the largest sample in the simulation.
6.3 Heterogeneity variance estimators
Tables 6.7 through 6.14 show the empirical biases of the eight estimators listed in Table 3.1
at ψ = 0.7 based on 1000 simulations as a function of the parameters of interest described
in Table 5.2, including the number of trials, number of clusters, cluster size, disease
rates for the control group, intracluster correlation coefficient and degree of heterogeneity.
Tables 6.15 through 6.30 present the empirical coverage, tail errors from the left and the
right, and average interval width of the confidence intervals described in Section 3.3. The
tables are tabulated by the degree of heterogeneity and the disease rates for the control
group. The simulation results are not shown for ψ = 1.0, which were fairly similar to that
of ψ = 0.7.
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6.3.1 Convergence issues
Note that the two iterative estimation procedures that calculate ML and REML rarely
required an excessive number of iterations in this simulation study. With large k, the
two iterative procedures converged within 20 iterations for all parameter combinations,
suggesting all 1000 replicates were used. However, for k = 4, the small numbers of
replicates was mostly found at ρ = 0.05, roughly in the range 969 to 975. The empirical
properties of the estimators were calculated on the basis of the actual number of replicates
for each parameter combination, instead of the intended number of replicates (i.e. 1000).
6.3.2 Comparing bias and mean square error
The magnitude of the bias is relatively large for small control group disease rates (i.e.
rA) in Tables 6.7 to 6.10 as compared to large control group disease rates (i.e. rB) in
Tables 6.11 to 6.14, particularly when ρ is large. It is noted that at ρ = 0.05, the bias
was approximately in the range of 0.05 to 0.07 for rA in Table 6.10 as compared to 0.01
to 0.02 for rB in Table 6.14.
An increase in the magnitude of the bias was observed with an increase in ρ, particularly for
large k and large degrees of heterogeneity. For instance, for (Nj,m) = (20, 100) at ρ = 0.05,
the bias was roughly -0.014 at k = 4 as compared to -0.020 at k = 40 for rB in Table
6.14. Similarly, for the same number of trials (i.e. k = 40), the bias was roughly 0.002 for
‘no’ heterogeneity in Table 6.11 as compared to -0.020 for ‘high’ heterogeneity in Table 6.14.
For a fixed number of subjects, the bias was considerately reduced for a large number of
small clusters (i.e, (Nj,m) = (40, 100)) as compared to a small number of large clusters
(i.e, (Nj,m) = (20, 200)). In particular, at k = 4 and ρ = 0.05, the bias of all the esti-
mators was reduced to approximately half from (Nj,m) = (20, 200) to (Nj,m) = (40, 100).
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Tables 6.7 to 6.14 show that the DLVC estimator had the largest average magnitude of
bias for ‘no’ and ‘low’ heterogeneity but had the smallest average magnitude of bias for
‘moderate’ and ‘high’ heterogeneity. For the remaining estimators, the magnitudes of
the bias were very similar. In particular, when there is ‘no’ heterogeneity, they tend to
overestimate the true τ 2c with positive average biases. Otherwise, when heterogeneity is
present, they underestimate the true τ 2c with negative average biases.
More specifically, it appears that the two-step estimator DL2 with the DL estimator as
the initial weights gave relatively similar bias as compared to the DL estimator for all
parameter combinations. On the other hand, another two-step estimator DLVC with
the VC estimator as the initial weights had a large magnitude of bias for ‘no’ and ‘low’
heterogeneity but small bias for ‘moderate’ and ‘high’ heterogeneity as compared to the
DL estimator, particularly for large ρ.
The VC and MVVC estimators were compared since they both use the VC estimator
in their calculation. The MVVC estimator tends to have a slightly larger magnitude of
bias as compared to the VC estimator for all parameter combinations. For instance, the
largest difference between the average biases for VC and MVVC calculated from Table 6.9
was approximately 0.002 where bias(V C) = −0.0108 and bias(MV V C) = −0.0128. As
expected, the MVVC estimator, an improved MV estimator, clearly outperforms the MV
estimator. The average bias for MVVC calculated from Table 6.7 was 0.0034 as compared
to 0.0056 for MV.
The magnitude of the bias for the intensive iterative estimators ML and REML decreases
as k increases, with k/(k − 1) the only factor distinguishing these two estimators. For
small k, it is noted that the ML estimator has a relatively small bias as compared to the
REML estimator when there is ‘no’ heterogeneity, but has a relatively large negative bias
as compared to the REML estimator when the degree of heterogeneity is ‘low’ to ‘high’.
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However, there was a small difference approximately of 0.001.
The mean square errors of the all estimators (not shown) were approximately zero to three
decimal places for most parameter combinations, except for large ρ. In this case, the MV
estimator resulted in a large MSE as compared to the other estimators. As for a fixed
sample size, the mean square errors were smaller for a large number of small clusters (i.e.
(Nj,m) = (40, 100)) than for a small number of large clusters (i.e. (Nj,m) = (20, 200)).
6.3.3 Confidence interval approaches
Empirical coverage (α = 0.05), tail errors from the left and the right, and average interval
widths for the Q profile (QP), Biggerstaff-Tweedie (BT), Sidik-Jonkman (SJ), nonpara-
metric bootstraps (NB), the ML and REML profile likelihood (pML and pRE) and the
ML and REML Wald-Type (wML and wRE) confidence intervals are presented in Tables
6.15 to 6.30 as a function of the parameters of interest listed in Table 5.2. The tables
again differ by the degrees of heterogeneity with four levels: ‘no’, ‘low’, ‘moderate’ and
‘high’ and the disease rates for the control group (i.e. rA and rB).
Empirical coverage
Overall, the Q profile confidence interval approach yielded the empirical coverage most
close to normal as compared to the other confidence interval approaches. Specifically, the
empirical coverage of the Q profile confidence interval approach fell within the desired
range (93.6% to 96.4%) for almost all parameter combinations for ‘low’ to ‘high’ hetero-
geneity with relatively small k. For ‘no’ heterogeneity, the empirical coverage was slightly
above the nominal; otherwise, the empirical coverage was generally below the nominal.
The Biggerstaff-Tweedie confidence interval approach appears to have coverage similar to
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the Q profile confidence interval approach when there is ‘no’ heterogeneity. The Biggerstaff-
Tweedie confidence interval approach shows consistently high coverage throughout at
almost all parameter combinations. However, the empirical coverage begins to drop below
nominal when the heterogeneity is ‘moderate’ at k = 40.
The Sidik-Jonkman confidence interval approach yielded unacceptably low empirical
coverage throughout all of the parameter combinations, showing slightly improvement as
the degree of heterogeneity increases. The highest empirical coverage was 75%.
The empirical coverage of the bootstraps confidence interval approach was unacceptably
high for ‘no’ heterogeneity and unacceptably low for ‘low’ to ‘high’ heterogeneity. For
the latter, the coverage approaches nominal as the number of trials increases. However,
the empirical coverage occasionally reached the desired range for large k at ρ = 0 for
‘moderate’ to ‘high’ heterogeneity.
The ML and REML profile likelihood confidence interval approaches begin to show rea-
sonable coverage for large degrees of heterogeneity, relatively large k and small ρ. In
addition, the large disease rates (i.e. rB) tend to lead to relatively better performance
as compared to the small disease rates (i.e. rA). Otherwise, the empirical coverage is
consistently higher than nominal.
The ML and REML Wald-type confidence interval approaches generally show poor empir-
ical coverage, either too high or too low.
Tail errors
The imbalance is observed with the Q profile confidence interval approach, which misses
the true parameter value more frequently on the left than on the right. On the other
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hand, the ML and REML profile likelihood confidence interval approach generally misses
the true parameter value more frequently on the right than on the left. Since the other
approaches do not have valid empirical coverage results, there is no need to compare their
tail errors.
Interval width
The Q profile and Biggerstaff-Tweedie approaches have relatively higher average inter-
val widths, while the bootstraps approach has relatively small average interval width.
Moreover, it is clearly seen that the approaches all demonstrate an increase in average
interval width as ρ increases. Overall, an increase in the number of trials or the degree of
heterogeneity reduces the average interval width.
6.4 Measures of heterogeneity
Tables 6.31 through Table 6.38, limited to ψ = 0.7 (with similar results for ψ = 1.0),
show the empirical biases and mean square errors corresponding the true Ha, Ra and I
2
a
statistics based on 1000 simulations as a function of the parameters of interest described in
Table 5.2. Tables 6.39 through Table 6.46 present the empirical coverage, tail errors from
the left and the right, and average interval width of the confidence interval approaches
described in Section 4.3. The tables are again tabulated by the degree of heterogeneity
and the disease rates for the control group.
6.4.1 Bias and mean square error
In Tables 6.31 to 6.38, the bias and MSE for small disease rates (i.e. rA) tend to be similar
to those for large disease rates (i.e. rB) for all parameter combinations. An increase in the
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number of trials or the degree of heterogeneity results in a great reduction in bias and MSE
of the three statistics. Moreover, it is noted that the bias and MSE tend to be relatively
small when ρ = 0 as compared to ρ ≥ 0. More specifically, among the three statistics, the
I2a statistic has the highest bias and MSE for almost all of parameter combinations, except
for k = 4. A bias above 0.15 observed mainly at k = 4 may be a concern. For instance,
‘no’ heterogeneity (Ha = 1.1) may be interpreted as ‘low’ heterogeneity (Ha = 1.25) with
a bias of 0.15.
6.4.2 Confidence interval approaches
The empirical coverage (α = 0.05), tail errors from the left and the right, and average
interval widths for the confidence intervals based on the MOVER, the Q distribution, the
test-based method, τ 2c , and the nonparametric bootstrap are presented in Tables 6.39 to
Table 6.46 as a function of the parameters listed in Table 5.2. It is noted that the results
for the confidence interval based on τ 2c were not shown for they were similar to ones for
the MOVER.
Empirical coverage
The empirical coverage of the MOVER generally falls within the desired range (93.6%-
96.4%) for ‘low’ to ‘high’ heterogeneity with small meta-analyses of large trials. When
there is ‘no’ heterogeneity, the empirical coverage tends to be slightly above the nominal
(approximately 97%-98%). Overall, the empirical coverage results are similar to those of
the Q profile confidence interval approach, which is used for constructing the MOVER.
Consequently, the confidence interval based on τ 2c tends to have identical coverage results
as compared to the MOVER since it also uses the Q profile confidence intervals to
construct the confidence limits for τ 2c .
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The confidence interval based on the Q distribution has coverage rates falling within the
desired range for most of the parameter combinations with ‘no’ heterogeneity. For ‘low’
heterogeneity, the coverage was also reasonable with small k. Otherwise, the empirical
coverage is usually below nominal.
The empirical coverage of the test-based confidence interval falls within the desired range
78% of the time for ‘no’ to ‘low’ heterogeneity at large control disease rates rB with small
k (Tables 6.43-6.44). Otherwise, the empirical coverage was either above the nominal for
‘no’ heterogeneity or below the nominal for ‘low’ to ‘high’ heterogeneity.
The bootstraps confidence interval for Ha generally performed poorly. The empirical
coverage was close to 100% when there is ‘no’ heterogeneity but unacceptably small when
the degree of heterogeneity is ‘low’ to ‘high’. However, few reasonable empirical coverage
levels were observed for k = 40, ρ = 0.05, and ‘high’ heterogeneity at small disease rates
rA (Table 6.42).
Tail errors
The MOVER resulted in unbalanced tail errors with the empirical coverage falling within
the desired range. For ρ = 0, the confidence intervals miss from the left more often than
from the right. On the contrary, the confidence intervals miss from the right more of-
ten than from the left for ρ 6= 0. Similar results apply to the confidence interval based on τ 2c .
The skewness of the Q distribution, which follows the chi square distribution, depends
on the degrees of freedom, with the distribution becoming less skewed as the degrees of
freedom increase, where the distribution is more likely skewed to the right. Consequently,
the confidence intervals miss less than 2.5% from the left and more than 2.5% from the
right as the number of trials or the degree of heterogeneity increases. The degree of
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imbalance in the tail errors tends to be reduced as the number of trials increases, as we
have observed for k = 40. However, it is noted that when the number of trials is large,
the confidence intervals tend to have more misses on the left then on the right at ρ = 0.
Interval width
The MOVER has the highest average interval width as compared to the confidence interval
based on the Q distribution and the test-based confidence interval, particularly at small k.
All the confidence interval approaches show a great improvement in the average interval
width as the number of trials increase. In general, the average interval widths were fairly
similar at the different values of ρ.
6.5 Discussion
In summary, the inflated Type I error rates of the unadjusted Q statistic may be explained
by the inflated estimates of the within study variances that results from clustered data.
However, after adjusting for the clustering, the adjusted Q statistic consistently main-
tained Type I error rates at nominal. It is noted that the truncation at zero in estimating
ρ may reduce the estimated within study variances (Murray et al., 1998). As a result, the
adjusted Q statistic with the truncated ρˆ tends to have Type I error rates below nominal
at ρ = 0. The comparisons between the unadjusted and adjusted Q statistic in terms of
Type I error clearly shows that the validity of the unadjusted Q statistic is in question for
clustered data without properly adjusting for clustering (Darlington and Donner, 2007;
Song, 2004).
The calculated power is fairly accurate as compared to the empirical power across all
parameter combinations investigated. It depends on number of trials, number of clusters,
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cluster size, intracluster correlation coefficient and degree of odds ratio heterogeneity
across trials but is not affected by the disease rates for the control group. An increase in
power is obtained by increasing the number of trials, number of clusters, cluster size and
degree of odds ratio heterogeneity across trials. However, the power decreases dramatically
for a small increase in intracluster correlation coefficient. Also, for a fixed sample size,
the power is greater for a large number of small clusters than for a small number of large
clusters.
In summary, when there is ‘no’ heterogeneity, the ML estimator tends to outperform the
other estimators in terms of bias, especially for large ρ. On the other hand, when the
heterogeneity is ‘low’ to ‘high’, the REML estimator appears to be the best estimator
even for small k and large ρ. As for other simpler estimators including DL, VC, MV,
MVVC, DLVC and DL2 estimators, the MVVC estimator may be recommended for small
k but the DLVC may be recommended for large k.
The mean square errors are very close to zero, which may be due to the enforcement of the
non-negativity that results in reducing the variances sufficiently to offset the squared bias.
A similar explanation applies in the comparison of estimators for variance components
(Swallow and Monahan, 1984). Therefore, it also implies that the bias may be more
informative as compared to the mean square errors for assessing variance estimators, an
argument given by Casella and Berger (2002, p.305).
The Q profile confidence interval may be recommended for ‘low’ to ‘high’ heterogeneity
for small meta-analyses with large trials. However, for a large number of trials and a
large degree of heterogeneity, the ML and REML profile likelihood confidence interval
approaches slightly perform better.
Overall, the three statistics generally show similar simulation results. However, it is noted
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that caution must be taken for a small number of trials, where a relatively large bias may
lead to misleading interpretation.
As expected, the MOVER and the confidence interval based on τ 2c have the similar
performance as compared to the Q profile confidence interval for τ 2c , which is used to
construct the confidence interval (Schuster and Metzger, 2010, CH 11). They should be
again used for ‘low’ to ‘high’ heterogeneity with small meta-analyses with large trials.
However, the confidence interval based on the Q distribution generally perform well for
‘no’ to ‘low’ heterogeneity. Although the test-based confidence interval is widely applied
due to its simplicity, the coverage for the test-based confidence interval were generally
inadequate for large heterogeneity according to the simulation results.
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Table 6.1: Type I error (%) of Q statistic (U: unadjusted; A: adjusted): based on 1000
simulations of k trials each with Nj clusters per group of size m, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13}, rB = {0.35, 0.40, 0.45, 0.50}, intracluster correlation ρ
and odds ratio ψ = 0.7.
rA rB
k/Nj/m ρ U A
1 A U A 1 A
4 / 20 / 100 0 4.3 3.3 5.1 4.5 3.3 4.6
0.01 25.9 4.6 4.8 28.6 5.6 5.6
0.05 71.3 3.6 3.6 71.6 6.1 6.1
4 / 20 / 200 0 3.7 2.9 4.5 5.3 4.1 5.5
0.01 44.7 4.2 4.3 47.8 5.0 5.0
0.05 82.7 4.5 4.5 87.6 6.2 6.2
4 / 40 / 100 0 5.0 4.4 5.4 4.6 3.9 5.0
0.01 24.0 5.3 5.3 28.1 5.5 5.5
0.05 71.8 4.4 4.4 71.8 5.5 5.5
12 / 20 / 100 0 4.3 3.2 6.2 4.8 2.6 4.7
0.01 52.7 4.5 4.8 53.7 5.8 5.8
0.05 98.8 2.7 2.9 98.5 5.1 5.1
12 / 20 / 200 0 4.8 3.0 4.9 3.2 1.8 3.6
0.01 81.1 4.4 4.4 82.9 6.2 6.2
0.05 99.9 4.1 4.1 99.9 4.8 4.8
12 / 40 / 100 0 5.4 3.6 5.3 5.6 4.1 5.6
0.01 52.9 4.3 4.4 54.4 5.6 5.6
0.05 98.4 4.9 4.9 98.2 5.1 5.1
20 / 20 / 100 0 4.2 2.2 5.3 5.2 2.8 6.1
0.01 67.4 3.9 4.1 72.3 6.9 6.9
0.05 100 3.0 3.0 99.9 5.2 5.2
20 / 20 / 200 0 6.3 2.8 5.9 5.9 3.4 6.5
0.01 93.4 4.5 4.6 95.3 5.0 5.0
0.05 100 4.5 4.5 100 4.2 4.2
20 / 40 / 100 0 4.9 2.6 5.1 6.1 4.0 6.3
0.01 69.7 4.9 4.9 72.6 4.6 4.6
0.05 99.8 4.5 4.5 100 5.8 5.8
40 / 20 / 100 0 3.9 1.8 4.7 4.5 2.2 5.4
0.01 91.4 3.7 4.1 91.9 5.4 5.4
0.05 100 3.1 3.1 100 6.6 6.6
40 / 20 / 200 0 5.0 1.8 5.0 4.4 2.2 5.2
0.01 99.7 4.4 4.7 99.8 5.3 5.3
0.05 100 3.5 3.5 100 5.0 5.0
40 / 40 / 100 0 5.8 3.5 6.1 5.0 2.6 5.1
0.01 91.4 4.5 4.5 92.2 4.7 4.7
0.05 100 4.0 4.0 100 4.9 4.9
1 Negative values of ˆ ρj set to zero.
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Table 6.2: Type I error (%) of Q statistic (U: unadjusted; A: adjusted): based on 1000
simulations of k trials each with Nj clusters per group of size m, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13}, rB = {0.35, 0.40, 0.45, 0.50}, intracluster correlation ρ
and odds ratio ψ = 1.0.
rA rB
k/Nj/m ρ U A A
1 U A A 1
4/20/100 0 5.6 4.4 6.7 4.2 3.2 4.8
0.01 25.3 5.3 5.6 25.4 5.6 5.6
0.05 70.2 4.1 4.1 72.9 5.4 5.4
4/20/200 0 4.6 3.0 5.1 5.3 4.2 5.8
0.01 48.0 5.1 5.1 46.5 4.5 4.5
0.05 86.4 4.8 4.8 87.9 4.3 4.3
4/40/100 0 5.1 4.1 5.4 5.4 4.4 5.7
0.01 27.2 5.0 5.1 26.4 4.5 4.5
0.05 71.4 4.2 4.2 73.3 5.5 5.5
12/20/100 0 4.0 2.8 4.5 6.4 3.4 6.5
0.01 51.0 3.1 3.1 54.6 4.3 4.3
0.05 98.1 4.4 4.4 98.3 4.4 4.4
12/20/200 0 4.6 3.6 5.5 4.8 3.2 5.5
0.01 81.8 4.5 4.6 82.2 5.4 5.4
0.05 99.9 3.4 3.4 100 6.1 6.1
12/40/100 0 4.6 3.7 4.7 4.5 3.5 5.0
0.01 52.2 4.9 4.9 53.3 4.6 4.6
0.05 98.4 4.4 4.4 98.5 6.0 6.0
20/20/100 0 3.2 1.6 3.9 5.3 2.4 5.1
0.01 67.5 5.2 5.3 71.6 5.4 5.4
0.05 100 4.5 4.6 100 5.9 5.9
20/20/200 0 5.3 3.0 5.7 5.9 2.5 5.9
0.01 95.6 4.4 4.5 95.4 5.8 5.8
0.05 100 4.2 4.2 100 4.9 4.9
20/40/100 0 4.7 2.8 4.9 5.0 2.6 5.9
0.01 71.6 4.6 4.6 70.1 4.3 4.3
0.05 100 4.1 4.1 100 4.5 4.5
40/20/100 0 5.4 1.7 6.0 6.9 3.1 7.3
0.01 90.7 4.1 4.3 92.0 5.1 5.1
0.05 100 4.4 4.4 100 4.5 4.5
40/20/200 0 5.8 2.5 5.6 4.5 1.2 4.6
0.01 99.9 3.7 3.8 99.7 5.4 5.4
0.05 100 4.0 4.1 100 6.2 6.2
40/40/100 0 5.1 2.3 5.2 5.9 2.8 5.7
0.01 91.6 5.3 5.4 93.8 4.1 4.1
0.05 100 3.5 3.5 100 5.3 5.3
1 negative value of ˆ ρj was set equal to zero.
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Table 6.3: Power (%) of adjusted Q statistic for odds ratio ψ = 0.7 with truncated
intracluster correlation ρ based on 1000 simulations of k trials each with Nj clusters
per group of size m, control group disease rates rA = {0.04, 0.07, 0.10, 0.13}, rB =
{0.35, 0.40, 0.45, 0.50}.
Degree of heterogeneity
Low Mo derate High
k/Nj/m ρ power
1 rA rB power
1 rA rB power
1 rA rB
4/20/100 0 11.2 7.1 8.4 18.9 15.1 17.8 27.1 21.9 24.6
0.01 7.9 8.2 10.4 11.5 10.4 13.3 15.2 13.2 17.5
0.05 5.9 5.8 5.9 7.0 5.1 7.2 8.1 6.0 8.5
4/20/200 0 18.3 15.2 14.6 35.3 29.2 32.7 51.1 43.6 47.0
0.01 9.0 9.9 10.0 13.9 11.2 14.6 19.0 18.9 20.6
0.05 6.0 4.8 6.7 7.2 6.3 8.0 8.4 5.8 7.2
4/40/100 0 18.3 16.1 16.4 35.3 30.8 31.2 51.1 48.2 48.8
0.01 11.2 10.3 11.5 19.0 17.8 19.9 27.2 28.8 26.0
0.05 6.9 6.4 7.1 9.2 8.9 10.3 11.5 11.0 10.8
12/20/100 0 15.1 10.2 8.9 30.3 22.3 22.7 46.3 35.3 40.5
0.01 9.5 7.3 11.1 15.7 14.9 14.7 22.8 23.4 23.5
0.05 6.4 4.7 7.0 8.0 6.3 6.6 9.7 7.1 11.9
12/20/200 0 29.0 24.7 21.9 61.0 52.2 52.0 82.6 74.1 77.2
0.01 11.2 11.2 10.8 20.3 19.9 20.3 30.5 28.5 33.7
0.05 6.5 4.6 7.6 8.3 5.8 7.7 10.2 8.7 9.3
12/40/100 0 29.0 21.2 24.5 61.0 53.5 55.3 82.6 78.3 76.9
0.01 15.2 15.4 15.1 30.5 29.2 30.7 46.6 47.7 48.7
0.05 7.9 6.5 7.0 11.6 10.5 14.4 15.8 14.7 17.0
20/20/100 0 18.7 10.9 10.3 40.4 31.3 29.0 61.4 48.9 49.9
0.01 10.8 11.3 11.9 19.6 17.9 18.7 29.8 28.8 29.6
0.05 6.7 4.0 7.8 8.8 6.8 8.2 11.2 8.0 10.6
20/20/200 0 38.6 25.2 28.3 77.6 71.1 68.9 94.5 90.5 91.2
0.01 13.2 11.3 13.6 26.1 27.4 27.7 40.6 39.5 39.7
0.05 6.8 5.5 7.3 9.2 7.6 9.8 11.8 8.9 13.9
20/40/100 0 38.6 31.0 33.1 77.6 72.0 70.7 94.5 90.8 91.7
0.01 18.8 20.0 19.4 40.6 40.5 42.4 61.7 62.9 60.7
0.05 8.6 7.1 8.9 13.7 11.4 14.6 19.7 18.2 21.8
40/20/100 0 26.7 13.6 15.9 60.5 40.4 44.4 84.2 68.3 72.3
0.01 13.7 12.0 14.1 28.2 25.6 27.6 44.8 41.3 44.1
0.05 7.3 5.5 7.4 10.5 7.0 12.3 14.2 9.3 15.8
40/20/200 0 58.0 41.6 40.3 95.1 88.0 90.4 99.8 99.0 99.1
0.01 17.6 15.9 17.4 39.0 36.5 33.3 60.8 60.9 62.8
0.05 7.6 7.3 7.9 11.1 8.7 11.3 15.3 10.7 16.8
40/40/100 0 58.0 43.4 44.3 95.1 92.1 92.8 99.8 99.4 99.9
0.01 26.9 25.0 27.3 60.8 59.7 59.7 84.4 84.7 84.3
0.05 10.3 6.2 11.3 18.4 15.4 19.1 28.3 25.5 28.4
1 Power is computed using equation (2.11).
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Table 6.4: Power (%) of adjusted Q statistic for odds ratio ψ = 1.0 with truncated
intracluster correlation ρ based on 1000 simulations of k trials each with Nj clusters
per group of size m, control group disease rates rA = {0.04, 0.07, 0.10, 0.13}, rB =
{0.35, 0.40, 0.45, 0.50}.
Degree of heterogeneity
Low Mo derate High
k/Nj/m ρ power
1 rA rB power
1 rA rB power
1 rA rB
4/20/100 0 11.2 9.5 7.9 18.9 12.8 14.1 27.1 26.7 25.7
0.01 7.9 8.6 6.7 11.5 10.6 11.8 15.2 15.2 17.9
0.05 5.9 5.1 6.5 7.0 6.0 7.3 8.1 8.5 8.1
4/20/200 0 18.3 15.6 16.1 35.2 29.3 27.7 51.1 44.9 49.4
0.01 9.0 8.2 8.3 13.9 14.1 15.4 19.0 20.1 21.1
0.05 6.0 4.9 5.6 7.2 6.7 8.5 8.4 8.6 9.8
4/40/100 0 18.3 17.6 17.7 35.2 31.3 31.9 51.1 47.9 48.9
0.01 11.2 12.2 10.7 19.0 19.8 20.7 27.2 28.7 27.6
0.05 6.9 6.6 7.3 9.2 8.9 8.6 11.5 11.9 12.1
12/20/100 0 15.1 10.2 10.1 30.3 21.8 23.1 46.4 37.0 37.6
0.01 9.5 9.3 8.6 15.7 16.5 17.1 22.8 21.2 21.4
0.05 6.4 4.7 5.6 8.0 7.1 8.3 9.7 8.4 9.6
12/20/200 0 29.1 22.1 20.9 60.9 51.9 52.6 82.6 76.7 74.7
0.01 11.3 10.3 12.4 20.3 20.3 20.4 30.5 31.4 29.1
0.05 6.5 4.2 6.9 8.3 5.8 8.8 10.2 8.4 11.2
12/40/100 0 29.1 24.5 25.5 60.9 52.2 52.0 82.6 78.7 78.7
0.01 15.2 15.2 15.7 30.4 31.4 29.4 46.6 46.4 48.3
0.05 7.9 7.1 7.4 11.6 8.4 12.6 15.8 14.7 14.5
20/20/100 0 18.7 9.3 11.8 40.3 29.4 29.6 61.4 52.2 49.3
0.01 10.8 10.4 10.7 19.5 18.5 19.5 29.8 28.6 28.3
0.05 6.7 5.7 6.5 8.8 6.1 8.0 11.2 9.6 9.0
20/20/200 0 38.7 29.1 26.3 77.5 66.0 69.2 94.5 90.2 90.9
0.01 13.3 13.7 14.3 26.1 26.1 27.3 40.7 38.5 39.3
0.05 6.8 6.2 6.8 9.2 6.4 9.4 11.8 9.0 13.7
20/40/100 0 38.7 28.8 31.6 77.5 68.3 71.5 94.5 91.5 91.2
0.01 18.8 19.5 21.4 40.5 40.9 40.8 61.7 63.3 60.0
0.05 8.6 7.1 8.2 13.7 10.8 13.9 19.7 18.7 18.8
40/20/100 0 26.8 14.5 14.1 60.3 44.5 45.3 84.2 73.7 74.3
0.01 13.7 12.0 14.1 28.1 26.7 30.0 44.8 41.0 46.1
0.05 7.4 5.6 9.4 10.5 7.5 10.8 14.2 12.3 16.3
40/20/200 0 58.1 41.3 43.0 95.0 89.6 91.0 99.8 98.9 99.7
0.01 17.6 16.5 17.3 38.9 38.6 39.2 60.8 59.7 59.8
0.05 7.6 6.1 7.4 11.1 8.2 10.9 15.3 14.6 15.6
40/40/100 0 58.1 49.5 44.8 95.0 91.4 91.8 99.8 99.2 99.3
0.01 26.9 29.7 26.7 60.6 62.1 61.4 84.4 83.4 83.2
0.05 10.3 9.3 9.7 18.4 17.1 15.6 28.3 27.0 27.1
1 Power is computed using equation (2.11).
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Table 6.5: Power (%) of adjusted Q statistic for odds ratio ψ = 0.7 omitting truncation
of intracluster correlation ρ based on 1000 simulations of k trials each with Nj clusters
per group of size m, control group disease rates rA = {0.04, 0.07, 0.10, 0.13}, rB =
{0.35, 0.40, 0.45, 0.50}.
Degree of heterogeneity
Low Mo derate High
k/Nj/m ρ power
1 rA rB power
1 rA rB power
1 rA rB
4/20/100 0 11.2 14.1 12.0 18.9 17.0 19.0 27.1 27.8 28.1
0.01 7.9 7.2 8.9 11.5 9.9 11.9 15.2 14.6 14.9
0.05 5.9 4.3 7.1 7.0 4.5 6.5 8.1 5.9 7.6
4/20/200 0 18.3 17.5 16.9 35.3 33.6 36.0 51.1 50.4 51.6
0.01 9.0 7.7 9.7 13.9 15.0 15.3 19.0 20.6 18.7
0.05 6.0 4.4 6.7 7.2 5.2 7.4 8.4 7.6 7.4
4/40/100 0 18.3 16.4 19.5 35.3 35.4 34.6 51.1 51.7 49.8
0.01 11.2 11.0 11.0 19.0 16.6 18.3 27.2 26.1 27.8
0.05 6.9 7.4 6.4 9.2 7.8 8.8 11.5 11.1 12.5
12/20/100 0 15.1 13.6 15.3 30.3 29.5 30.4 46.3 46.7 43.9
0.01 9.5 10.4 11.6 15.7 13.4 16.2 22.8 21.9 26.8
0.05 6.4 4.7 5.5 8.0 5.2 7.4 9.7 7.7 9.7
12/20/200 0 29.0 29.6 30.4 61.0 62.2 61.7 82.6 84.2 81.4
0.01 11.2 10.3 9.8 20.3 19.2 19.6 30.5 29.8 29.4
0.05 6.5 4.0 7.6 8.3 7.5 8.7 10.2 8.4 11.0
12/40/100 0 29.0 26.5 28.0 61.0 63.2 58.1 82.6 82.2 82.3
0.01 15.2 17.1 16.3 30.5 31.2 30.2 46.6 47.0 46.9
0.05 7.9 7.4 9.1 11.6 11.6 10.4 15.8 13.0 16.9
20/20/100 0 18.7 17.6 20.7 40.4 39.6 41.4 61.4 61.2 60.4
0.01 10.8 10.1 12.3 19.6 18.3 21.0 29.8 29.4 27.0
0.05 6.7 3.7 7.2 8.8 5.4 8.7 11.2 9.3 10.9
20/20/200 0 38.6 38.0 38.7 77.6 78.6 76.1 94.5 95.0 94.5
0.01 13.2 13.0 13.3 26.1 24.9 27.9 40.6 40.8 41.9
0.05 6.8 5.2 5.8 9.2 6.5 11.4 11.8 9.1 11.8
20/40/100 0 38.6 37.6 37.7 77.6 79.4 78.4 94.5 94.9 94.5
0.01 18.8 16.3 17.5 40.6 37.4 41.1 61.7 63.2 62.3
0.05 8.6 7.0 8.3 13.7 11.8 15.7 19.7 17.0 19.5
40/20/100 0 26.7 23.8 27.5 60.5 59.8 61.9 84.2 83.4 84.2
0.01 13.7 10.9 12.3 28.2 26.0 29.1 44.8 42.3 45.2
0.05 7.3 3.9 7.8 10.5 6.8 9.8 14.2 10.8 14.0
40/20/200 0 58.0 59.5 60.0 95.1 95.7 96.5 99.8 99.8 99.9
0.01 17.6 16.0 17.6 39.0 37.0 39.8 60.8 60.2 59.9
0.05 7.6 5.1 6.8 11.1 9.9 12.7 15.3 11.9 17.0
40/40/100 0 58.0 57.3 59.4 95.1 93.1 95.4 99.8 99.8 100.0
0.01 26.9 26.0 26.3 60.8 57.5 64.5 84.4 84.7 84.0
0.05 10.3 9.5 9.4 18.4 14.5 17.8 28.3 24.8 30.0
1 Power is computed using equation (2.11).
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Table 6.6: Power (%) of adjusted Q statistic for odds ratio ψ = 1.0 omitting truncation
of intracluster correlation ρ based on 1000 simulations of k trials each with Nj clusters
per group of size m, control group disease rates rA = {0.04, 0.07, 0.10, 0.13}, rB =
{0.35, 0.40, 0.45, 0.50}.
Degree of heterogeneity
Low Mo derate High
k/Nj/m ρ power
1 rA rB power
1 rA rB power
1 rA rB
4/20/100 0 11.2 10.3 13.0 18.9 17.4 17.7 27.1 26.1 26.4
0.01 7.9 7.9 10.4 11.5 12.5 12.0 15.2 13.4 15.4
0.05 5.9 4.8 6.2 7.0 5.5 7.5 8.1 8.1 8.3
4/20/200 0 18.3 19.0 20.0 35.2 36.5 34.8 51.1 49.0 51.3
0.01 9.0 10.0 11.2 13.9 14.3 13.0 19.0 21.2 19.6
0.05 6.0 5.3 7.5 7.2 7.5 6.9 8.4 8.3 9.4
4/40/100 0 18.3 15.9 19.6 35.2 35.5 34.1 51.1 54.6 52.4
0.01 11.2 9.9 10.1 19.0 19.9 21.5 27.2 30.7 29.2
0.05 6.9 6.6 7.0 9.2 9.0 9.7 11.5 13.6 12.2
12/20/100 0 15.1 14.4 16.7 30.3 29.4 30.9 46.4 48.2 44.6
0.01 9.5 10.1 10.4 15.7 17.5 17.3 22.8 22.1 22.6
0.05 6.4 5.0 6.1 8.0 6.6 8.4 9.7 8.0 10.3
12/20/200 0 29.1 30.5 28.4 60.9 64.1 62.5 82.6 83.2 83.8
0.01 11.3 11.9 11.5 20.3 21.8 20.9 30.5 29.4 29.9
0.05 6.5 4.9 6.3 8.3 8.2 9.6 10.2 8.1 11.4
12/40/100 0 29.1 29.1 28.9 60.9 60.1 62.9 82.6 82.6 82.2
0.01 15.2 15.5 14.9 30.4 27.0 30.1 46.6 47.4 46.0
0.05 7.9 6.2 6.9 11.6 10.1 13.2 15.8 15.8 13.7
20/20/100 0 18.7 19.6 18.0 40.3 43.3 38.8 61.4 58.2 62.8
0.01 10.8 11.7 11.4 19.5 19.7 20.4 29.8 29.2 30.5
0.05 6.7 6.5 7.0 8.8 6.2 10.8 11.2 9.3 11.7
20/20/200 0 38.7 37.6 43.6 77.5 78.5 77.4 94.5 93.7 94.1
0.01 13.3 13.9 14.7 26.1 28.3 25.1 40.7 42.8 41.3
0.05 6.8 6.2 7.3 9.2 7.9 10.0 11.8 11.3 14.2
20/40/100 0 38.7 38.4 39.3 77.5 73.8 76.6 94.5 94.8 93.7
0.01 18.8 19.3 18.1 40.5 42.2 41.7 61.7 60.5 60.1
0.05 8.6 7.3 8.6 13.7 12.5 14.8 19.7 19.0 17.9
40/20/100 0 26.8 26.5 28.4 60.3 58.4 62.3 84.2 83.8 84.2
0.01 13.7 12.5 13.8 28.1 28.8 29.5 44.8 44.9 43.7
0.05 7.4 5.0 6.4 10.5 8.9 10.7 14.2 11.2 13.8
40/20/200 0 58.1 57.8 59.9 95.0 94.9 95.4 99.8 99.7 99.7
0.01 17.6 18.3 17.3 38.9 39.5 38.4 60.8 60.8 62.1
0.05 7.6 6.0 8.9 11.1 9.3 11.7 15.3 14.3 15.2
40/40/100 0 58.1 56.8 58.5 95.0 95.2 94.0 99.8 99.6 99.8
0.01 26.9 26.8 25.5 60.6 61.5 60.2 84.4 86.0 82.6
0.05 10.3 9.3 10.4 18.4 17.1 19.6 28.3 26.5 30.0
1 Power is computed using equation (2.11).
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Table 6.7: Bias for τ 2c with ‘no’ heterogeneity and control group disease rates rA =
{0.04, 0.07, 0.10, 0.13} based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.005 0.004 0.008 0.005 0.002 0.004 0.005 0.004
0.01 0.010 0.009 0.017 0.010 0.004 0.009 0.010 0.009
0.05 0.028 0.028 0.049 0.028 0.013 0.028 0.029 0.027
4/20/200 0 0.002 0.002 0.004 0.002 0.001 0.002 0.002 0.002
0.01 0.008 0.007 0.013 0.008 0.003 0.007 0.008 0.007
0.05 0.024 0.022 0.043 0.023 0.009 0.022 0.024 0.022
4/40/100 0 0.003 0.002 0.005 0.003 0.001 0.002 0.003 0.003
0.01 0.005 0.004 0.008 0.005 0.002 0.004 0.005 0.004
0.05 0.015 0.013 0.025 0.015 0.006 0.013 0.015 0.014
12/20/100 0 0.003 0.002 0.009 0.003 0.001 0.002 0.002 0.002
0.01 0.006 0.005 0.017 0.005 0.003 0.005 0.005 0.005
0.05 0.015 0.014 0.049 0.015 0.010 0.014 0.015 0.014
12/20/200 0 0.001 0.001 0.004 0.001 0.001 0.001 0.001 0.001
0.01 0.005 0.004 0.013 0.004 0.003 0.004 0.004 0.004
0.05 0.011 0.012 0.043 0.011 0.008 0.012 0.012 0.011
12/40/100 0 0.002 0.001 0.004 0.001 0.001 0.001 0.001 0.001
0.01 0.003 0.003 0.009 0.003 0.002 0.003 0.003 0.003
0.05 0.008 0.007 0.025 0.008 0.005 0.007 0.007 0.007
20/20/100 0 0.002 0.001 0.009 0.002 0.001 0.001 0.002 0.002
0.01 0.005 0.004 0.017 0.004 0.003 0.004 0.004 0.004
0.05 0.009 0.010 0.048 0.009 0.008 0.010 0.010 0.010
20/20/200 0 0.001 0.001 0.004 0.001 0.000 0.001 0.001 0.001
0.01 0.003 0.003 0.013 0.003 0.002 0.003 0.003 0.003
0.05 0.008 0.009 0.043 0.008 0.008 0.010 0.010 0.009
20/40/100 0 0.001 0.001 0.004 0.001 0.001 0.001 0.001 0.001
0.01 0.002 0.002 0.009 0.002 0.001 0.002 0.002 0.002
0.05 0.006 0.005 0.025 0.006 0.004 0.005 0.005 0.005
40/20/100 0 0.001 0.001 0.008 0.001 0.001 0.001 0.001 0.001
0.01 0.003 0.003 0.017 0.003 0.002 0.003 0.003 0.003
0.05 0.006 0.006 0.047 0.005 0.006 0.007 0.006 0.006
40/20/200 0 0.001 0.000 0.004 0.001 0.000 0.000 0.000 0.000
0.01 0.002 0.002 0.012 0.002 0.002 0.002 0.002 0.002
0.05 0.005 0.006 0.043 0.005 0.006 0.007 0.006 0.006
40/40/100 0 0.001 0.001 0.004 0.001 0.000 0.000 0.001 0.001
0.01 0.002 0.001 0.009 0.002 0.001 0.001 0.001 0.001
0.05 0.004 0.004 0.025 0.004 0.003 0.004 0.004 0.004
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Table 6.8: Bias for τ 2c with ‘low’ heterogeneity and control group disease rates rA =
{0.04, 0.07, 0.10, 0.13} based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.004 0.003 0.008 0.004 -0.001 0.003 0.004 0.003
0.01 0.004 0.001 0.010 0.003 -0.005 0.001 0.003 0.002
0.05 0.001 -0.004 0.021 -0.001 -0.019 -0.004 -0.001 -0.003
4/20/200 0 0.004 0.003 0.005 0.003 0.000 0.003 0.003 0.003
0.01 0.005 0.003 0.010 0.004 -0.002 0.003 0.005 0.004
0.05 -0.003 -0.005 0.017 -0.004 -0.018 -0.005 -0.003 -0.005
4/40/100 0 0.004 0.003 0.006 0.004 0.001 0.004 0.004 0.004
0.01 0.004 0.002 0.007 0.004 -0.001 0.003 0.004 0.003
0.05 0.004 0.001 0.014 0.003 -0.009 0.000 0.003 0.002
12/20/100 0 0.001 -0.001 0.007 0.000 -0.002 -0.001 -0.000 -0.000
0.01 -0.002 -0.004 0.010 -0.002 -0.006 -0.004 -0.003 -0.003
0.05 -0.015 -0.016 0.020 -0.015 -0.020 -0.016 -0.015 -0.016
12/20/200 0 0.002 0.001 0.005 0.002 0.000 0.001 0.002 0.002
0.01 -0.001 -0.002 0.008 -0.001 -0.003 -0.002 -0.001 -0.002
0.05 -0.014 -0.015 0.019 -0.014 -0.019 -0.014 -0.014 -0.015
12/40/100 0 0.002 0.001 0.005 0.002 0.000 0.001 0.002 0.002
0.01 0.001 -0.000 0.007 0.001 -0.002 -0.000 0.000 0.000
0.05 -0.005 -0.006 0.013 -0.005 -0.009 -0.007 -0.005 -0.006
20/20/100 0 -0.000 - 0.002 0.007 -0.001 -0.002 -0.002 -0.001 -0.001
0.01 -0.003 -0.004 0.010 -0.004 -0.006 -0.005 -0.004 -0.004
0.05 -0.018 -0.019 0.021 -0.018 -0.021 -0.019 -0.018 -0.019
20/20/200 0 0.002 0.001 0.005 0.001 0.000 0.001 0.001 0.001
0.01 -0.001 -0.002 0.008 -0.002 -0.004 -0.003 -0.002 -0.002
0.05 -0.017 -0.017 0.019 -0.017 -0.018 -0.016 -0.016 -0.017
20/40/100 0 0.002 0.001 0.005 0.002 0.000 0.001 0.001 0.001
0.01 0.001 -0.000 0.007 0.000 -0.001 -0.001 0.000 -0.000
0.05 -0.006 -0.007 0.013 -0.007 -0.009 -0.008 -0.007 -0.007
40/20/100 0 -0.001 - 0.002 0.007 -0.001 -0.003 -0.002 -0.002 -0.002
0.01 -0.004 -0.005 0.011 -0.004 -0.006 -0.006 -0.005 -0.005
0.05 -0.022 -0.022 0.021 -0.022 -0.023 -0.022 -0.022 -0.022
40/20/200 0 0.001 0.000 0.005 0.001 -0.000 0.000 0.001 0.001
0.01 -0.003 -0.003 0.008 -0.003 -0.004 -0.004 -0.003 -0.003
0.05 -0.021 -0.020 0.019 -0.021 -0.021 -0.020 -0.020 -0.020
40/40/100 0 0.001 0.001 0.005 0.001 0.000 0.000 0.001 0.001
0.01 -0.000 -0.001 0.007 -0.000 -0.002 -0.001 -0.001 -0.001
0.05 -0.008 -0.009 0.013 -0.009 -0.010 -0.009 -0.009 -0.009
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Table 6.9: Bias for τ 2c with ‘moderate’ heterogeneity and control group disease rates
rA = {0.04, 0.07, 0.10, 0.13} based on 1000 simulations of k trials each with Nj clusters
per group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.003 0.000 0.006 0.002 -0.005 0.001 0.002 0.001
0.01 -0.002 -0.005 0.005 -0.003 -0.013 -0.005 -0.003 -0.004
0.05 -0.028 -0.030 -0.006 -0.029 -0.049 -0.030 -0.027 -0.030
4/20/200 0 0.007 0.005 0.008 0.007 0.001 0.006 0.007 0.006
0.01 0.001 -0.002 0.006 0.000 -0.009 -0.002 0.000 -0.001
0.05 -0.024 -0.027 -0.005 -0.025 -0.045 -0.028 -0.024 -0.027
4/40/100 0 0.007 0.005 0.008 0.007 0.001 0.006 0.007 0.006
0.01 0.003 0.002 0.006 0.003 -0.004 0.002 0.003 0.002
0.05 -0.009 -0.012 0.002 -0.010 -0.022 -0.012 -0.009 -0.011
12/20/100 0 0.000 -0.002 0.006 -0.000 -0.004 -0.002 -0.001 -0.001
0.01 -0.008 -0.011 0.003 -0.009 -0.014 -0.011 -0.010 -0.010
0.05 -0.041 -0.044 -0.006 -0.042 -0.050 -0.045 -0.042 -0.044
12/20/200 0 0.004 0.002 0.007 0.003 0.001 0.002 0.003 0.003
0.01 -0.004 -0.006 0.005 -0.005 -0.009 -0.006 -0.005 -0.006
0.05 -0.038 -0.039 -0.005 -0.039 -0.044 -0.039 -0.038 -0.039
12/40/100 0 0.004 0.002 0.007 0.004 0.001 0.003 0.003 0.003
0.01 0.000 -0.002 0.006 -0.000 -0.004 -0.002 -0.000 -0.001
0.05 -0.017 -0.019 0.001 -0.018 -0.023 -0.020 -0.018 -0.019
20/20/100 0 -0.001 - 0.003 0.006 -0.002 -0.005 -0.004 -0.002 -0.002
0.01 -0.010 -0.012 0.003 -0.010 -0.014 -0.013 -0.011 -0.011
0.05 -0.046 -0.047 -0.006 -0.047 -0.050 -0.048 -0.046 -0.047
20/20/200 0 0.003 0.002 0.006 0.003 0.001 0.002 0.003 0.003
0.01 -0.005 -0.007 0.005 -0.006 -0.009 -0.007 -0.006 -0.006
0.05 -0.043 -0.043 -0.006 -0.043 -0.046 -0.043 -0.042 -0.043
20/40/100 0 0.004 0.002 0.006 0.003 0.001 0.002 0.003 0.003
0.01 -0.001 -0.002 0.006 -0.001 -0.004 -0.003 -0.001 -0.002
0.05 -0.018 -0.021 0.002 -0.019 -0.023 -0.021 -0.019 -0.020
40/20/100 0 -0.003 - 0.004 0.005 -0.003 -0.006 -0.005 -0.004 -0.004
0.01 -0.011 -0.012 0.004 -0.011 -0.014 -0.013 -0.012 -0.012
0.05 -0.050 -0.050 -0.006 -0.051 -0.051 -0.050 -0.050 -0.050
40/20/200 0 0.003 0.002 0.006 0.003 0.001 0.002 0.003 0.002
0.01 -0.006 -0.008 0.004 -0.007 -0.009 -0.008 -0.007 -0.007
0.05 -0.046 -0.046 -0.006 -0.046 -0.047 -0.045 -0.045 -0.046
40/40/100 0 0.004 0.002 0.006 0.003 0.001 0.002 0.003 0.003
0.01 -0.001 -0.002 0.006 -0.001 -0.003 -0.003 -0.002 -0.002
0.05 -0.020 -0.022 0.002 -0.020 -0.024 -0.023 -0.021 -0.022
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Table 6.10: Bias for τ 2c with ‘high’ heterogeneity and control group disease rates rA =
{0.04, 0.07, 0.10, 0.13} based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.002 -0.000 0.005 0.001 -0.007 0.000 0.002 0.001
0.01 -0.009 -0.012 -0.002 -0.009 -0.021 -0.011 -0.009 -0.010
0.05 -0.059 -0.063 -0.037 -0.061 -0.080 -0.063 -0.060 -0.063
4/20/200 0 0.010 0.008 0.011 0.009 0.002 0.009 0.009 0.009
0.01 -0.001 -0.005 0.003 -0.002 -0.013 -0.004 -0.002 -0.003
0.05 -0.050 -0.056 -0.032 -0.052 -0.073 -0.057 -0.052 -0.055
4/40/100 0 0.010 0.008 0.011 0.009 0.002 0.009 0.010 0.009
0.01 0.004 0.002 0.007 0.003 -0.006 0.002 0.004 0.003
0.05 -0.019 -0.023 -0.009 -0.020 -0.036 -0.023 -0.020 -0.022
12/20/100 0 -0.000 - 0.003 0.006 -0.001 -0.006 -0.003 -0.001 -0.002
0.01 -0.014 -0.017 -0.002 -0.015 -0.021 -0.018 -0.015 -0.016
0.05 -0.067 -0.070 -0.031 -0.069 -0.077 -0.071 -0.068 -0.070
12/20/200 0 0.006 0.004 0.009 0.006 0.002 0.004 0.006 0.005
0.01 -0.007 -0.010 0.001 -0.008 -0.013 -0.011 -0.009 -0.009
0.05 -0.062 -0.064 -0.029 -0.063 -0.070 -0.064 -0.062 -0.063
12/40/100 0 0.006 0.004 0.008 0.006 0.002 0.004 0.005 0.005
0.01 0.000 -0.003 0.005 -0.001 -0.005 -0.003 -0.001 -0.001
0.05 -0.027 -0.031 -0.009 -0.028 -0.035 -0.032 -0.029 -0.030
20/20/100 0 -0.002 - 0.005 0.004 -0.003 -0.006 -0.005 -0.003 -0.004
0.01 -0.014 -0.018 -0.002 -0.015 -0.020 -0.018 -0.016 -0.017
0.05 -0.073 -0.074 -0.032 -0.074 -0.077 -0.074 -0.073 -0.074
20/20/200 0 0.006 0.003 0.008 0.005 0.003 0.004 0.005 0.005
0.01 -0.009 -0.011 0.001 -0.009 -0.013 -0.012 -0.010 -0.010
0.05 -0.066 -0.067 -0.029 -0.067 -0.070 -0.067 -0.066 -0.067
20/40/100 0 0.006 0.004 0.008 0.006 0.003 0.004 0.005 0.005
0.01 -0.001 -0.003 0.005 -0.002 -0.005 -0.004 -0.002 -0.002
0.05 -0.028 -0.031 -0.008 -0.029 -0.035 -0.032 -0.030 -0.031
40/20/100 0 -0.003 - 0.005 0.004 -0.003 -0.006 -0.006 -0.004 -0.004
0.01 -0.016 -0.019 -0.002 -0.017 -0.021 -0.020 -0.018 -0.018
0.05 -0.076 -0.077 -0.031 -0.076 -0.078 -0.077 -0.076 -0.076
40/20/200 0 0.006 0.003 0.008 0.005 0.003 0.003 0.005 0.004
0.01 -0.009 -0.011 0.001 -0.010 -0.013 -0.012 -0.010 -0.011
0.05 -0.071 -0.071 -0.030 -0.072 -0.072 -0.071 -0.071 -0.071
40/40/100 0 0.005 0.003 0.008 0.005 0.003 0.003 0.005 0.004
0.01 -0.001 -0.004 0.004 -0.002 -0.005 -0.004 -0.003 -0.003
0.05 -0.031 -0.034 -0.010 -0.032 -0.036 -0.035 -0.033 -0.034
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Table 6.11: Bias for τ 2c with ‘no’ heterogeneity and control group disease rates rB =
{0.35, 0.40, 0.45, 0.50} based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 0.003 0.003 0.005 0.003 0.001 0.003 0.003 0.003
0.05 0.009 0.009 0.014 0.009 0.004 0.009 0.009 0.009
4/20/200 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 0.002 0.002 0.003 0.002 0.001 0.002 0.002 0.002
0.05 0.008 0.007 0.012 0.008 0.004 0.007 0.008 0.008
4/40/100 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.05 0.005 0.005 0.007 0.005 0.002 0.005 0.005 0.005
12/20/100 0 0.001 0.001 0.002 0.001 0.000 0.001 0.001 0.001
0.01 0.001 0.001 0.004 0.001 0.001 0.001 0.001 0.001
0.05 0.005 0.004 0.013 0.004 0.003 0.004 0.004 0.004
12/20/200 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.003 0.001 0.001 0.001 0.001 0.001
0.05 0.004 0.004 0.012 0.004 0.003 0.004 0.004 0.004
12/40/100 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.05 0.002 0.002 0.007 0.002 0.002 0.002 0.002 0.002
20/20/100 0 0.001 0.000 0.002 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.004 0.001 0.001 0.001 0.001 0.001
0.05 0.003 0.003 0.013 0.003 0.002 0.003 0.003 0.003
20/20/200 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.003 0.001 0.001 0.001 0.001 0.001
0.05 0.003 0.003 0.012 0.003 0.002 0.003 0.003 0.003
20/40/100 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.002 0.001 0.000 0.001 0.001 0.001
0.05 0.002 0.002 0.006 0.002 0.001 0.002 0.002 0.002
40/20/100 0 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.004 0.001 0.001 0.001 0.001 0.001
0.05 0.002 0.002 0.013 0.002 0.002 0.002 0.002 0.002
40/20/200 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.001 0.001 0.003 0.001 0.000 0.001 0.001 0.001
0.05 0.002 0.002 0.012 0.002 0.002 0.002 0.002 0.002
40/40/100 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000
0.05 0.001 0.001 0.006 0.001 0.001 0.001 0.001 0.001
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Table 6.12: Bias for τ 2c with ‘low’ heterogeneity and control group disease rates rB =
{0.35, 0.40, 0.45, 0.50} based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.001 0.001 0.002 0.001 -0.000 0.001 0.001 0.001
0.01 0.001 0.001 0.003 0.001 -0.001 0.001 0.001 0.001
0.05 0.001 0.001 0.006 0.001 -0.004 0.001 0.001 0.001
4/20/200 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 0.001 0.001 0.002 0.001 -0.001 0.001 0.001 0.001
0.05 0.000 -0.000 0.005 0.000 -0.004 -0.000 0.000 0.000
4/40/100 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 0.001 0.001 0.002 0.001 -0.000 0.001 0.001 0.001
0.05 0.000 0.000 0.003 0.000 -0.002 0.000 0.000 0.000
12/20/100 0 -0.000 - 0.000 0.002 -0.000 -0.000 -0.000 -0.000 -0.000
0.01 -0.000 -0.000 0.003 -0.000 -0.001 -0.000 -0.000 -0.000
0.05 -0.003 -0.003 0.006 -0.003 -0.005 -0.003 -0.003 -0.003
12/20/200 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 -0.000 -0.000 0.002 -0.000 -0.001 -0.000 -0.000 -0.000
0.05 -0.003 -0.003 0.005 -0.003 -0.004 -0.003 -0.003 -0.003
12/40/100 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 0.000 0.000 0.002 0.000 -0.000 0.000 0.000 0.000
0.05 -0.001 -0.002 0.003 -0.001 -0.002 -0.002 -0.002 -0.002
20/20/100 0 -0.000 - 0.000 0.001 -0.000 -0.001 -0.000 -0.000 -0.000
0.01 -0.001 -0.001 0.002 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.004 -0.004 0.005 -0.004 -0.005 -0.005 -0.004 -0.004
20/20/200 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 -0.001 -0.001 0.002 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.004 -0.004 0.005 -0.004 -0.005 -0.004 -0.004 -0.004
20/40/100 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 -0.000 -0.000 0.002 -0.000 -0.000 -0.000 -0.000 -0.000
0.05 -0.002 -0.002 0.003 -0.002 -0.002 -0.002 -0.002 -0.002
40/20/100 0 -0.001 - 0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.01 -0.001 -0.001 0.002 -0.001 -0.002 -0.001 -0.001 -0.001
0.05 -0.005 -0.005 0.005 -0.005 -0.006 -0.005 -0.005 -0.005
40/20/200 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 -0.001 -0.001 0.002 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.005 -0.005 0.005 -0.005 -0.005 -0.005 -0.005 -0.005
40/40/100 0 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
0.01 -0.000 -0.000 0.002 -0.000 -0.000 -0.000 -0.000 -0.000
0.05 -0.002 -0.002 0.003 -0.002 -0.003 -0.002 -0.002 -0.002
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Table 6.13: Bias for τ 2c with ‘moderate’ heterogeneity and control group disease rates
rB = {0.35, 0.40, 0.45, 0.50} based on 1000 simulations of k trials each with Nj clusters
per group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.000 0.000 0.001 0.000 -0.001 0.000 0.000 0.000
0.01 -0.001 -0.001 0.001 -0.001 -0.003 -0.001 -0.001 -0.001
0.05 -0.007 -0.007 -0.002 -0.007 -0.012 -0.007 -0.007 -0.007
4/20/200 0 0.002 0.001 0.002 0.001 0.000 0.001 0.001 0.001
0.01 -0.000 -0.000 0.001 -0.000 -0.002 -0.000 -0.000 -0.000
0.05 -0.006 -0.007 -0.002 -0.007 -0.011 -0.007 -0.007 -0.007
4/40/100 0 0.002 0.002 0.002 0.002 0.000 0.002 0.002 0.002
0.01 0.001 0.001 0.002 0.001 -0.001 0.001 0.001 0.001
0.05 -0.002 -0.002 0.000 -0.002 -0.005 -0.002 -0.002 -0.002
12/20/100 0 -0.001 - 0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.01 -0.003 -0.003 0.000 -0.003 -0.004 -0.003 -0.003 -0.003
0.05 -0.011 -0.011 -0.003 -0.011 -0.013 -0.011 -0.011 -0.011
12/20/200 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 -0.002 -0.002 0.001 -0.002 -0.002 -0.002 -0.002 -0.002
0.05 -0.010 -0.010 -0.002 -0.010 -0.012 -0.010 -0.010 -0.010
12/40/100 0 0.001 0.001 0.002 0.001 0.000 0.001 0.001 0.001
0.01 -0.000 -0.000 0.001 -0.000 -0.001 -0.000 -0.000 -0.000
0.05 -0.005 -0.005 -0.001 -0.005 -0.006 -0.005 -0.005 -0.005
20/20/100 0 -0.001 - 0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.01 -0.003 -0.003 0.000 -0.003 -0.004 -0.003 -0.003 -0.003
0.05 -0.012 -0.012 -0.002 -0.012 -0.013 -0.012 -0.012 -0.012
20/20/200 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 -0.002 -0.002 0.001 -0.002 -0.002 -0.002 -0.002 -0.002
0.05 -0.011 -0.012 -0.002 -0.011 -0.012 -0.012 -0.011 -0.011
20/40/100 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 -0.000 -0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.005 -0.005 -0.000 -0.005 -0.006 -0.005 -0.005 -0.005
40/20/100 0 -0.001 - 0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.01 -0.003 -0.003 0.000 -0.003 -0.004 -0.003 -0.003 -0.003
0.05 -0.013 -0.014 -0.002 -0.013 -0.014 -0.014 -0.014 -0.014
40/20/200 0 0.001 0.001 0.001 0.001 0.000 0.001 0.001 0.001
0.01 -0.002 -0.002 0.001 -0.002 -0.002 -0.002 -0.002 -0.002
0.05 -0.012 -0.012 -0.002 -0.012 -0.013 -0.012 -0.012 -0.012
40/40/100 0 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
0.01 -0.001 -0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.006 -0.006 -0.001 -0.006 -0.006 -0.006 -0.006 -0.006
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Table 6.14: Bias for τ 2c with ‘high’ heterogeneity and control group disease rates rB =
{0.35, 0.40, 0.45, 0.50} based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ (truncated), and odds ratio ψ = 0.7.
k/Nj/m ρ VC DL DLVC DL2 MV MVVC ML REML
4/20/100 0 0.000 0.000 0.001 0.000 -0.002 0.000 0.000 0.000
0.01 -0.003 -0.003 -0.001 -0.003 -0.005 -0.003 -0.003 -0.003
0.05 -0.014 -0.014 -0.009 -0.014 -0.020 -0.014 -0.014 -0.014
4/20/200 0 0.002 0.002 0.002 0.002 0.000 0.002 0.002 0.002
0.01 -0.001 -0.001 0.000 -0.001 -0.004 -0.001 -0.001 -0.001
0.05 -0.013 -0.013 -0.008 -0.013 -0.019 -0.013 -0.013 -0.013
4/40/100 0 0.002 0.002 0.002 0.002 0.001 0.002 0.002 0.002
0.01 0.000 0.000 0.001 0.000 -0.002 0.000 0.000 0.000
0.05 -0.005 -0.006 -0.003 -0.005 -0.009 -0.006 -0.005 -0.005
12/20/100 0 -0.001 - 0.001 0.001 -0.001 -0.002 -0.001 -0.001 -0.001
0.01 -0.004 -0.005 -0.002 -0.005 -0.005 -0.005 -0.005 -0.005
0.05 -0.019 -0.019 -0.010 -0.019 -0.020 -0.019 -0.019 -0.019
12/20/200 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 -0.003 -0.003 -0.000 -0.003 -0.003 -0.003 -0.003 -0.003
0.05 -0.017 -0.017 -0.009 -0.017 -0.019 -0.017 -0.017 -0.017
12/40/100 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 -0.001 -0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.008 -0.008 -0.003 -0.008 -0.009 -0.008 -0.008 -0.008
20/20/100 0 -0.001 - 0.001 0.000 -0.001 -0.002 -0.001 -0.001 -0.001
0.01 -0.005 -0.005 -0.002 -0.005 -0.006 -0.005 -0.005 -0.005
0.05 -0.020 -0.020 -0.010 -0.020 -0.021 -0.020 -0.020 -0.020
20/20/200 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 -0.003 -0.003 -0.001 -0.003 -0.003 -0.003 -0.003 -0.003
0.05 -0.018 -0.019 -0.009 -0.018 -0.019 -0.019 -0.018 -0.018
20/40/100 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 -0.001 -0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.009 -0.009 -0.004 -0.009 -0.009 -0.009 -0.009 -0.009
40/20/100 0 -0.001 - 0.001 0.000 -0.001 -0.002 -0.001 -0.001 -0.001
0.01 -0.005 -0.005 -0.002 -0.005 -0.006 -0.005 -0.005 -0.005
0.05 -0.021 -0.021 -0.010 -0.021 -0.022 -0.021 -0.021 -0.021
40/20/200 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 -0.003 -0.003 -0.001 -0.003 -0.003 -0.003 -0.003 -0.003
0.05 -0.020 -0.020 -0.010 -0.020 -0.020 -0.020 -0.020 -0.020
40/40/100 0 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001
0.01 -0.001 -0.001 0.001 -0.001 -0.001 -0.001 -0.001 -0.001
0.05 -0.009 -0.009 -0.004 -0.009 -0.010 -0.009 -0.009 -0.009
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Table 6.15: Confidence intervals for τ 2c with ‘no’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for Q profile(PQ), Biggerstaff-Tweedie(BT), Sidik-
Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k trials
each with Nj clusters per group of size m, intracluster correlation ρ (truncated), and odds
ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 98.6(1.4, 0.0)0.22 99.3(0.7, 0.0)0.27 0.0(100, 0.0)0.06 100(0.0, 0.0)0.01
0.01 98.0(2.0, 0.0)0.46 98.9(1.1, 0.0)0.52 0.0(100, 0.0)0.14 100(0.0, 0.0)0.02
0.05 98.5(1.5, 0.0)1.29 99.4(0.6, 0.0)1.51 0.0(100, 0.0)0.37 100(0.0, 0.0)0.06
4/20/200 0 98.6(1.4, 0.0)0.11 99.2(0.8, 0.0)0.13 0.0(100, 0.0)0.03 100(0.0, 0.0)0.01
0.01 97.5(2.5, 0.0)0.33 98.2(1.8, 0.0)0.38 0.0(100, 0.0)0.11 100(0.0, 0.0)0.02
0.05 98.1(1.9, 0.0)1.15 99.3(0.7, 0.0)1.39 0.0(100, 0.0)0.33 100(0.0, 0.0)0.06
4/40/100 0 97.7(2.3, 0.0)0.12 98.7(1.3, 0.0)0.13 0.0(100, 0.0)0.04 100(0.0, 0.0)0.01
0.01 97.8(2.2, 0.0)0.22 99.3(0.7, 0.0)0.25 0.0(100, 0.0)0.07 100(0.0, 0.0)0.01
0.05 98.0(2.0, 0.0)0.68 99.0(1.0, 0.0)0.77 0.0(100, 0.0)0.21 100(0.0, 0.0)0.04
12/20/100 0 98.6(1.4, 0.0)0.03 99.1(0.9, 0.0)0.04 0.0(100, 0.0)0.01 99.9(0.1, 0.0)0.01
0.01 98.3(1.7, 0.0)0.07 98.8(1.2, 0.0)0.07 0.0(100, 0.0)0.01 99.7(0.3, 0.0)0.02
0.05 98.7(1.3, 0.0)0.17 99.2(0.8, 0.0)0.19 0.0(100, 0.0)0.03 99.8(0.2, 0.0)0.05
12/20/200 0 98.4(1.6, 0.0)0.02 99.1(0.9, 0.0)0.02 0.0(100, 0.0)0.00 99.9(0.1, 0.0)0.00
0.01 97.9(2.1, 0.0)0.05 99.3(0.7, 0.0)0.05 0.0(100, 0.0)0.01 99.7(0.3, 0.0)0.01
0.05 98.6(1.4, 0.0)0.16 99.6(0.4, 0.0)0.18 0.0(100, 0.0)0.03 100(0.0, 0.0)0.05
12/40/100 0 98.1(1.9, 0.0)0.02 99.0(1.0, 0.0)0.02 0.0(100, 0.0)0.00 99.9(0.1, 0.0)0.00
0.01 97.6(2.4, 0.0)0.03 98.4(1.6, 0.0)0.03 0.0(100, 0.0)0.01 99.9(0.1, 0.0)0.01
0.05 97.7(2.3, 0.0)0.10 98.9(1.1, 0.0)0.10 0.0(100, 0.0)0.02 99.8(0.2, 0.0)0.03
20/20/100 0 98.9(1.1, 0.0)0.02 99.6(0.4, 0.0)0.02 0.0(100, 0.0)0.00 99.8(0.2, 0.0)0.01
0.01 97.6(2.4, 0.0)0.04 98.9(1.1, 0.0)0.04 0.0(100, 0.0)0.01 99.7(0.3, 0.0)0.02
0.05 98.7(1.3, 0.0)0.11 99.1(0.9, 0.0)0.11 0.0(100, 0.0)0.01 99.6(0.4, 0.0)0.05
20/20/200 0 98.4(1.6, 0.0)0.01 98.8(1.2, 0.0)0.01 0.0(100, 0.0)0.00 99.6(0.4, 0.0)0.00
0.01 98.2(1.8, 0.0)0.03 98.8(1.2, 0.0)0.03 0.0(100, 0.0)0.00 99.6(0.4, 0.0)0.01
0.05 97.7(2.3, 0.0)0.10 98.5(1.5, 0.0)0.11 0.0(100, 0.0)0.01 99.7(0.3, 0.0)0.04
20/40/100 0 98.7(1.3, 0.0)0.01 99.0(1.0, 0.0)0.01 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.01 97.2(2.8, 0.0)0.02 98.1(1.9, 0.0)0.02 0.0(100, 0.0)0.00 99.1(0.9, 0.0)0.01
0.05 98.1(1.9, 0.0)0.06 98.8(1.2, 0.0)0.06 0.0(100, 0.0)0.01 99.4(0.6, 0.0)0.02
40/20/100 0 99.4(0.6, 0.0)0.01 99.7(0.3, 0.0)0.01 0.0(100, 0.0)0.00 99.8(0.2, 0.0)0.01
0.01 98.3(1.7, 0.0)0.02 99.0(1.0, 0.0)0.02 0.0(100, 0.0)0.00 99.2(0.8, 0.0)0.01
0.05 98.5(1.5, 0.0)0.06 99.2(0.8, 0.0)0.06 0.0(100, 0.0)0.01 99.6(0.4, 0.0)0.03
40/20/200 0 99.2(0.8, 0.0)0.01 99.7(0.3, 0.0)0.01 0.0(100, 0.0)0.00 99.8(0.2, 0.0)0.00
0.01 97.8(2.2, 0.0)0.02 98.9(1.1, 0.0)0.02 0.0(100, 0.0)0.00 99.3(0.7, 0.0)0.01
0.05 98.4(1.6, 0.0)0.05 99.0(1.0, 0.0)0.06 0.0(100, 0.0)0.01 99.5(0.5, 0.0)0.03
40/40/100 0 98.6(1.4, 0.0)0.01 99.0(1.0, 0.0)0.01 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.01 97.8(2.2, 0.0)0.01 98.3(1.7, 0.0)0.01 0.0(100, 0.0)0.00 99.4(0.6, 0.0)0.01
0.05 98.0(2.0, 0.0)0.03 99.1(0.9, 0.0)0.03 0.0(100, 0.0)0.00 99.5(0.5, 0.0)0.02
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.16: Confidence intervals for τ 2c with ‘no’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for profile likelihood, and Wald-Type based on 1000
simulations of k trials each with Nj clusters per group of size m, intracluster correlation
ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.9(0.1, 0.0)0.07 99.3(0.7, 0.0)0.14 100(0.0, 0.0)0.05 100(0.0, 0.0)0.07
0.01 99.5(0.5, 0.0)0.14 98.8(1.2, 0.0)0.28 100(0.0, 0.0)0.09 100(0.0, 0.0)0.13
0.05 99.7(0.3, 0.0)0.38 99.2(0.8, 0.0)0.80 100(0.0, 0.0)0.26 100(0.0, 0.0)0.37
4/20/200 0 100(0.0, 0.0)0.03 99.6(0.4, 0.0)0.07 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.01 99.2(0.8, 0.0)0.10 98.1(1.9, 0.0)0.21 100(0.0, 0.0)0.07 100(0.0, 0.0)0.10
0.05 99.4(0.6, 0.0)0.36 98.7(1.3, 0.0)0.73 100(0.0, 0.0)0.24 100(0.0, 0.0)0.34
4/40/100 0 99.5(0.5, 0.0)0.04 98.9(1.1, 0.0)0.07 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.01 99.9(0.1, 0.0)0.07 99.3(0.7, 0.0)0.14 100(0.0, 0.0)0.05 100(0.0, 0.0)0.06
0.05 99.4(0.6, 0.0)0.20 98.8(1.2, 0.0)0.42 100(0.0, 0.0)0.13 100(0.0, 0.0)0.19
12/20/100 0 99.4(0.6, 0.0)0.02 99.1(0.9, 0.0)0.03 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.01 99.0(1.0, 0.0)0.04 98.5(1.5, 0.0)0.06 100(0.0, 0.0)0.05 100(0.0, 0.0)0.06
0.05 99.2(0.8, 0.0)0.13 99.1(0.9, 0.0)0.15 100(0.0, 0.0)0.15 100(0.0, 0.0)0.16
12/20/200 0 99.4(0.6, 0.0)0.01 98.8(1.2, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.01 99.2(0.8, 0.0)0.03 98.9(1.1, 0.0)0.04 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
0.05 99.4(0.6, 0.0)0.12 98.5(1.5, 0.0)0.14 100(0.0, 0.0)0.14 100(0.0, 0.0)0.15
12/40/100 0 99.4(0.6, 0.0)0.01 98.9(1.1, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.4(1.6, 0.0)0.02 97.9(2.1, 0.0)0.03 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.05 98.6(1.4, 0.0)0.07 98.0(2.0, 0.0)0.08 100(0.0, 0.0)0.08 100(0.0, 0.0)0.09
20/20/100 0 99.4(0.6, 0.0)0.01 99.1(0.9, 0.0)0.02 99.9(0.1, 0.0)0.02 99.9(0.1, 0.0)0.02
0.01 99.0(1.0, 0.0)0.03 98.3(1.7, 0.0)0.03 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
0.05 99.1(0.9, 0.0)0.08 98.4(1.6, 0.0)0.10 100(0.0, 0.0)0.11 100(0.0, 0.0)0.12
20/20/200 0 98.9(1.1, 0.0)0.01 98.8(1.2, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.0(1.0, 0.0)0.02 98.5(1.5, 0.0)0.02 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.05 98.6(1.4, 0.0)0.08 97.5(2.5, 0.0)0.09 100(0.0, 0.0)0.10 100(0.0, 0.0)0.11
20/40/100 0 99.0(1.0, 0.0)0.01 98.8(1.2, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.0(2.0, 0.0)0.01 97.6(2.4, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.05 98.7(1.3, 0.0)0.04 98.0(2.0, 0.0)0.05 100(0.0, 0.0)0.06 100(0.0, 0.0)0.06
40/20/100 0 99.6(0.4, 0.0)0.01 99.5(0.5, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.2(0.8, 0.0)0.02 98.7(1.3, 0.0)0.02 99.9(0.1, 0.0)0.03 99.9(0.1, 0.0)0.03
0.05 98.4(1.6, 0.0)0.05 97.9(2.1, 0.0)0.06 99.9(0.1, 0.0)0.08 99.9(0.1, 0.0)0.08
40/20/200 0 99.7(0.3, 0.0)0.00 99.5(0.5, 0.0)0.00 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.5(1.5, 0.0)0.01 97.9(2.1, 0.0)0.01 99.9(0.1, 0.0)0.02 99.9(0.1, 0.0)0.02
0.05 97.5(2.5, 0.0)0.05 97.0(3.0, 0.0)0.05 100(0.0, 0.0)0.07 100(0.0, 0.0)0.07
40/40/100 0 98.7(1.3, 0.0)0.00 98.5(1.5, 0.0)0.00 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.3(1.7, 0.0)0.01 97.8(2.2, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 98.4(1.6, 0.0)0.03 97.9(2.1, 0.0)0.03 100(0.0, 0.0)0.04 99.9(0.1, 0.0)0.04
C me ans the probability c overage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.17: Confidence intervals for τ 2c with ‘low’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for Q profile(PQ), Biggerstaff-Tweedie(BT), Sidik-
Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k trials
each with Nj clusters per group of size m, intracluster correlation ρ (truncated), and odds
ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 94.1(1.7, 4.2)0.29 99.3(0.7, 0.0)0.32 23.8(17.0,59.2)0.11 50.9(0.0,49.1)0.02
0.01 95.6(1.0, 3.3)0.55 99.4(0.6, 0.0)0.59 27.0(16.6,56.4)0.21 50.2(0.0,49.8)0.03
0.05 95.9(0.3, 3.8)1.34 99.8(0.2, 0.0)1.58 23.4(11.3,65.3)0.40 44.2(0.0,55.8)0.07
4/20/200 0 93.9(4.5, 1.6)0.20 98.2(1.8, 0.0)0.20 26.6(30.4,43.0)0.09 63.3(0.0,36.7)0.01
0.01 97.3(1.3, 1.4)0.44 99.4(0.6, 0.0)0.46 30.7(17.4,52.0)0.17 55.7(0.0,44.3)0.03
0.05 96.9(0.4, 2.7)1.22 99.9(0.1, 0.0)1.43 28.6(10.6,60.9)0.34 46.1(0.0,53.9)0.06
4/40/100 0 92.7(6.0, 1.3)0.20 97.6(2.4, 0.0)0.19 26.9(30.9,42.2)0.10 66.3(0.0,33.7)0.01
0.01 95.7(1.8, 2.5)0.32 98.7(1.3, 0.0)0.32 31.1(21.2,47.6)0.13 59.5(0.0,40.5)0.02
0.05 95.3(0.6, 4.1)0.72 99.7(0.3, 0.0)0.83 25.5(14.3,60.2)0.24 46.0(0.0,54.0)0.04
12/20/100 0 95.7(0.9, 3.4)0.05 99.8(0.2, 0.0)0.04 25.9(21.9,52.2)0.01 73.4(0.1,26.5)0.01
0.01 96.5(0.6, 2.9)0.08 99.7(0.3, 0.0)0.07 29.2(14.5,56.3)0.02 69.1(0.1,30.8)0.02
0.05 95.0(0.0, 5.0)0.20 100(0.0, 0.0)0.20 26.9(8.5,64.6)0.04 63.6(0.0,36.4)0.06
12/20/200 0 94.0(4.7, 1.3)0.03 97.9(2.1, 0.0)0.03 29.9(38.6,31.5)0.01 87.2(0.4,12.4)0.01
0.01 96.1(1.0, 2.9)0.06 99.7(0.3, 0.0)0.06 30.8(19.4,49.8)0.02 72.8(0.0,27.2)0.02
0.05 94.9(0.1, 5.0)0.18 100(0.0, 0.0)0.18 25.8(7.9,66.3)0.03 64.1(0.0,35.9)0.06
12/40/100 0 94.5(3.9, 1.6)0.03 98.4(1.6, 0.0)0.02 29.6(34.8,35.6)0.01 83.9(0.6,15.5)0.01
0.01 95.1(1.6, 3.3)0.05 98.9(1.1, 0.0)0.04 31.8(25.0,43.2)0.01 78.4(0.4,21.2)0.02
0.05 94.8(0.3, 4.9)0.11 99.9(0.1, 0.0)0.11 29.0(13.0,58.0)0.03 67.8(0.1,32.1)0.04
20/20/100 0 94.7(0.6, 4.7)0.03 99.8(0.2, 0.0)0.03 27.7(20.9,51.4)0.01 77.3(0.1,22.6)0.01
0.01 93.7(0.2, 6.1)0.05 99.7(0.3, 0.0)0.04 27.7(16.0,56.3)0.01 70.2(0.1,29.7)0.02
0.05 92.0(0.0, 8.0)0.11 100(0.0, 0.0)0.12 23.1(5.2,71.7)0.02 60.6(0.0,39.4)0.05
20/20/200 0 94.0(4.5, 1.5)0.02 98.5(1.5, 0.0)0.02 30.3(37.6,32.1)0.01 88.1(0.6,11.3)0.01
0.01 94.8(0.7, 4.5)0.04 99.8(0.2, 0.0)0.03 31.5(14.2,54.3)0.01 75.5(0.1,24.4)0.02
0.05 91.3(0.1, 8.6)0.10 99.9(0.1, 0.0)0.11 23.8(5.0,71.2)0.02 63.2(0.0,36.8)0.05
20/40/100 0 92.8(6.0, 1.2)0.02 97.4(2.6, 0.0)0.02 27.2(41.1,31.7)0.01 88.5(0.8,10.7)0.01
0.01 95.3(1.6, 3.1)0.03 99.2(0.8, 0.0)0.03 29.5(26.4,44.1)0.01 81.9(0.5,17.6)0.01
0.05 93.4(0.1, 6.5)0.06 99.9(0.1, 0.0)0.06 24.8(10.6,64.6)0.01 67.7(0.1,32.2)0.03
40/20/100 0 93.2(0.7, 6.1)0.02 99.6(0.4, 0.0)0.01 26.7(16.8,56.5)0.00 77.0(0.2,22.8)0.01
0.01 93.2(0.3, 6.5)0.03 99.9(0.1, 0.0)0.03 25.6(10.8,63.6)0.01 72.8(0.1,27.1)0.02
0.05 86.1(0.0,13.9)0.07 100(0.0, 0.0)0.07 17.9(2.4,79.7)0.01 60.9(0.0,39.1)0.04
40/20/200 0 94.5(5.1, 0.4)0.01 98.2(1.8, 0.0)0.01 31.6(41.9,26.5)0.00 93.5(0.9, 5.6)0.01
0.01 92.2(0.5, 7.3)0.02 99.9(0.1, 0.0)0.02 30.3(12.4,57.3)0.00 77.1(0.0,22.9)0.01
0.05 86.6(0.0,13.4)0.06 100(0.0, 0.0)0.06 17.5(2.3,80.2)0.01 60.8(0.0,39.2)0.04
40/40/100 0 91.9(7.4, 0.7)0.01 96.7(3.3, 0.0)0.01 30.0(44.5,25.5)0.00 91.9(2.2, 5.9)0.01
0.01 96.2(1.5, 2.3)0.02 99.9(0.1, 0.0)0.02 33.2(22.3,44.5)0.00 85.0(0.1,14.9)0.01
0.05 88.3(0.0,11.7)0.04 100(0.0, 0.0)0.04 20.3(6.6,73.1)0.01 65.3(0.0,34.7)0.02
C means the probability coverage. L and R denote tail errors from le ft and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.18: Confidence intervals for τ 2c with ‘low’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for profile likelihood, and Wald-Type based on 1000
simulations of k trials each with Nj clusters per group of size m, intracluster correlation
ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.5(0.5, 0.0)0.09 99.3(0.7, 0.0)0.18 100(0.0, 0.0)0.05 100(0.0, 0.0)0.08
0.01 99.7(0.3, 0.0)0.16 99.4(0.6, 0.0)0.33 100(0.0, 0.0)0.10 100(0.0, 0.0)0.14
0.05 100(0.0, 0.0)0.40 99.9(0.1, 0.0)0.83 100(0.0, 0.0)0.26 100(0.0, 0.0)0.37
4/20/200 0 98.9(1.1, 0.0)0.06 98.3(1.7, 0.0)0.12 100(0.0, 0.0)0.03 100(0.0, 0.0)0.05
0.01 99.6(0.4, 0.0)0.13 99.4(0.6, 0.0)0.26 100(0.0, 0.0)0.08 100(0.0, 0.0)0.11
0.05 99.9(0.1, 0.0)0.36 99.9(0.1, 0.0)0.75 100(0.0, 0.0)0.24 100(0.0, 0.0)0.34
4/40/100 0 99.6(0.4, 0.0)0.06 97.9(2.1, 0.0)0.12 100(0.0, 0.0)0.03 100(0.0, 0.0)0.05
0.01 99.7(0.3, 0.0)0.09 99.0(1.0, 0.0)0.19 100(0.0, 0.0)0.05 100(0.0, 0.0)0.08
0.05 100(0.0, 0.0)0.21 99.7(0.3, 0.0)0.44 100(0.0, 0.0)0.14 100(0.0, 0.0)0.20
12/20/100 0 99.9(0.1, 0.0)0.03 99.7(0.3, 0.0)0.04 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.01 100(0.0, 0.0)0.05 99.7(0.3, 0.0)0.06 100(0.0, 0.0)0.05 100(0.0, 0.0)0.06
0.05 100(0.0, 0.0)0.13 100(0.0, 0.0)0.16 100(0.0, 0.0)0.15 100(0.0, 0.0)0.17
12/20/200 0 98.5(1.5, 0.0)0.02 97.7(2.3, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.01 99.9(0.1, 0.0)0.04 99.4(0.6, 0.0)0.05 100(0.0, 0.0)0.04 100(0.0, 0.0)0.05
0.05 100(0.0, 0.0)0.12 100(0.0, 0.0)0.15 100(0.0, 0.0)0.14 100(0.0, 0.0)0.15
12/40/100 0 99.1(0.9, 0.0)0.02 98.5(1.5, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.01 99.2(0.8, 0.0)0.03 98.7(1.3, 0.0)0.04 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.05 99.9(0.1, 0.0)0.07 99.8(0.2, 0.0)0.09 100(0.0, 0.0)0.08 100(0.0, 0.0)0.09
20/20/100 0 99.8(0.0, 0.2)0.02 99.8(0.2, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.01 98.9(0.3, 0.8)0.04 99.4(0.3, 0.3)0.04 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
0.05 99.0(0.0, 1.0)0.09 99.5(0.0, 0.5)0.10 100(0.0, 0.0)0.11 100(0.0, 0.0)0.12
20/20/200 0 99.1(0.9, 0.0)0.01 98.0(2.0, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.1(0.2, 0.7)0.03 99.4(0.3, 0.3)0.03 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.05 98.5(0.1, 1.4)0.08 99.3(0.1, 0.6)0.09 100(0.0, 0.0)0.10 100(0.0, 0.0)0.11
20/40/100 0 98.1(1.8, 0.1)0.01 97.4(2.6, 0.0)0.02 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.9(0.7, 0.4)0.02 99.1(0.9, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.05 98.7(0.1, 1.2)0.05 99.5(0.1, 0.4)0.06 100(0.0, 0.0)0.06 100(0.0, 0.0)0.06
40/20/100 0 94.3(0.2, 5.5)0.01 96.1(0.3, 3.6)0.01 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.01 91.8(0.1, 8.1)0.02 94.4(0.1, 5.5)0.02 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
0.05 85.2(0.0,14.8)0.06 89.2(0.0,10.8)0.06 99.9(0.0, 0.1)0.08 100(0.0, 0.0)0.08
40/20/200 0 97.7(1.6, 0.7)0.01 97.6(2.0, 0.4)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 92.1(0.1, 7.8)0.02 93.2(0.2, 6.6)0.02 99.9(0.0, 0.1)0.02 99.9(0.0, 0.1)0.02
0.05 85.9(0.0,14.1)0.05 89.7(0.0,10.3)0.06 100(0.0, 0.0)0.07 100(0.0, 0.0)0.08
40/40/100 0 96.5(2.6, 0.9)0.01 95.9(3.5, 0.6)0.01 99.5(0.5, 0.0)0.01 99.5(0.5, 0.0)0.01
0.01 95.6(0.3, 4.1)0.01 96.8(0.5, 2.7)0.01 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.05 87.5(0.0,12.5)0.03 90.0(0.0,10.0)0.03 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.19: Confidence intervals for τ 2c with ‘moderate’ heterogeneity, control group
disease rates rA = {0.04, 0.07, 0.10, 0.13} for Q profile(PQ), Biggerstaff-Tweedie(BT),
Sidik-Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k
trials each with Nj clusters per group of size m, intracluster correlation ρ (truncated),
and odds ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 96.6(1.5, 1.9)0.42 99.4(0.6, 0.0)0.40 45.5(13.3,41.2)0.19 59.4(0.0,40.6)0.03
0.01 96.5(0.8, 2.7)0.61 99.8(0.2, 0.0)0.64 41.1(7.6,51.4)0.24 46.8(0.0,53.2)0.04
0.05 95.7(0.1, 4.2)1.42 99.9(0.1, 0.0)1.62 34.4(3.2,62.4)0.43 36.3(0.0,63.7)0.07
4/20/200 0 94.6(4.6, 0.8)0.28 98.1(1.9, 0.0)0.26 44.7(27.8,27.6)0.16 72.6(0.0,27.4)0.02
0.01 96.6(0.5, 2.9)0.49 99.7(0.3, 0.0)0.49 45.9(8.5,45.7)0.20 50.9(0.0,49.1)0.03
0.05 95.8(0.1, 4.1)1.35 100(0.0, 0.0)1.54 37.3(3.2,59.5)0.44 36.7(0.0,63.3)0.07
4/40/100 0 93.6(5.5, 0.9)0.29 97.5(2.5, 0.0)0.26 49.5(26.7,23.8)0.16 75.3(0.0,24.7)0.02
0.01 96.7(0.9, 2.4)0.38 99.6(0.4, 0.0)0.37 45.7(13.8,40.5)0.18 58.8(0.0,41.2)0.02
0.05 96.2(0.2, 3.6)0.84 99.9(0.1, 0.0)0.90 40.8(5.2,54.1)0.30 45.0(0.0,55.0)0.05
12/20/100 0 97.0(1.0, 2.0)0.06 99.7(0.3, 0.0)0.05 48.9(14.0,37.1)0.02 75.5(0.0,24.5)0.02
0.01 94.5(0.1, 5.4)0.09 100(0.0, 0.0)0.08 39.8(7.5,52.7)0.03 60.9(0.0,39.1)0.03
0.05 90.8(0.0, 9.2)0.21 100(0.0, 0.0)0.21 29.0(1.6,69.4)0.05 46.6(0.0,53.4)0.07
12/20/200 0 94.9(4.8, 0.3)0.04 97.6(2.4, 0.0)0.04 49.6(34.4,16.0)0.02 90.7(0.6, 8.7)0.02
0.01 95.6(0.3, 4.1)0.07 99.9(0.1, 0.0)0.07 48.7(6.8,44.5)0.03 66.6(0.0,33.4)0.03
0.05 89.6(0.0,10.4)0.19 100(0.0, 0.0)0.19 26.8(1.2,72.0)0.04 44.5(0.0,55.5)0.06
12/40/100 0 94.4(5.5, 0.1)0.04 97.6(2.4, 0.0)0.04 48.4(36.2,15.4)0.02 91.4(0.4, 8.2)0.02
0.01 96.2(1.3, 2.5)0.06 99.7(0.3, 0.0)0.05 50.8(14.7,34.5)0.02 76.1(0.0,23.9)0.02
0.05 92.5(0.0, 7.5)0.13 100(0.0, 0.0)0.12 39.0(3.2,57.8)0.04 55.6(0.0,44.4)0.04
20/20/100 0 94.8(0.7, 4.5)0.04 99.7(0.3, 0.0)0.03 48.3(13.5,38.2)0.01 76.8(0.3,22.9)0.02
0.01 89.0(0.1,10.9)0.06 99.9(0.1, 0.0)0.05 37.5(4.2,58.3)0.02 58.7(0.1,41.2)0.03
0.05 82.1(0.0,17.9)0.12 100(0.0, 0.0)0.12 20.6(0.3,79.1)0.02 40.2(0.0,59.8)0.06
20/20/200 0 93.4(6.5, 0.1)0.03 97.3(2.7, 0.0)0.02 45.6(45.1, 9.3)0.01 95.3(1.1, 3.6)0.01
0.01 93.3(0.2, 6.5)0.05 99.9(0.1, 0.0)0.04 44.7(6.0,49.3)0.02 67.4(0.1,32.5)0.02
0.05 82.2(0.0,17.8)0.11 100(0.0, 0.0)0.11 20.7(0.6,78.7)0.02 41.6(0.0,58.4)0.05
20/40/100 0 90.7(9.3, 0.0)0.03 95.5(4.5, 0.0)0.02 43.8(45.8,10.4)0.01 92.4(2.4, 5.2)0.01
0.01 97.0(0.8, 2.2)0.04 99.7(0.3, 0.0)0.03 49.7(15.7,34.6)0.01 80.4(0.0,19.6)0.02
0.05 87.1(0.0,12.9)0.07 100(0.0, 0.0)0.07 31.1(2.1,66.8)0.02 51.8(0.0,48.2)0.03
40/20/100 0 93.5(0.0, 6.5)0.02 90.5(0.0, 9.5)0.02 43.0(10.5,46.5)0.01 72.8(0.0,27.2)0.01
0.01 83.0(0.0,17.0)0.03 76.3(0.0,23.7)0.03 30.4(2.4,67.2)0.01 53.9(0.0,46.1)0.02
0.05 56.8(0.0,43.2)0.07 45.6(0.0,54.4)0.07 7.1(0.2,92.7)0.01 21.3(0.0,78.7)0.04
40/20/200 0 92.3(7.4, 0.3)0.02 96.7(2.8, 0.5)0.01 39.6(52.0, 8.4)0.01 94.8(2.3, 2.9)0.01
0.01 89.6(0.2,10.2)0.03 83.8(0.1,16.1)0.02 38.0(3.5,58.5)0.01 63.2(0.0,36.8)0.02
0.05 61.8(0.0,38.2)0.07 49.2(0.0,50.8)0.06 9.0(0.0,91.0)0.01 24.2(0.0,75.8)0.04
40/40/100 0 90.1(9.8, 0.1)0.02 94.6(5.0, 0.4)0.01 41.0(54.2, 4.8)0.01 94.0(4.4, 1.6)0.01
0.01 96.2(0.6, 3.2)0.02 94.3(0.2, 5.5)0.02 51.1(13.5,35.4)0.01 83.3(0.2,16.5)0.02
0.05 73.9(0.0,26.1)0.04 65.7(0.0,34.3)0.04 21.4(0.6,78.0)0.01 42.1(0.0,57.9)0.03
C means the probability coverage. L and R de note tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.20: Confidence intervals for τ 2c with ‘moderate’ heterogeneity, control group
disease rates rA = {0.04, 0.07, 0.10, 0.13} for profile likelihood, and Wald-Type based
on 1000 simulations of k trials each with Nj clusters per group of size m, intracluster
correlation ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.8(0.2, 0.0)0.12 99.5(0.5, 0.0)0.25 100(0.0, 0.0)0.06 100(0.0, 0.0)0.10
0.01 100(0.0, 0.0)0.18 99.8(0.2, 0.0)0.37 100(0.0, 0.0)0.10 100(0.0, 0.0)0.15
0.05 100(0.0, 0.0)0.40 99.9(0.1, 0.0)0.85 98.9(0.0, 1.1)0.26 99.7(0.0, 0.3)0.37
4/20/200 0 99.4(0.6, 0.0)0.08 97.6(2.4, 0.0)0.17 100(0.0, 0.0)0.04 100(0.0, 0.0)0.06
0.01 99.8(0.2, 0.0)0.14 99.7(0.3, 0.0)0.29 99.6(0.0, 0.4)0.08 100(0.0, 0.0)0.12
0.05 100(0.0, 0.0)0.39 100(0.0, 0.0)0.82 98.7(0.0, 1.3)0.24 99.7(0.0, 0.3)0.36
4/40/100 0 98.9(1.1, 0.0)0.08 97.5(2.5, 0.0)0.17 100(0.0, 0.0)0.04 100(0.0, 0.0)0.06
0.01 99.7(0.3, 0.0)0.11 99.6(0.4, 0.0)0.23 100(0.0, 0.0)0.06 100(0.0, 0.0)0.09
0.05 100(0.0, 0.0)0.24 99.9(0.1, 0.0)0.50 100(0.0, 0.0)0.14 100(0.0, 0.0)0.21
12/20/100 0 98.5(0.2, 1.3)0.04 99.5(0.4, 0.1)0.05 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
0.01 95.4(0.0, 4.6)0.06 98.4(0.1, 1.5)0.07 90.1(0.0, 9.9)0.06 97.6(0.0, 2.4)0.07
0.05 90.3(0.0, 9.7)0.14 96.9(0.0, 3.1)0.18 80.4(0.0,19.6)0.15 91.3(0.0, 8.7)0.17
12/20/200 0 98.3(1.5, 0.2)0.03 96.6(3.4, 0.0)0.04 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.01 95.9(0.1, 4.0)0.05 97.7(0.2, 2.1)0.06 90.2(0.0, 9.8)0.05 97.0(0.0, 3.0)0.05
0.05 89.3(0.0,10.7)0.13 96.8(0.0, 3.2)0.16 78.7(0.0,21.3)0.14 90.7(0.0, 9.3)0.15
12/40/100 0 98.7(1.3, 0.0)0.03 96.8(3.2, 0.0)0.04 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.01 97.6(0.2, 2.2)0.04 99.1(0.5, 0.4)0.05 96.6(0.0, 3.4)0.03 99.5(0.0, 0.5)0.04
0.05 92.5(0.0, 7.5)0.08 97.0(0.0, 3.0)0.10 88.6(0.0,11.4)0.08 97.4(0.0, 2.6)0.09
20/20/100 0 92.5(0.2, 7.3)0.03 95.3(0.3, 4.4)0.03 71.8(0.0,28.2)0.03 80.9(0.0,19.1)0.03
0.01 82.9(0.1,17.0)0.04 88.6(0.1,11.3)0.05 54.1(0.0,45.9)0.04 65.2(0.0,34.8)0.05
0.05 71.6(0.0,28.4)0.10 78.4(0.0,21.6)0.11 38.4(0.0,61.6)0.12 48.5(0.0,51.5)0.12
20/20/200 0 97.2(2.3, 0.5)0.02 95.8(4.0, 0.2)0.02 94.8(0.1, 5.1)0.02 96.7(0.1, 3.2)0.02
0.01 87.5(0.1,12.4)0.04 91.9(0.1, 8.0)0.04 64.3(0.0,35.7)0.03 71.4(0.0,28.6)0.04
0.05 71.3(0.0,28.7)0.09 79.8(0.0,20.2)0.10 40.5(0.0,59.5)0.11 49.1(0.0,50.9)0.11
20/40/100 0 94.9(4.1, 1.0)0.02 93.2(6.6, 0.2)0.02 94.0(0.0, 6.0)0.02 96.0(0.0, 4.0)0.02
0.01 94.7(0.3, 5.0)0.03 96.6(0.4, 3.0)0.03 74.5(0.0,25.5)0.03 81.2(0.0,18.8)0.03
0.05 77.5(0.0,22.5)0.06 85.1(0.0,14.9)0.06 47.0(0.0,53.0)0.06 55.6(0.0,44.4)0.07
40/20/100 0 84.1(0.0,15.9)0.02 87.0(0.0,13.0)0.02 68.0(0.0,32.0)0.02 72.0(0.0,28.0)0.02
0.01 69.6(0.0,30.4)0.03 74.5(0.0,25.5)0.03 48.0(0.0,52.0)0.03 53.1(0.0,46.9)0.03
0.05 41.8(0.0,58.2)0.06 47.9(0.0,52.1)0.06 20.7(0.0,79.3)0.08 25.4(0.0,74.6)0.08
40/20/200 0 96.5(2.6, 0.9)0.01 95.1(4.0, 0.9)0.01 95.6(0.1, 4.3)0.01 96.9(0.1, 3.0)0.01
0.01 78.4(0.1,21.5)0.02 81.9(0.1,18.0)0.02 56.2(0.0,43.8)0.02 62.2(0.0,37.8)0.03
0.05 44.9(0.0,55.1)0.06 51.0(0.0,49.0)0.06 25.6(0.0,74.4)0.07 29.8(0.0,70.2)0.08
40/40/100 0 94.3(5.1, 0.6)0.01 93.4(6.2, 0.4)0.02 97.0(0.5, 2.5)0.01 97.4(0.9, 1.7)0.01
0.01 91.3(0.3, 8.4)0.02 93.5(0.3, 6.2)0.02 79.1(0.0,20.9)0.02 82.3(0.0,17.7)0.02
0.05 59.4(0.0,40.6)0.04 65.0(0.0,35.0)0.04 37.5(0.0,62.5)0.04 43.8(0.0,56.2)0.04
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.21: Confidence intervals for τ 2c with ‘high’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for Q profile(PQ), Biggerstaff-Tweedie(BT), Sidik-
Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k trials
each with Nj clusters per group of size m, intracluster correlation ρ (truncated), and odds
ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 98.1(0.8, 1.1)0.48 99.9(0.1, 0.0)0.45 55.1(9.5,35.4)0.24 57.6(0.0,42.4)0.03
0.01 97.1(0.2, 2.7)0.69 100(0.0, 0.0)0.69 49.4(4.2,46.4)0.29 44.5(0.0,55.5)0.04
0.05 96.9(0.0, 3.1)1.55 100(0.0, 0.0)1.71 40.7(0.5,58.8)0.49 32.2(0.0,67.8)0.08
4/20/200 0 93.0(6.1, 0.9)0.36 98.5(1.5, 0.0)0.33 56.0(25.9,18.1)0.23 78.7(0.0,21.3)0.03
0.01 97.5(0.3, 2.2)0.58 100(0.0, 0.0)0.56 54.0(4.8,41.1)0.27 52.2(0.0,47.8)0.04
0.05 96.3(0.0, 3.7)1.41 100(0.0, 0.0)1.57 42.1(1.1,56.8)0.46 31.6(0.0,68.4)0.07
4/40/100 0 92.8(6.7, 0.5)0.37 97.8(2.2, 0.0)0.33 56.0(27.8,16.2)0.24 80.3(0.0,19.7)0.03
0.01 97.3(1.5, 1.2)0.48 99.6(0.4, 0.0)0.45 56.7(11.8,31.5)0.27 60.7(0.0,39.3)0.03
0.05 95.2(0.3, 4.4)0.93 99.9(0.1, 0.0)0.96 45.7(2.8,51.5)0.37 39.4(0.0,60.6)0.05
12/20/100 0 97.2(0.4, 2.4)0.07 99.9(0.1, 0.0)0.06 58.8(7.9,33.3)0.03 71.7(0.1,28.2)0.03
0.01 93.2(0.1, 6.7)0.11 100(0.0, 0.0)0.09 48.3(3.1,48.5)0.04 54.7(0.0,45.3)0.04
0.05 85.0(0.0,15.0)0.22 100(0.0, 0.0)0.21 25.5(0.0,74.5)0.05 28.8(0.0,71.2)0.07
12/20/200 0 91.4(8.4, 0.2)0.05 97.8(2.2, 0.0)0.05 57.8(33.7, 8.5)0.03 92.2(0.6, 7.2)0.02
0.01 95.5(0.2, 4.3)0.09 100(0.0, 0.0)0.08 55.0(3.4,41.6)0.03 60.5(0.0,39.5)0.03
0.05 83.1(0.0,16.9)0.20 100(0.0, 0.0)0.20 26.8(0.1,73.1)0.05 30.0(0.0,70.0)0.06
12/40/100 0 91.4(8.4, 0.2)0.06 97.6(2.4, 0.0)0.05 58.1(36.3, 5.6)0.03 95.0(0.5, 4.5)0.02
0.01 97.5(1.2, 1.3)0.07 99.7(0.3, 0.0)0.06 64.9(10.5,24.6)0.03 77.3(0.0,22.7)0.03
0.05 90.0(0.0,10.0)0.14 100(0.0, 0.0)0.12 38.0(0.6,61.4)0.04 44.9(0.0,55.1)0.05
20/20/100 0 95.3(0.2, 4.5)0.05 100(0.0, 0.0)0.04 57.4(9.2,33.4)0.02 74.6(0.1,25.3)0.02
0.01 88.2(0.0,11.8)0.07 94.6(0.0, 5.4)0.06 43.0(1.4,55.6)0.02 53.1(0.0,46.9)0.03
0.05 68.3(0.0,31.7)0.13 82.1(0.0,17.9)0.13 16.1(0.1,83.8)0.03 20.7(0.0,79.3)0.06
20/20/200 0 87.8(12.2, 0.0)0.04 97.0(3.0, 0.0)0.03 50.8(44.5, 4.7)0.02 95.1(1.8, 3.1)0.02
0.01 94.2(0.1, 5.7)0.06 97.5(0.0, 2.5)0.05 50.7(3.0,46.3)0.02 59.8(0.0,40.2)0.03
0.05 71.4(0.0,28.6)0.12 80.2(0.0,19.8)0.12 14.7(0.0,85.3)0.03 23.5(0.0,76.5)0.06
20/40/100 0 87.3(12.6, 0.1)0.04 96.6(3.4, 0.0)0.03 47.9(47.2, 4.9)0.02 93.8(1.9, 4.3)0.02
0.01 97.3(0.5, 2.2)0.05 99.3(0.1, 0.6)0.04 63.4(10.3,26.3)0.02 79.8(0.1,20.1)0.02
0.05 82.1(0.0,17.9)0.08 91.9(0.0, 8.1)0.07 29.7(0.4,69.9)0.02 36.7(0.0,63.3)0.04
40/20/100 0 93.8(0.0, 6.2)0.03 89.2(0.0,10.8)0.02 54.3(5.5,40.2)0.01 69.8(0.0,30.2)0.02
0.01 74.3(0.0,25.7)0.04 60.8(0.0,39.2)0.03 25.8(0.9,73.3)0.01 37.3(0.0,62.7)0.03
0.05 33.2(0.0,66.8)0.07 21.5(0.0,78.5)0.07 2.2(0.0,97.8)0.01 7.1(0.0,92.9)0.05
40/20/200 0 80.2(19.8, 0.0)0.02 95.0(5.0, 0.0)0.02 39.4(58.3, 2.3)0.01 92.6(6.4, 1.0)0.01
0.01 85.9(0.0,14.1)0.04 77.3(0.0,22.7)0.03 43.1(1.0,55.9)0.01 53.2(0.0,46.8)0.02
0.05 38.4(0.0,61.6)0.07 25.9(0.0,74.1)0.07 2.9(0.0,97.1)0.01 7.7(0.0,92.3)0.04
40/40/100 0 77.9(22.1, 0.0)0.02 94.0(5.8, 0.2)0.02 39.4(58.9, 1.7)0.01 92.8(6.6, 0.6)0.01
0.01 95.8(0.2, 4.0)0.03 94.0(0.0, 6.0)0.02 66.5(7.1,26.4)0.01 80.5(0.0,19.5)0.02
0.05 59.1(0.0,40.9)0.05 44.8(0.0,55.2)0.04 15.0(0.0,85.0)0.01 20.7(0.0,79.3)0.03
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.22: Confidence intervals for τ 2c with ‘high’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for profile likelihood, and Wald-Type based on 1000
simulations of k trials each with Nj clusters per group of size m, intracluster correlation
ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 100(0.0, 0.0)0.14 99.8(0.2, 0.0)0.28 100(0.0, 0.0)0.07 100(0.0, 0.0)0.11
0.01 100(0.0, 0.0)0.19 100(0.0, 0.0)0.41 90.9(0.0, 9.1)0.11 99.9(0.0, 0.1)0.16
0.05 99.9(0.0, 0.1)0.44 100(0.0, 0.0)0.92 82.0(0.0,18.0)0.27 97.1(0.0, 2.9)0.39
4/20/200 0 99.5(0.5, 0.0)0.11 98.2(1.8, 0.0)0.22 100(0.0, 0.0)0.05 100(0.0, 0.0)0.08
0.01 100(0.0, 0.0)0.16 100(0.0, 0.0)0.34 89.6(0.0,10.4)0.09 99.1(0.0, 0.9)0.13
0.05 99.9(0.0, 0.1)0.40 100(0.0, 0.0)0.84 80.6(0.0,19.4)0.24 97.0(0.0, 3.0)0.36
4/40/100 0 99.2(0.8, 0.0)0.11 97.4(2.6, 0.0)0.22 100(0.0, 0.0)0.05 100(0.0, 0.0)0.08
0.01 99.8(0.2, 0.0)0.14 99.6(0.4, 0.0)0.29 97.7(0.0, 2.3)0.07 100(0.0, 0.0)0.11
0.05 100(0.0, 0.0)0.26 99.9(0.1, 0.0)0.55 91.1(0.0, 8.9)0.15 99.6(0.0, 0.4)0.22
12/20/100 0 95.2(0.1, 4.7)0.05 97.8(0.1, 2.1)0.06 70.1(0.0,29.9)0.04 78.9(0.0,21.1)0.05
0.01 86.7(0.0,13.3)0.07 93.5(0.0, 6.5)0.09 53.1(0.0,46.9)0.06 65.4(0.0,34.6)0.07
0.05 69.1(0.0,30.9)0.14 82.4(0.0,17.6)0.18 27.7(0.0,72.3)0.15 39.6(0.0,60.4)0.17
12/20/200 0 97.5(2.1, 0.4)0.04 96.0(3.8, 0.2)0.05 92.4(0.0, 7.6)0.03 95.9(0.0, 4.1)0.03
0.01 89.4(0.1,10.5)0.06 94.5(0.1, 5.4)0.07 58.2(0.0,41.8)0.05 70.2(0.0,29.8)0.06
0.05 69.5(0.0,30.5)0.14 80.0(0.0,20.0)0.17 30.1(0.0,69.9)0.14 41.8(0.0,58.2)0.16
12/40/100 0 96.9(2.3, 0.8)0.04 96.2(3.7, 0.1)0.05 95.0(0.0, 5.0)0.03 97.2(0.0, 2.8)0.03
0.01 96.2(0.3, 3.5)0.05 97.9(0.5, 1.6)0.06 76.2(0.0,23.8)0.04 83.8(0.0,16.2)0.05
0.05 77.9(0.0,22.1)0.09 88.7(0.0,11.3)0.11 41.5(0.0,58.5)0.08 52.8(0.0,47.2)0.10
20/20/100 0 89.2(0.1,10.7)0.03 92.7(0.1, 7.2)0.04 70.6(0.0,29.4)0.03 77.1(0.0,22.9)0.03
0.01 75.5(0.0,24.5)0.05 82.2(0.0,17.8)0.06 49.0(0.0,51.0)0.05 57.4(0.0,42.6)0.05
0.05 47.4(0.0,52.6)0.10 56.8(0.0,43.2)0.11 20.7(0.0,79.3)0.12 27.1(0.0,72.9)0.12
20/20/200 0 96.0(3.3, 0.7)0.03 94.3(5.2, 0.5)0.03 96.4(0.1, 3.5)0.02 97.5(0.1, 2.4)0.03
0.01 82.9(0.0,17.1)0.04 89.4(0.1,10.5)0.05 56.5(0.0,43.5)0.04 65.3(0.0,34.7)0.04
0.05 51.7(0.0,48.3)0.09 59.5(0.0,40.5)0.11 24.0(0.0,76.0)0.11 30.5(0.0,69.5)0.12
20/40/100 0 95.6(3.8, 0.6)0.03 93.9(5.6, 0.5)0.03 95.8(0.0, 4.2)0.02 97.5(0.0, 2.5)0.03
0.01 92.5(0.1, 7.4)0.04 95.4(0.1, 4.5)0.04 76.3(0.0,23.7)0.03 81.9(0.0,18.1)0.03
0.05 62.2(0.0,37.8)0.06 71.7(0.0,28.3)0.07 33.7(0.0,66.3)0.06 42.5(0.0,57.5)0.07
40/20/100 0 84.9(0.0,15.1)0.02 88.4(0.0,11.6)0.02 65.1(0.0,34.9)0.02 71.7(0.0,28.3)0.02
0.01 54.0(0.0,46.0)0.03 60.3(0.0,39.7)0.03 32.4(0.0,67.6)0.03 37.8(0.0,62.2)0.03
0.05 18.7(0.0,81.3)0.06 22.7(0.0,77.3)0.07 5.8(0.0,94.2)0.08 8.4(0.0,91.6)0.08
40/20/200 0 93.0(6.9, 0.1)0.02 90.8(9.2, 0.0)0.02 97.8(1.0, 1.2)0.02 97.9(1.4, 0.7)0.02
0.01 71.6(0.0,28.4)0.03 76.0(0.0,24.0)0.03 48.9(0.0,51.1)0.03 55.2(0.0,44.8)0.03
0.05 22.3(0.0,77.7)0.06 28.4(0.0,71.6)0.07 7.9(0.0,92.1)0.08 10.2(0.0,89.8)0.08
40/40/100 0 92.6(7.2, 0.2)0.02 90.4(9.5, 0.1)0.02 98.3(0.9, 0.8)0.02 98.1(1.4, 0.5)0.02
0.01 91.3(0.0, 8.7)0.02 93.2(0.0, 6.8)0.03 77.5(0.0,22.5)0.02 81.6(0.0,18.4)0.02
0.05 38.4(0.0,61.6)0.04 43.4(0.0,56.6)0.04 17.8(0.0,82.2)0.04 22.2(0.0,77.8)0.05
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.23: Confidence intervals for τ 2c with ‘no’ heterogeneity, control group disease
rates rB = {0.35, 0.40, 0.45, 0.50} for Q profile(PQ), Biggerstaff-Tweedie(BT), Sidik-
Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k trials
each with Nj clusters per group of size m, intracluster correlation ρ (truncated), and odds
ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 98.4(1.6, 0.0)0.06 99.3(0.7, 0.0)0.06 0.0(100, 0.0)0.02 100(0.0, 0.0)0.00
0.01 97.0(3.0, 0.0)0.12 98.0(2.0, 0.0)0.12 0.0(100, 0.0)0.04 100(0.0, 0.0)0.01
0.05 97.4(2.6, 0.0)0.33 98.6(1.4, 0.0)0.35 0.0(100, 0.0)0.11 100(0.0, 0.0)0.02
4/20/200 0 98.2(1.8, 0.0)0.03 98.9(1.1, 0.0)0.03 0.0(100, 0.0)0.01 100(0.0, 0.0)0.00
0.01 97.0(3.0, 0.0)0.09 98.2(1.8, 0.0)0.09 0.0(100, 0.0)0.03 100(0.0, 0.0)0.00
0.05 97.2(2.8, 0.0)0.32 97.9(2.1, 0.0)0.33 0.0(100, 0.0)0.11 100(0.0, 0.0)0.02
4/40/100 0 98.1(1.9, 0.0)0.03 98.7(1.3, 0.0)0.03 0.0(100, 0.0)0.01 100(0.0, 0.0)0.00
0.01 97.3(2.7, 0.0)0.06 98.3(1.7, 0.0)0.06 0.0(100, 0.0)0.02 100(0.0, 0.0)0.00
0.05 97.0(3.0, 0.0)0.17 98.1(1.9, 0.0)0.17 0.0(100, 0.0)0.06 100(0.0, 0.0)0.01
12/20/100 0 99.1(0.9, 0.0)0.01 99.2(0.8, 0.0)0.01 0.0(100, 0.0)0.00 100(0.0, 0.0)0.00
0.01 96.4(3.6, 0.0)0.02 98.2(1.8, 0.0)0.02 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.01
0.05 96.4(3.6, 0.0)0.05 97.9(2.1, 0.0)0.05 0.0(100, 0.0)0.01 99.7(0.3, 0.0)0.02
12/20/200 0 99.3(0.7, 0.0)0.00 99.5(0.5, 0.0)0.00 0.0(100, 0.0)0.00 100(0.0, 0.0)0.00
0.01 97.1(2.9, 0.0)0.01 98.0(2.0, 0.0)0.01 0.0(100, 0.0)0.00 99.6(0.4, 0.0)0.00
0.05 97.3(2.7, 0.0)0.05 98.1(1.9, 0.0)0.05 0.0(100, 0.0)0.01 99.8(0.2, 0.0)0.02
12/40/100 0 98.0(2.0, 0.0)0.00 98.7(1.3, 0.0)0.00 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.01 97.5(2.5, 0.0)0.01 98.3(1.7, 0.0)0.01 0.0(100, 0.0)0.00 99.4(0.6, 0.0)0.00
0.05 97.2(2.8, 0.0)0.03 97.7(2.3, 0.0)0.03 0.0(100, 0.0)0.01 99.3(0.7, 0.0)0.01
20/20/100 0 98.1(1.9, 0.0)0.00 98.8(1.2, 0.0)0.01 0.0(100, 0.0)0.00 99.3(0.7, 0.0)0.00
0.01 96.2(3.8, 0.0)0.01 96.9(3.1, 0.0)0.01 0.0(100, 0.0)0.00 99.1(0.9, 0.0)0.01
0.05 96.8(3.2, 0.0)0.03 98.3(1.7, 0.0)0.03 0.0(100, 0.0)0.01 98.9(1.1, 0.0)0.01
20/20/200 0 98.8(1.2, 0.0)0.00 99.1(0.9, 0.0)0.00 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.01 97.4(2.6, 0.0)0.01 98.5(1.5, 0.0)0.01 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.05 97.7(2.3, 0.0)0.03 98.8(1.2, 0.0)0.03 0.0(100, 0.0)0.00 99.5(0.5, 0.0)0.01
20/40/100 0 97.8(2.2, 0.0)0.00 98.3(1.7, 0.0)0.00 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.01 97.5(2.5, 0.0)0.01 98.6(1.4, 0.0)0.01 0.0(100, 0.0)0.00 99.4(0.6, 0.0)0.00
0.05 96.4(3.6, 0.0)0.02 97.7(2.3, 0.0)0.02 0.0(100, 0.0)0.00 98.9(1.1, 0.0)0.01
40/20/100 0 98.7(1.3, 0.0)0.00 99.0(1.0, 0.0)0.00 0.0(100, 0.0)0.00 99.4(0.6, 0.0)0.00
0.01 97.3(2.7, 0.0)0.01 98.2(1.8, 0.0)0.01 0.0(100, 0.0)0.00 98.9(1.1, 0.0)0.00
0.05 96.8(3.2, 0.0)0.02 97.9(2.1, 0.0)0.02 0.0(100, 0.0)0.00 99.2(0.8, 0.0)0.01
40/20/200 0 98.7(1.3, 0.0)0.00 99.2(0.8, 0.0)0.00 0.0(100, 0.0)0.00 99.7(0.3, 0.0)0.00
0.01 97.1(2.9, 0.0)0.00 97.8(2.2, 0.0)0.00 0.0(100, 0.0)0.00 99.0(1.0, 0.0)0.00
0.05 97.5(2.5, 0.0)0.02 98.4(1.6, 0.0)0.02 0.0(100, 0.0)0.00 99.3(0.7, 0.0)0.01
40/40/100 0 98.6(1.4, 0.0)0.00 99.0(1.0, 0.0)0.00 0.0(100, 0.0)0.00 99.5(0.5, 0.0)0.00
0.01 97.7(2.3, 0.0)0.00 98.4(1.6, 0.0)0.00 0.0(100, 0.0)0.00 99.3(0.7, 0.0)0.00
0.05 97.2(2.8, 0.0)0.01 98.1(1.9, 0.0)0.01 0.0(100, 0.0)0.00 98.6(1.4, 0.0)0.01
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.24: Confidence intervals for τ 2c with ‘no’ heterogeneity, control group disease
rates rB = {0.35, 0.40, 0.45, 0.50} for profile likelihood, and Wald-Type based on 1000
simulations of k trials each with Nj clusters per group of size m, intracluster correlation
ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.5(0.5, 0.0)0.02 99.5(0.5, 0.0)0.04 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.01 98.9(1.1, 0.0)0.04 98.2(1.8, 0.0)0.08 100(0.0, 0.0)0.03 100(0.0, 0.0)0.04
0.05 99.0(1.0, 0.0)0.11 98.7(1.3, 0.0)0.22 100(0.0, 0.0)0.08 100(0.0, 0.0)0.11
4/20/200 0 99.6(0.4, 0.0)0.01 99.1(0.9, 0.0)0.02 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.1(0.9, 0.0)0.03 98.5(1.5, 0.0)0.06 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.05 98.9(1.1, 0.0)0.11 98.1(1.9, 0.0)0.21 100(0.0, 0.0)0.08 100(0.0, 0.0)0.10
4/40/100 0 99.4(0.6, 0.0)0.01 98.9(1.1, 0.0)0.02 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.2(0.8, 0.0)0.02 98.5(1.5, 0.0)0.04 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.05 99.2(0.8, 0.0)0.06 98.2(1.8, 0.0)0.11 100(0.0, 0.0)0.04 100(0.0, 0.0)0.05
12/20/100 0 99.4(0.6, 0.0)0.01 99.2(0.8, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.4(1.6, 0.0)0.01 97.7(2.3, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.05 98.5(1.5, 0.0)0.04 97.7(2.3, 0.0)0.04 100(0.0, 0.0)0.05 100(0.0, 0.0)0.05
12/20/200 0 99.8(0.2, 0.0)0.00 99.5(0.5, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 98.6(1.4, 0.0)0.01 97.7(2.3, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 98.6(1.4, 0.0)0.03 97.7(2.3, 0.0)0.04 100(0.0, 0.0)0.04 100(0.0, 0.0)0.05
12/40/100 0 98.9(1.1, 0.0)0.00 98.5(1.5, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 98.8(1.2, 0.0)0.01 98.2(1.8, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 98.4(1.6, 0.0)0.02 97.6(2.4, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
20/20/100 0 99.2(0.8, 0.0)0.00 98.4(1.6, 0.0)0.00 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 97.4(2.6, 0.0)0.01 96.7(3.3, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 98.4(1.6, 0.0)0.03 97.7(2.3, 0.0)0.03 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
20/20/200 0 99.3(0.7, 0.0)0.00 99.1(0.9, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 98.9(1.1, 0.0)0.01 98.2(1.8, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 99.1(0.9, 0.0)0.02 98.1(1.9, 0.0)0.03 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
20/40/100 0 99.3(0.7, 0.0)0.00 98.2(1.8, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 98.7(1.3, 0.0)0.00 98.2(1.8, 0.0)0.00 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 97.9(2.1, 0.0)0.01 96.7(3.3, 0.0)0.01 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
40/20/100 0 99.1(0.9, 0.0)0.00 98.9(1.1, 0.0)0.00 99.9(0.1, 0.0)0.00 99.9(0.1, 0.0)0.00
0.01 98.3(1.7, 0.0)0.01 97.9(2.1, 0.0)0.01 99.7(0.3, 0.0)0.01 99.6(0.4, 0.0)0.01
0.05 98.1(1.9, 0.0)0.02 97.3(2.7, 0.0)0.02 99.8(0.2, 0.0)0.02 99.8(0.2, 0.0)0.03
40/20/200 0 99.4(0.6, 0.0)0.00 99.0(1.0, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 97.8(2.2, 0.0)0.00 97.5(2.5, 0.0)0.00 99.9(0.1, 0.0)0.01 99.9(0.1, 0.0)0.01
0.05 98.3(1.7, 0.0)0.01 97.9(2.1, 0.0)0.02 99.9(0.1, 0.0)0.02 99.8(0.2, 0.0)0.02
40/40/100 0 99.4(0.6, 0.0)0.00 99.0(1.0, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 98.7(1.3, 0.0)0.00 98.2(1.8, 0.0)0.00 99.9(0.1, 0.0)0.00 99.9(0.1, 0.0)0.00
0.05 98.1(1.9, 0.0)0.01 97.4(2.6, 0.0)0.01 99.8(0.2, 0.0)0.01 99.8(0.2, 0.0)0.01
C me ans the probability c overage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.25: Confidence intervals for τ 2c with ‘low’ heterogeneity, control group disease
rates rB = {0.35, 0.40, 0.45, 0.50} for Q profile(PQ), Biggerstaff-Tweedie(BT), Sidik-
Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k trials
each with Nj clusters per group of size m, intracluster correlation ρ (truncated), and odds
ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 96.1(2.4, 1.5)0.08 98.7(1.3, 0.0)0.07 31.6(19.0,49.4)0.03 56.0(0.0,44.0)0.00
0.01 95.2(1.3, 3.5)0.14 99.6(0.4, 0.0)0.13 30.0(17.6,52.4)0.05 51.6(0.0,48.4)0.01
0.05 95.1(1.0, 3.9)0.35 99.5(0.5, 0.0)0.36 26.4(12.2,61.4)0.12 44.5(0.0,55.5)0.02
4/20/200 0 89.9(9.0, 1.1)0.05 98.4(1.6, 0.0)0.04 51.9(28.8,19.3)0.02 64.4(0.0,35.6)0.00
0.01 95.4(1.7, 2.9)0.11 98.8(1.2, 0.0)0.10 30.0(19.2,50.8)0.04 53.8(0.0,46.2)0.01
0.05 96.6(1.2, 2.2)0.33 99.4(0.6, 0.0)0.33 29.0(12.6,58.4)0.11 46.0(0.0,54.0)0.02
4/40/100 0 88.5(10.1, 1.4)0.05 97.4(2.6, 0.0)0.04 53.7(28.5,17.8)0.02 66.0(0.0,34.0)0.00
0.01 95.3(2.7, 2.0)0.08 98.8(1.2, 0.0)0.07 31.5(20.6,47.9)0.03 56.0(0.0,44.0)0.00
0.05 95.6(1.0, 3.4)0.19 99.6(0.4, 0.0)0.18 27.8(14.7,57.5)0.07 48.0(0.0,52.0)0.01
12/20/100 0 95.1(1.6, 3.3)0.01 99.8(0.2, 0.0)0.01 33.2(15.8,51.0)0.00 72.3(0.0,27.7)0.00
0.01 94.6(1.8, 3.6)0.02 99.7(0.3, 0.0)0.02 31.0(15.1,53.9)0.01 70.3(0.0,29.7)0.01
0.05 93.4(0.7, 5.9)0.05 99.7(0.3, 0.0)0.06 31.5(10.7,57.8)0.01 63.5(0.1,36.4)0.02
12/20/200 0 84.8(14.5, 0.7)0.01 97.7(2.3, 0.0)0.01 32.5(31.5,36.0)0.00 80.5(1.0,18.5)0.00
0.01 96.5(0.9, 2.6)0.02 99.6(0.4, 0.0)0.02 33.8(15.3,50.9)0.00 72.1(0.1,27.8)0.01
0.05 92.9(0.5, 6.6)0.05 99.6(0.4, 0.0)0.05 29.3(10.3,60.4)0.01 63.1(0.0,36.9)0.02
12/40/100 0 83.4(16.0, 0.6)0.01 98.0(2.0, 0.0)0.01 33.6(35.7,30.7)0.00 85.3(0.4,14.3)0.00
0.01 95.3(3.2, 1.5)0.01 99.1(0.9, 0.0)0.01 34.1(20.4,45.5)0.00 76.6(0.2,23.2)0.00
0.05 95.7(0.4, 3.9)0.03 99.7(0.3, 0.0)0.03 32.5(10.9,56.6)0.01 66.9(0.0,33.1)0.01
20/20/100 0 95.3(1.4, 3.3)0.01 99.5(0.5, 0.0)0.01 33.2(13.3,53.5)0.00 75.8(0.3,23.9)0.00
0.01 95.7(0.9, 3.4)0.01 99.9(0.1, 0.0)0.01 32.9(12.7,54.4)0.00 75.5(0.0,24.5)0.01
0.05 92.7(0.1, 7.2)0.03 100(0.0, 0.0)0.03 27.6(8.7,63.7)0.01 67.4(0.0,32.6)0.02
20/20/200 0 81.1(18.5, 0.4)0.00 97.7(2.3, 0.0)0.00 34.7(33.7,31.6)0.00 87.8(0.8,11.4)0.00
0.01 93.8(1.0, 5.2)0.01 99.4(0.6, 0.0)0.01 34.3(14.5,51.2)0.00 78.4(0.1,21.5)0.01
0.05 92.6(0.4, 7.0)0.03 99.9(0.1, 0.0)0.03 26.8(7.9,65.3)0.01 67.7(0.0,32.3)0.01
20/40/100 0 78.3(21.7, 0.0)0.00 97.8(2.2, 0.0)0.00 35.2(38.1,26.7)0.00 89.7(1.0, 9.3)0.00
0.01 94.4(3.6, 2.0)0.01 99.0(1.0, 0.0)0.01 36.2(20.4,43.4)0.00 83.4(0.3,16.3)0.00
0.05 91.9(0.6, 7.5)0.02 99.5(0.5, 0.0)0.02 28.3(9.2,62.5)0.00 68.2(0.0,31.8)0.01
40/20/100 0 94.8(1.0, 4.2)0.00 99.6(0.4, 0.0)0.00 28.8(12.7,58.5)0.00 78.3(0.2,21.5)0.00
0.01 93.8(0.3, 5.9)0.01 100(0.0, 0.0)0.01 25.8(8.8,65.4)0.00 74.1(0.0,25.9)0.00
0.05 86.5(0.0,13.5)0.02 100(0.0, 0.0)0.02 20.4(4.5,75.1)0.00 65.2(0.0,34.8)0.01
40/20/200 0 70.2(29.8, 0.0)0.00 97.8(2.2, 0.0)0.00 36.7(35.1,28.2)0.00 92.4(1.5, 6.1)0.00
0.01 93.3(0.6, 6.1)0.01 99.8(0.2, 0.0)0.01 29.5(11.3,59.2)0.00 77.9(0.1,22.0)0.00
0.05 87.1(0.1,12.8)0.02 100(0.0, 0.0)0.02 21.7(5.1,73.2)0.00 65.2(0.0,34.8)0.01
40/40/100 0 67.6(32.4, 0.0)0.00 97.3(2.7, 0.0)0.00 34.8(37.4,27.8)0.00 92.4(1.1, 6.5)0.00
0.01 95.8(2.6, 1.6)0.00 99.4(0.6, 0.0)0.00 36.1(19.2,44.7)0.00 85.5(0.3,14.2)0.00
0.05 87.7(0.4,11.9)0.01 99.7(0.3, 0.0)0.01 25.3(6.6,68.1)0.00 70.5(0.1,29.4)0.01
C means the probability coverage. L and R denote tail e rrors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.26: Confidence intervals for τ 2c with ‘low’ heterogeneity, control group disease
rates rB = {0.35, 0.40, 0.45, 0.50} for profile likelihood, and Wald-Type based on 1000
simulations of k trials each with Nj clusters per group of size m, intracluster correlation
ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.7(0.3, 0.0)0.02 98.8(1.2, 0.0)0.05 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.01 99.9(0.1, 0.0)0.04 99.6(0.4, 0.0)0.09 100(0.0, 0.0)0.03 100(0.0, 0.0)0.04
0.05 100(0.0, 0.0)0.11 99.6(0.4, 0.0)0.23 100(0.0, 0.0)0.08 100(0.0, 0.0)0.11
4/20/200 0 99.5(0.5, 0.0)0.01 98.7(1.3, 0.0)0.03 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.7(0.3, 0.0)0.03 99.0(1.0, 0.0)0.07 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.05 99.9(0.1, 0.0)0.11 99.5(0.5, 0.0)0.21 100(0.0, 0.0)0.08 100(0.0, 0.0)0.10
4/40/100 0 99.2(0.8, 0.0)0.01 97.9(2.1, 0.0)0.03 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.6(0.4, 0.0)0.02 98.8(1.2, 0.0)0.05 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.05 100(0.0, 0.0)0.06 99.6(0.4, 0.0)0.12 100(0.0, 0.0)0.04 100(0.0, 0.0)0.06
12/20/100 0 99.8(0.2, 0.0)0.01 99.8(0.2, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.8(0.2, 0.0)0.02 99.3(0.7, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
0.05 99.9(0.1, 0.0)0.04 99.6(0.4, 0.0)0.05 100(0.0, 0.0)0.05 100(0.0, 0.0)0.05
12/20/200 0 98.2(1.8, 0.0)0.01 97.4(2.6, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.6(0.4, 0.0)0.01 99.4(0.6, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 99.6(0.4, 0.0)0.04 99.6(0.4, 0.0)0.04 100(0.0, 0.0)0.04 100(0.0, 0.0)0.05
12/40/100 0 98.6(1.4, 0.0)0.01 97.5(2.5, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.3(0.7, 0.0)0.01 99.1(0.9, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 99.8(0.2, 0.0)0.02 99.7(0.3, 0.0)0.03 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
20/20/100 0 99.6(0.4, 0.0)0.01 99.5(0.5, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 99.9(0.1, 0.0)0.01 99.8(0.2, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 99.8(0.0, 0.2)0.03 99.9(0.1, 0.0)0.03 100(0.0, 0.0)0.04 100(0.0, 0.0)0.04
20/20/200 0 97.9(2.1, 0.0)0.00 97.5(2.5, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 99.3(0.5, 0.2)0.01 99.3(0.7, 0.0)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 99.7(0.1, 0.2)0.03 99.8(0.1, 0.1)0.03 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
20/40/100 0 98.4(1.6, 0.0)0.00 97.1(2.9, 0.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 98.6(1.0, 0.4)0.01 98.5(1.3, 0.2)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 99.4(0.5, 0.1)0.01 99.5(0.5, 0.0)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
40/20/100 0 95.4(0.4, 4.2)0.00 96.6(0.4, 3.0)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.01 92.7(0.0, 7.3)0.01 94.4(0.0, 5.6)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 88.1(0.0,11.9)0.02 89.6(0.0,10.4)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
40/20/200 0 97.7(2.1, 0.2)0.00 97.0(2.8, 0.2)0.00 99.6(0.4, 0.0)0.00 99.6(0.4, 0.0)0.00
0.01 94.5(0.2, 5.3)0.01 96.2(0.5, 3.3)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 87.5(0.0,12.5)0.02 90.4(0.0, 9.6)0.02 100(0.0, 0.0)0.02 100(0.0, 0.0)0.02
40/40/100 0 96.9(2.5, 0.6)0.00 96.7(2.9, 0.4)0.00 99.6(0.4, 0.0)0.00 99.6(0.4, 0.0)0.00
0.01 96.9(0.6, 2.5)0.00 97.6(0.7, 1.7)0.00 100(0.0, 0.0)0.00 100(0.0, 0.0)0.00
0.05 89.1(0.3,10.6)0.01 92.4(0.4, 7.2)0.01 100(0.0, 0.0)0.01 99.9(0.1, 0.0)0.01
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.27: Confidence intervals for τ 2c with ‘moderate’ heterogeneity, control group
disease rates rB = {0.35, 0.40, 0.45, 0.50} for Q profile(PQ), Biggerstaff-Tweedie(BT),
Sidik-Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k
trials each with Nj clusters per group of size m, intracluster correlation ρ (truncated),
and odds ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 94.6(3.0, 2.4)0.10 99.0(1.0, 0.0)0.09 46.9(13.4,39.7)0.05 56.2(0.0,43.8)0.01
0.01 95.8(0.9, 3.3)0.15 99.7(0.3, 0.0)0.14 42.5(7.8,49.7)0.07 45.5(0.0,54.5)0.01
0.05 94.8(0.3, 4.9)0.38 99.9(0.1, 0.0)0.37 38.1(3.8,58.1)0.14 38.6(0.0,61.4)0.02
4/20/200 0 90.7(8.6, 0.7)0.07 96.6(3.4, 0.0)0.06 48.6(27.8,23.6)0.04 73.7(0.0,26.3)0.01
0.01 95.9(0.9, 3.2)0.12 99.7(0.3, 0.0)0.11 43.9(9.8,46.3)0.06 50.3(0.0,49.7)0.01
0.05 95.9(0.5, 3.6)0.35 99.6(0.4, 0.0)0.35 38.4(4.8,56.8)0.13 38.0(0.0,62.0)0.02
4/40/100 0 90.7(8.5, 0.8)0.07 96.9(3.1, 0.0)0.06 51.4(24.8,23.8)0.04 73.4(0.0,26.6)0.00
0.01 95.2(3.5, 1.3)0.10 98.7(1.3, 0.0)0.08 49.2(13.3,37.5)0.05 57.1(0.0,42.9)0.01
0.05 94.9(0.6, 4.5)0.21 99.9(0.1, 0.0)0.20 40.7(5.4,53.9)0.09 41.7(0.0,58.3)0.01
12/20/100 0 95.4(1.8, 2.8)0.01 100(0.0, 0.0)0.01 49.6(8.9,41.5)0.01 69.8(0.1,30.1)0.01
0.01 94.5(0.4, 5.1)0.02 100(0.0, 0.0)0.02 42.9(4.1,53.0)0.01 59.1(0.0,40.9)0.01
0.05 87.1(0.2,12.7)0.06 99.9(0.1, 0.0)0.06 33.9(1.6,64.5)0.01 47.6(0.0,52.4)0.02
12/20/200 0 88.2(11.4, 0.4)0.01 96.7(3.3, 0.0)0.01 52.9(31.9,15.2)0.01 89.9(0.7, 9.4)0.00
0.01 95.0(0.9, 4.1)0.02 99.7(0.3, 0.0)0.02 49.8(5.5,44.7)0.01 68.0(0.0,32.0)0.01
0.05 90.1(0.0, 9.9)0.05 100(0.0, 0.0)0.05 32.0(1.5,66.5)0.01 49.1(0.0,50.9)0.02
12/40/100 0 89.4(10.2, 0.4)0.01 97.3(2.7, 0.0)0.01 56.4(29.1,14.5)0.01 90.1(0.3, 9.6)0.00
0.01 96.0(3.0, 1.0)0.02 99.5(0.5, 0.0)0.01 55.3(11.1,33.6)0.01 75.4(0.1,24.5)0.01
0.05 91.8(0.1, 8.1)0.03 99.9(0.1, 0.0)0.03 37.2(3.6,59.2)0.01 54.3(0.0,45.7)0.01
20/20/100 0 96.4(0.9, 2.7)0.01 100(0.0, 0.0)0.01 46.7(6.8,46.5)0.00 75.1(0.0,24.9)0.00
0.01 91.6(0.2, 8.2)0.01 100(0.0, 0.0)0.01 38.0(2.0,60.0)0.00 61.1(0.0,38.9)0.01
0.05 82.2(0.0,17.8)0.04 100(0.0, 0.0)0.04 25.7(0.3,74.0)0.01 47.1(0.0,52.9)0.02
20/20/200 0 84.7(15.0, 0.3)0.01 96.6(3.4, 0.0)0.01 52.8(34.3,12.9)0.00 93.3(1.8, 4.9)0.00
0.01 94.0(0.5, 5.5)0.01 100(0.0, 0.0)0.01 43.4(5.7,50.9)0.00 67.6(0.0,32.4)0.01
0.05 82.7(0.0,17.3)0.03 100(0.0, 0.0)0.03 25.1(0.8,74.1)0.01 45.4(0.0,54.6)0.02
20/40/100 0 86.7(13.0, 0.3)0.01 96.7(3.3, 0.0)0.01 56.7(34.1, 9.2)0.00 94.1(1.4, 4.5)0.00
0.01 94.9(4.1, 1.0)0.01 99.3(0.7, 0.0)0.01 53.6(11.6,34.8)0.00 78.9(0.4,20.7)0.01
0.05 86.1(0.1,13.8)0.02 100(0.0, 0.0)0.02 32.5(1.7,65.8)0.01 53.7(0.0,46.3)0.01
40/20/100 0 95.5(1.3, 3.2)0.01 89.2(0.0,10.8)0.01 43.9(4.9,51.2)0.00 75.8(0.0,24.2)0.00
0.01 85.3(0.0,14.7)0.01 75.9(0.0,24.1)0.01 27.1(0.9,72.0)0.00 57.8(0.0,42.2)0.01
0.05 59.6(0.0,40.4)0.02 52.1(0.0,47.9)0.02 11.5(0.0,88.5)0.00 31.4(0.0,68.6)0.01
40/20/200 0 78.2(21.8, 0.0)0.00 95.1(4.9, 0.0)0.00 51.2(40.9, 7.9)0.00 95.2(2.6, 2.2)0.00
0.01 90.9(0.0, 9.1)0.01 85.1(0.0,14.9)0.01 30.6(2.8,66.6)0.00 64.3(0.0,35.7)0.01
0.05 64.5(0.1,35.4)0.02 54.2(0.0,45.8)0.02 11.4(0.2,88.4)0.00 34.3(0.0,65.7)0.01
40/40/100 0 72.6(27.4, 0.0)0.00 93.8(5.9, 0.3)0.00 49.9(44.0, 6.1)0.00 94.4(3.9, 1.7)0.00
0.01 95.1(3.2, 1.7)0.01 92.9(0.1, 7.0)0.01 52.1(7.5,40.4)0.00 82.0(0.0,18.0)0.00
0.05 76.6(0.0,23.4)0.01 65.5(0.0,34.5)0.01 18.5(0.1,81.4)0.00 44.2(0.0,55.8)0.01
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.28: Confidence intervals for τ 2c with ‘moderate’ heterogeneity, control group
disease rates rB = {0.35, 0.40, 0.45, 0.50} for profile likelihood, and Wald-Type based
on 1000 simulations of k trials each with Nj clusters per group of size m, intracluster
correlation ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.6(0.4, 0.0)0.03 99.0(1.0, 0.0)0.06 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.01 100(0.0, 0.0)0.05 99.7(0.3, 0.0)0.10 100(0.0, 0.0)0.03 100(0.0, 0.0)0.04
0.05 100(0.0, 0.0)0.12 99.9(0.1, 0.0)0.24 100(0.0, 0.0)0.09 100(0.0, 0.0)0.12
4/20/200 0 98.7(1.3, 0.0)0.02 96.7(3.3, 0.0)0.04 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.01 100(0.0, 0.0)0.04 99.7(0.3, 0.0)0.08 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.05 99.8(0.2, 0.0)0.11 99.7(0.3, 0.0)0.23 100(0.0, 0.0)0.08 100(0.0, 0.0)0.11
4/40/100 0 98.9(1.1, 0.0)0.02 97.0(3.0, 0.0)0.04 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.01 99.4(0.6, 0.0)0.03 98.7(1.3, 0.0)0.06 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.05 100(0.0, 0.0)0.07 100(0.0, 0.0)0.13 100(0.0, 0.0)0.05 100(0.0, 0.0)0.06
12/20/100 0 98.1(0.0, 1.9)0.01 99.5(0.1, 0.4)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 96.0(0.0, 4.0)0.02 98.8(0.0, 1.2)0.02 99.9(0.0, 0.1)0.02 100(0.0, 0.0)0.02
0.05 90.8(0.0, 9.2)0.04 96.1(0.2, 3.7)0.05 100(0.0, 0.0)0.05 100(0.0, 0.0)0.05
12/20/200 0 97.0(2.9, 0.1)0.01 95.4(4.5, 0.1)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 96.4(0.2, 3.4)0.01 97.8(0.6, 1.6)0.02 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.05 92.0(0.0, 8.0)0.04 96.5(0.0, 3.5)0.05 100(0.0, 0.0)0.04 100(0.0, 0.0)0.05
12/40/100 0 97.8(1.9, 0.3)0.01 96.6(3.3, 0.1)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.01 98.8(0.3, 0.9)0.01 99.2(0.7, 0.1)0.01 100(0.0, 0.0)0.01 100(0.0, 0.0)0.01
0.05 93.9(0.1, 6.0)0.02 97.2(0.1, 2.7)0.03 100(0.0, 0.0)0.03 100(0.0, 0.0)0.03
20/20/100 0 93.1(0.0, 6.9)0.01 95.9(0.0, 4.1)0.01 89.3(0.0,10.7)0.01 96.9(0.0, 3.1)0.01
0.01 85.1(0.0,14.9)0.01 90.4(0.1, 9.5)0.01 64.3(0.0,35.7)0.01 74.7(0.0,25.3)0.01
0.05 76.0(0.0,24.0)0.03 82.7(0.0,17.3)0.03 49.1(0.0,50.9)0.04 59.2(0.0,40.8)0.04
20/20/200 0 96.3(3.2, 0.5)0.01 94.6(5.0, 0.4)0.01 99.0(0.0, 1.0)0.01 99.8(0.0, 0.2)0.01
0.01 90.3(0.0, 9.7)0.01 93.9(0.2, 5.9)0.01 70.2(0.0,29.8)0.01 78.3(0.0,21.7)0.01
0.05 74.5(0.0,25.5)0.03 82.0(0.0,18.0)0.03 44.3(0.0,55.7)0.03 53.2(0.0,46.8)0.04
20/40/100 0 96.3(3.1, 0.6)0.01 95.3(4.2, 0.5)0.01 97.3(0.1, 2.6)0.01 99.2(0.1, 0.7)0.01
0.01 95.0(0.6, 4.4)0.01 96.6(0.9, 2.5)0.01 81.6(0.0,18.4)0.01 85.6(0.0,14.4)0.01
0.05 79.3(0.0,20.7)0.02 85.3(0.0,14.7)0.02 55.4(0.0,44.6)0.02 63.5(0.0,36.5)0.02
40/20/100 0 87.5(0.0,12.5)0.01 89.8(0.0,10.2)0.01 76.3(0.0,23.7)0.01 79.0(0.0,21.0)0.01
0.01 74.6(0.0,25.4)0.01 77.4(0.0,22.6)0.01 57.2(0.0,42.8)0.01 61.6(0.0,38.4)0.01
0.05 48.6(0.0,51.4)0.02 56.0(0.0,44.0)0.02 29.1(0.0,70.9)0.03 34.1(0.0,65.9)0.03
40/20/200 0 94.4(5.1, 0.5)0.00 93.4(6.4, 0.2)0.00 98.1(0.1, 1.8)0.00 98.3(0.5, 1.2)0.00
0.01 82.9(0.0,17.1)0.01 86.4(0.0,13.6)0.01 64.3(0.0,35.7)0.01 70.2(0.0,29.8)0.01
0.05 51.4(0.0,48.6)0.02 57.0(0.0,43.0)0.02 31.2(0.0,68.8)0.02 37.3(0.0,62.7)0.02
40/40/100 0 93.5(6.2, 0.3)0.00 92.4(7.3, 0.3)0.00 98.5(0.4, 1.1)0.00 99.1(0.4, 0.5)0.00
0.01 91.6(0.1, 8.3)0.01 94.2(0.2, 5.6)0.01 83.2(0.0,16.8)0.01 86.5(0.0,13.5)0.01
0.05 62.2(0.0,37.8)0.01 67.7(0.0,32.3)0.01 41.9(0.0,58.1)0.01 48.1(0.0,51.9)0.01
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.29: Confidence intervals for τ 2c with ‘high’ heterogeneity, control group disease
rates rB = {0.35, 0.40, 0.45, 0.50} for Q profile(PQ), Biggerstaff-Tweedie(BT), Sidik-
Jonkman(SJ) and nonparametric bootstraps(NB) based on 1000 simulations of k trials
each with Nj clusters per group of size m, intracluster correlation ρ (truncated), and odds
ratio ψ = 0.7.
QP BT SJ NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 96.6(1.6, 1.8)0.12 99.4(0.6, 0.0)0.10 56.3(8.5,35.2)0.06 53.5(0.0,46.5)0.01
0.01 96.0(0.5, 3.5)0.18 99.8(0.2, 0.0)0.16 52.8(3.2,44.0)0.09 44.5(0.0,55.5)0.01
0.05 95.0(0.1, 4.9)0.40 99.9(0.1, 0.0)0.38 41.4(2.2,56.4)0.16 30.7(0.0,69.3)0.02
4/20/200 0 94.3(4.8, 0.9)0.09 97.8(2.2, 0.0)0.07 63.1(23.6,13.3)0.06 78.3(0.0,21.7)0.01
0.01 97.2(0.7, 2.1)0.14 99.7(0.3, 0.0)0.12 56.8(5.1,38.1)0.07 47.7(0.0,52.3)0.01
0.05 94.2(0.0, 5.8)0.34 100(0.0, 0.0)0.34 39.8(0.5,59.7)0.12 28.8(0.0,71.2)0.02
4/40/100 0 94.4(5.2, 0.4)0.09 97.9(2.1, 0.0)0.07 64.4(21.3,14.3)0.06 76.6(0.0,23.4)0.01
0.01 96.3(2.0, 1.7)0.12 99.2(0.8, 0.0)0.10 61.6(8.4,30.0)0.07 58.9(0.0,41.1)0.01
0.05 95.7(0.4, 3.9)0.22 99.8(0.2, 0.0)0.21 46.4(2.6,51.0)0.10 36.3(0.0,63.7)0.01
12/20/100 0 97.7(0.4, 1.9)0.02 99.9(0.1, 0.0)0.02 64.5(5.5,30.0)0.01 72.6(0.0,27.4)0.01
0.01 93.6(0.2, 6.2)0.03 100(0.0, 0.0)0.02 47.0(1.1,51.9)0.01 52.7(0.0,47.3)0.01
0.05 85.5(0.0,14.5)0.06 100(0.0, 0.0)0.06 31.8(0.2,68.0)0.02 38.4(0.0,61.6)0.02
12/20/200 0 93.4(6.3, 0.3)0.01 96.7(3.3, 0.0)0.01 63.0(28.4, 8.6)0.01 92.2(0.4, 7.4)0.01
0.01 94.7(0.4, 4.9)0.02 99.9(0.1, 0.0)0.02 58.3(2.9,38.8)0.01 65.0(0.0,35.0)0.01
0.05 84.9(0.0,15.1)0.06 100(0.0, 0.0)0.06 32.8(0.1,67.1)0.02 37.7(0.0,62.3)0.02
12/40/100 0 92.2(7.7, 0.1)0.01 96.9(3.1, 0.0)0.01 64.3(29.2, 6.5)0.01 92.5(0.5, 7.0)0.01
0.01 96.3(0.7, 3.0)0.02 99.7(0.3, 0.0)0.02 66.7(7.4,25.9)0.01 75.3(0.0,24.7)0.01
0.05 90.3(0.0, 9.7)0.04 100(0.0, 0.0)0.03 40.1(0.6,59.3)0.01 44.9(0.0,55.1)0.01
20/20/100 0 97.6(0.1, 2.3)0.01 100(0.0, 0.0)0.01 59.3(4.1,36.6)0.00 72.7(0.0,27.3)0.01
0.01 88.2(0.1,11.7)0.02 92.3(0.0, 7.7)0.02 39.5(0.5,60.0)0.01 52.1(0.0,47.9)0.01
0.05 70.5(0.0,29.5)0.04 88.7(0.0,11.3)0.04 17.2(0.0,82.8)0.01 28.1(0.0,71.9)0.02
20/20/200 0 91.3(8.7, 0.0)0.01 96.0(4.0, 0.0)0.01 63.1(32.5, 4.4)0.00 94.9(1.7, 3.4)0.01
0.01 93.0(0.1, 6.9)0.01 97.2(0.0, 2.8)0.01 52.4(0.8,46.8)0.01 63.8(0.0,36.2)0.01
0.05 71.8(0.0,28.2)0.04 92.9(0.0, 7.1)0.04 20.9(0.1,79.0)0.01 30.5(0.0,69.5)0.02
20/40/100 0 88.8(11.1, 0.1)0.01 94.6(5.4, 0.0)0.01 59.3(35.9, 4.8)0.01 94.1(2.5, 3.4)0.01
0.01 97.1(0.6, 2.3)0.01 98.6(0.1, 1.3)0.01 65.5(5.3,29.2)0.01 77.6(0.0,22.4)0.01
0.05 79.9(0.0,20.1)0.02 91.4(0.0, 8.6)0.02 30.2(0.3,69.5)0.01 41.3(0.0,58.7)0.01
40/20/100 0 92.5(0.0, 7.5)0.01 87.6(0.0,12.4)0.01 54.8(1.1,44.1)0.00 72.4(0.0,27.6)0.01
0.01 74.0(0.0,26.0)0.01 62.5(0.0,37.5)0.01 22.1(0.1,77.8)0.00 40.1(0.0,59.9)0.01
0.05 39.5(0.0,60.5)0.02 30.5(0.0,69.5)0.02 4.8(0.0,95.2)0.00 13.5(0.0,86.5)0.02
40/20/200 0 84.9(15.0, 0.1)0.01 93.1(6.6, 0.3)0.01 53.8(44.2, 2.0)0.00 93.9(5.2, 0.9)0.00
0.01 86.3(0.0,13.7)0.01 78.4(0.0,21.6)0.01 39.3(0.1,60.6)0.00 57.9(0.0,42.1)0.01
0.05 39.3(0.0,60.7)0.02 29.7(0.0,70.3)0.02 5.2(0.0,94.8)0.00 14.5(0.0,85.5)0.01
40/40/100 0 83.8(16.2, 0.0)0.01 92.8(7.2, 0.0)0.01 49.8(48.6, 1.6)0.00 93.6(6.0, 0.4)0.00
0.01 95.5(0.2, 4.3)0.01 93.4(0.0, 6.6)0.01 62.0(2.4,35.6)0.00 78.8(0.0,21.2)0.01
0.05 61.0(0.0,39.0)0.01 46.8(0.0,53.2)0.01 10.8(0.0,89.2)0.00 25.7(0.0,74.3)0.01
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.30: Confidence intervals for τ 2c with ‘high’ heterogeneity, control group disease
rates rB = {0.35, 0.40, 0.45, 0.50} for profile likelihood, and Wald-Type based on 1000
simulations of k trials each with Nj clusters per group of size m, intracluster correlation
ρ (truncated), and odds ratio ψ = 0.7.
pML pRE wML wRE
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 99.9(0.1, 0.0)0.04 99.5(0.5, 0.0)0.07 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.01 99.9(0.1, 0.0)0.06 99.8(0.2, 0.0)0.11 100(0.0, 0.0)0.03 100(0.0, 0.0)0.05
0.05 100(0.0, 0.0)0.13 99.9(0.1, 0.0)0.26 100(0.0, 0.0)0.09 100(0.0, 0.0)0.12
4/20/200 0 99.0(1.0, 0.0)0.03 97.8(2.2, 0.0)0.05 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.01 99.9(0.1, 0.0)0.05 99.7(0.3, 0.0)0.09 100(0.0, 0.0)0.03 100(0.0, 0.0)0.04
0.05 100(0.0, 0.0)0.11 100(0.0, 0.0)0.22 100(0.0, 0.0)0.08 100(0.0, 0.0)0.10
4/40/100 0 99.0(1.0, 0.0)0.03 98.1(1.9, 0.0)0.05 100(0.0, 0.0)0.01 100(0.0, 0.0)0.02
0.01 99.9(0.1, 0.0)0.04 99.2(0.8, 0.0)0.07 100(0.0, 0.0)0.02 100(0.0, 0.0)0.03
0.05 100(0.0, 0.0)0.07 99.9(0.1, 0.0)0.14 100(0.0, 0.0)0.05 100(0.0, 0.0)0.06
12/20/100 0 95.8(0.1, 4.1)0.01 98.3(0.1, 1.6)0.02 77.6(0.0,22.4)0.01 84.9(0.0,15.1)0.01
0.01 87.2(0.0,12.8)0.02 93.4(0.0, 6.6)0.02 56.8(0.0,43.2)0.02 66.7(0.0,33.3)0.02
0.05 74.3(0.0,25.7)0.05 85.2(0.0,14.8)0.06 40.7(0.0,59.3)0.05 50.4(0.0,49.6)0.06
12/20/200 0 97.0(2.5, 0.5)0.01 95.8(3.8, 0.4)0.01 95.1(0.0, 4.9)0.01 97.1(0.0, 2.9)0.01
0.01 91.5(0.1, 8.4)0.02 94.6(0.1, 5.3)0.02 67.7(0.0,32.3)0.02 76.3(0.0,23.7)0.02
0.05 74.9(0.0,25.1)0.04 84.4(0.0,15.6)0.05 41.4(0.0,58.6)0.05 51.4(0.0,48.6)0.05
12/40/100 0 96.8(2.8, 0.4)0.01 95.7(4.2, 0.1)0.01 96.3(0.0, 3.7)0.01 97.1(0.0, 2.9)0.01
0.01 94.4(0.2, 5.4)0.01 96.4(0.3, 3.3)0.02 80.9(0.0,19.1)0.01 86.2(0.0,13.8)0.01
0.05 81.2(0.0,18.8)0.03 89.4(0.0,10.6)0.03 50.2(0.0,49.8)0.03 59.8(0.0,40.2)0.03
20/20/100 0 93.3(0.0, 6.7)0.01 95.6(0.0, 4.4)0.01 77.4(0.0,22.6)0.01 83.4(0.0,16.6)0.01
0.01 75.7(0.0,24.3)0.01 83.0(0.0,17.0)0.02 53.7(0.0,46.3)0.01 60.8(0.0,39.2)0.02
0.05 55.0(0.0,45.0)0.03 63.9(0.0,36.1)0.03 28.7(0.0,71.3)0.04 35.8(0.0,64.2)0.04
20/20/200 0 95.9(3.9, 0.2)0.01 94.9(5.0, 0.1)0.01 98.4(0.0, 1.6)0.01 99.0(0.0, 1.0)0.01
0.01 85.9(0.0,14.1)0.01 90.1(0.0, 9.9)0.01 66.6(0.0,33.4)0.01 72.5(0.0,27.5)0.01
0.05 55.9(0.0,44.1)0.03 64.7(0.0,35.3)0.03 32.3(0.0,67.7)0.04 39.7(0.0,60.3)0.04
20/40/100 0 94.3(5.1, 0.6)0.01 92.2(7.5, 0.3)0.01 97.7(0.0, 2.3)0.01 98.2(0.0, 1.8)0.01
0.01 93.5(0.1, 6.4)0.01 95.8(0.3, 3.9)0.01 81.9(0.0,18.1)0.01 86.2(0.0,13.8)0.01
0.05 66.1(0.0,33.9)0.02 72.5(0.0,27.5)0.02 41.4(0.0,58.6)0.02 50.4(0.0,49.6)0.02
40/20/100 0 87.1(0.0,12.9)0.01 88.6(0.0,11.4)0.01 75.0(0.0,25.0)0.01 78.1(0.0,21.9)0.01
0.01 61.3(0.0,38.7)0.01 65.4(0.0,34.6)0.01 40.6(0.0,59.4)0.01 46.3(0.0,53.7)0.01
0.05 28.0(0.0,72.0)0.02 32.5(0.0,67.5)0.02 13.2(0.0,86.8)0.03 16.2(0.0,83.8)0.03
40/20/200 0 92.2(7.5, 0.3)0.01 90.6(9.2, 0.2)0.01 98.4(0.9, 0.7)0.00 98.2(1.1, 0.7)0.00
0.01 76.6(0.0,23.4)0.01 80.3(0.0,19.7)0.01 58.8(0.0,41.2)0.01 63.7(0.0,36.3)0.01
0.05 28.1(0.0,71.9)0.02 31.9(0.0,68.1)0.02 13.5(0.0,86.5)0.02 16.8(0.0,83.2)0.02
40/40/100 0 91.9(8.1, 0.0)0.01 90.1(9.9, 0.0)0.01 99.5(0.4, 0.1)0.00 99.4(0.5, 0.1)0.00
0.01 92.5(0.0, 7.5)0.01 93.8(0.1, 6.1)0.01 80.7(0.0,19.3)0.01 84.9(0.0,15.1)0.01
0.05 43.9(0.0,56.1)0.01 50.1(0.0,49.9)0.01 24.1(0.0,75.9)0.01 29.1(0.0,70.9)0.01
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.31: Bias and MSE for the measures of heterogeneity with ‘no’ heterogeneity and
control group disease rates rA = {0.04, 0.07, 0.10, 0.13} based on 1000 simulations of k
trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated), and
odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.117 0.099 0.128 0.070 0.050 0.065
0.01 0.156 0.132 0.165 0.100 0.071 0.088
0.05 0.148 0.127 0.160 0.089 0.065 0.084
4/20/200 0 0.131 0.110 0.145 0.076 0.053 0.074
0.01 0.163 0.138 0.171 0.109 0.077 0.091
0.05 0.150 0.129 0.160 0.094 0.069 0.085
4/40/100 0 0.143 0.121 0.152 0.092 0.065 0.080
0.01 0.145 0.122 0.150 0.094 0.066 0.082
0.05 0.158 0.134 0.167 0.102 0.073 0.088
12/20/100 0 0.059 0.059 0.084 0.016 0.016 0.028
0.01 0.080 0.081 0.114 0.023 0.023 0.039
0.05 0.067 0.068 0.098 0.017 0.018 0.031
12/20/200 0 0.059 0.059 0.085 0.016 0.016 0.028
0.01 0.072 0.073 0.103 0.020 0.020 0.036
0.05 0.075 0.077 0.108 0.020 0.021 0.037
12/40/100 0 0.064 0.064 0.091 0.018 0.018 0.031
0.01 0.081 0.082 0.113 0.024 0.024 0.040
0.05 0.083 0.084 0.117 0.024 0.024 0.041
20/20/100 0 0.041 0.043 0.065 0.008 0.009 0.017
0.01 0.053 0.056 0.082 0.011 0.012 0.023
0.05 0.051 0.055 0.081 0.010 0.011 0.021
20/20/200 0 0.044 0.046 0.068 0.009 0.010 0.019
0.01 0.058 0.061 0.090 0.012 0.013 0.025
0.05 0.059 0.063 0.090 0.012 0.014 0.026
20/40/100 0 0.045 0.047 0.070 0.009 0.009 0.019
0.01 0.061 0.064 0.093 0.013 0.015 0.027
0.05 0.060 0.063 0.092 0.013 0.014 0.026
40/20/100 0 0.022 0.024 0.037 0.003 0.003 0.007
0.01 0.040 0.043 0.066 0.005 0.006 0.014
0.05 0.035 0.038 0.058 0.005 0.006 0.012
40/20/200 0 0.023 0.025 0.039 0.003 0.003 0.007
0.01 0.044 0.047 0.073 0.006 0.007 0.015
0.05 0.039 0.043 0.066 0.005 0.006 0.013
40/40/100 0 0.030 0.032 0.049 0.004 0.005 0.010
0.01 0.042 0.045 0.069 0.006 0.007 0.015
0.05 0.039 0.043 0.065 0.006 0.006 0.014
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Table 6.32: Bias and MSE for the measures of heterogeneity with ‘low’ heterogeneity and
control group disease rates rA = {0.04, 0.07, 0.10, 0.13} based on 1000 simulations of k
trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated), and
odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.004 0.005 0.117 0.116 0.083 0.088
0.01 0.012 0.008 0.100 0.119 0.085 0.087
0.05 0.050 0.045 0.151 0.081 0.060 0.084
4/20/200 0 0.133 0.110 0.007 0.200 0.142 0.093
0.01 0.040 0.032 0.079 0.140 0.100 0.088
0.05 0.048 0.042 0.147 0.083 0.062 0.082
4/40/100 0 0.148 0.122 0.002 0.210 0.148 0.095
0.01 0.062 0.051 0.055 0.141 0.100 0.086
0.05 0.021 0.020 0.126 0.096 0.070 0.085
12/20/100 0 0.047 0.050 0.104 0.028 0.029 0.048
0.01 0.061 0.063 0.119 0.025 0.026 0.047
0.05 0.086 0.089 0.150 0.023 0.024 0.048
12/20/200 0 0.053 0.050 0.007 0.048 0.046 0.048
0.01 0.035 0.037 0.087 0.028 0.029 0.045
0.05 0.084 0.087 0.148 0.023 0.025 0.048
12/40/100 0 0.037 0.033 0.009 0.042 0.041 0.046
0.01 0.001 0.004 0.051 0.036 0.036 0.046
0.05 0.067 0.070 0.127 0.025 0.026 0.047
20/20/100 0 0.058 0.063 0.108 0.019 0.021 0.038
0.01 0.065 0.070 0.119 0.020 0.022 0.041
0.05 0.103 0.109 0.168 0.019 0.021 0.045
20/20/200 0 0.014 0.012 0.017 0.024 0.025 0.033
0.01 0.059 0.064 0.109 0.019 0.021 0.038
0.05 0.094 0.100 0.156 0.019 0.021 0.043
20/40/100 0 0.035 0.033 0.004 0.029 0.030 0.035
0.01 0.019 0.022 0.060 0.023 0.025 0.036
0.05 0.082 0.087 0.139 0.018 0.021 0.041
40/20/100 0 0.075 0.082 0.124 0.014 0.016 0.032
0.01 0.083 0.090 0.134 0.014 0.017 0.033
0.05 0.109 0.118 0.173 0.016 0.019 0.041
40/20/200 0 0.010 0.008 0.009 0.013 0.015 0.021
0.01 0.069 0.075 0.114 0.013 0.015 0.030
0.05 0.103 0.112 0.165 0.016 0.019 0.039
40/40/100 0 0.020 0.019 0.001 0.017 0.018 0.023
0.01 0.039 0.043 0.072 0.012 0.014 0.025
0.05 0.100 0.108 0.159 0.015 0.018 0.038
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Table 6.33: Bias and MSE for the measures of heterogeneity with ‘moderate’ heterogeneity
and control group disease rates rA = {0.04, 0.07, 0.10, 0.13} based on 1000 simulations of
k trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated),
and odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.046 0.040 0.168 0.178 0.128 0.120
0.01 0.129 0.111 0.233 0.158 0.115 0.137
0.05 0.220 0.191 0.306 0.133 0.100 0.157
4/20/200 0 0.153 0.126 0.046 0.296 0.209 0.101
0.01 0.098 0.085 0.208 0.165 0.119 0.131
0.05 0.198 0.171 0.286 0.134 0.100 0.150
4/40/100 0 0.187 0.155 0.021 0.306 0.216 0.095
0.01 0.017 0.016 0.151 0.194 0.139 0.117
0.05 0.164 0.141 0.258 0.142 0.104 0.143
12/20/100 0 0.101 0.103 0.151 0.053 0.053 0.068
0.01 0.161 0.164 0.221 0.061 0.062 0.092
0.05 0.220 0.223 0.286 0.067 0.069 0.111
12/20/200 0 0.068 0.064 0.004 0.067 0.063 0.042
0.01 0.123 0.125 0.176 0.055 0.056 0.077
0.05 0.224 0.227 0.293 0.070 0.072 0.115
12/40/100 0 0.085 0.080 0.014 0.073 0.069 0.044
0.01 0.061 0.063 0.116 0.057 0.056 0.063
0.05 0.184 0.186 0.243 0.061 0.062 0.097
20/20/100 0 0.110 0.115 0.151 0.040 0.043 0.058
0.01 0.171 0.178 0.224 0.051 0.055 0.083
0.05 0.229 0.239 0.297 0.063 0.070 0.109
20/20/200 0 0.074 0.073 0.032 0.040 0.040 0.025
0.01 0.134 0.139 0.177 0.043 0.046 0.066
0.05 0.226 0.235 0.291 0.062 0.068 0.106
20/40/100 0 0.095 0.093 0.043 0.050 0.050 0.029
0.01 0.068 0.072 0.107 0.038 0.040 0.048
0.05 0.201 0.209 0.260 0.056 0.061 0.094
40/20/100 0 0.133 0.140 0.164 0.032 0.036 0.049
0.01 0.178 0.188 0.222 0.042 0.048 0.069
0.05 0.245 0.261 0.319 0.065 0.075 0.114
40/20/200 0 0.050 0.050 0.026 0.020 0.021 0.014
0.01 0.147 0.155 0.182 0.035 0.039 0.055
0.05 0.238 0.253 0.308 0.063 0.071 0.108
40/40/100 0 0.074 0.075 0.046 0.024 0.025 0.014
0.01 0.075 0.079 0.095 0.021 0.023 0.029
0.05 0.206 0.218 0.260 0.051 0.058 0.085
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Table 6.34: Bias and MSE for the measures of heterogeneity with ‘high’ heterogeneity
and control group disease rates rA = {0.04, 0.07, 0.10, 0.13} based on 1000 simulations of
k trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated),
and odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.116 0.100 0.210 0.226 0.163 0.143
0.01 0.242 0.207 0.297 0.218 0.158 0.177
0.05 0.350 0.302 0.380 0.217 0.162 0.213
4/20/200 0 0.207 0.173 0.034 0.377 0.267 0.089
0.01 0.167 0.142 0.244 0.217 0.157 0.158
0.05 0.344 0.295 0.376 0.220 0.164 0.212
4/40/100 0 0.252 0.210 0.008 0.397 0.281 0.080
0.01 0.038 0.033 0.169 0.267 0.191 0.132
0.05 0.288 0.246 0.332 0.217 0.159 0.192
12/20/100 0 0.161 0.161 0.180 0.076 0.076 0.079
0.01 0.235 0.234 0.256 0.098 0.098 0.112
0.05 0.349 0.350 0.383 0.142 0.143 0.178
12/20/200 0 0.103 0.097 0.017 0.087 0.081 0.032
0.01 0.197 0.196 0.218 0.089 0.088 0.096
0.05 0.337 0.338 0.369 0.136 0.138 0.170
12/40/100 0 0.136 0.129 0.040 0.092 0.085 0.028
0.01 0.087 0.087 0.117 0.070 0.068 0.058
0.05 0.293 0.292 0.317 0.118 0.118 0.141
20/20/100 0 0.161 0.164 0.169 0.060 0.063 0.063
0.01 0.244 0.249 0.256 0.086 0.090 0.100
0.05 0.350 0.360 0.387 0.135 0.144 0.173
20/20/200 0 0.102 0.100 0.038 0.052 0.051 0.018
0.01 0.197 0.201 0.207 0.071 0.075 0.078
0.05 0.338 0.348 0.371 0.128 0.137 0.162
20/40/100 0 0.125 0.122 0.050 0.058 0.057 0.020
0.01 0.101 0.103 0.112 0.047 0.049 0.043
0.05 0.299 0.306 0.321 0.109 0.116 0.134
40/20/100 0 0.169 0.175 0.162 0.045 0.049 0.045
0.01 0.259 0.269 0.265 0.081 0.088 0.092
0.05 0.357 0.375 0.398 0.134 0.148 0.172
40/20/200 0 0.096 0.097 0.049 0.029 0.029 0.010
0.01 0.198 0.205 0.194 0.056 0.061 0.059
0.05 0.346 0.363 0.381 0.127 0.140 0.160
40/40/100 0 0.111 0.112 0.057 0.033 0.033 0.010
0.01 0.103 0.106 0.097 0.028 0.030 0.025
0.05 0.304 0.317 0.323 0.103 0.113 0.124
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Table 6.35: Bias and MSE for the measures of heterogeneity with ‘no’ heterogeneity and
control group disease rates rB = {0.35, 0.45, 0.50, 0.55} based on 1000 simulations of k
trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated), and
odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.123 0.097 0.135 0.073 0.046 0.068
0.01 0.168 0.133 0.174 0.118 0.075 0.094
0.05 0.156 0.124 0.160 0.108 0.070 0.087
4/20/200 0 0.141 0.111 0.153 0.086 0.054 0.080
0.01 0.162 0.128 0.170 0.106 0.068 0.091
0.05 0.178 0.141 0.180 0.125 0.081 0.100
4/40/100 0 0.137 0.108 0.148 0.086 0.054 0.077
0.01 0.167 0.132 0.174 0.109 0.069 0.093
0.05 0.161 0.127 0.167 0.107 0.069 0.090
12/20/100 0 0.060 0.055 0.087 0.015 0.013 0.028
0.01 0.082 0.076 0.115 0.025 0.022 0.041
0.05 0.080 0.074 0.111 0.024 0.021 0.040
12/20/200 0 0.050 0.046 0.075 0.012 0.010 0.023
0.01 0.092 0.085 0.129 0.027 0.024 0.046
0.05 0.081 0.075 0.114 0.024 0.021 0.040
12/40/100 0 0.065 0.060 0.092 0.019 0.016 0.032
0.01 0.081 0.075 0.114 0.023 0.020 0.040
0.05 0.084 0.078 0.117 0.026 0.022 0.042
20/20/100 0 0.042 0.040 0.065 0.009 0.008 0.018
0.01 0.070 0.067 0.104 0.017 0.016 0.032
0.05 0.059 0.057 0.090 0.013 0.012 0.026
20/20/200 0 0.043 0.041 0.066 0.009 0.008 0.018
0.01 0.062 0.060 0.095 0.013 0.012 0.028
0.05 0.057 0.054 0.086 0.012 0.011 0.025
20/40/100 0 0.047 0.045 0.072 0.010 0.009 0.020
0.01 0.061 0.058 0.093 0.013 0.012 0.027
0.05 0.062 0.060 0.094 0.014 0.013 0.028
40/20/100 0 0.025 0.024 0.041 0.003 0.003 0.008
0.01 0.045 0.044 0.074 0.007 0.006 0.016
0.05 0.047 0.046 0.076 0.007 0.007 0.017
40/20/200 0 0.025 0.024 0.041 0.003 0.003 0.008
0.01 0.045 0.044 0.074 0.007 0.006 0.016
0.05 0.042 0.041 0.069 0.006 0.006 0.015
40/40/100 0 0.029 0.029 0.049 0.004 0.004 0.010
0.01 0.043 0.043 0.072 0.006 0.006 0.015
0.05 0.039 0.038 0.064 0.006 0.006 0.014
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Table 6.36: Bias and MSE for the measures of heterogeneity with ‘low’ heterogeneity and
control group disease rates rB = {0.35, 0.45, 0.50, 0.55} based on 1000 simulations of k
trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated), and
odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.033 0.031 0.073 0.119 0.077 0.080
0.01 0.029 0.028 0.079 0.113 0.073 0.085
0.05 0.030 0.019 0.133 0.092 0.059 0.083
4/20/200 0 0.126 0.105 0.001 0.170 0.111 0.089
0.01 0.044 0.040 0.069 0.131 0.085 0.085
0.05 0.022 0.013 0.124 0.095 0.061 0.081
4/40/100 0 0.142 0.119 0.009 0.191 0.126 0.090
0.01 0.072 0.063 0.047 0.145 0.095 0.088
0.05 0.007 0.001 0.109 0.097 0.062 0.081
12/20/100 0 0.044 0.040 0.097 0.027 0.023 0.045
0.01 0.043 0.039 0.100 0.029 0.025 0.047
0.05 0.065 0.060 0.126 0.026 0.023 0.048
12/20/200 0 0.036 0.034 0.012 0.044 0.039 0.048
0.01 0.038 0.035 0.093 0.030 0.026 0.046
0.05 0.070 0.064 0.132 0.026 0.023 0.049
12/40/100 0 0.056 0.053 0.012 0.046 0.040 0.047
0.01 0.008 0.007 0.059 0.034 0.030 0.046
0.05 0.061 0.056 0.119 0.025 0.022 0.046
20/20/100 0 0.060 0.057 0.109 0.018 0.017 0.037
0.01 0.057 0.055 0.107 0.019 0.017 0.038
0.05 0.082 0.079 0.141 0.019 0.017 0.042
20/20/200 0 0.021 0.021 0.011 0.027 0.025 0.035
0.01 0.046 0.044 0.092 0.019 0.018 0.037
0.05 0.084 0.081 0.144 0.019 0.017 0.042
20/40/100 0 0.041 0.040 0.014 0.028 0.026 0.034
0.01 0.018 0.017 0.059 0.023 0.021 0.036
0.05 0.076 0.072 0.132 0.020 0.018 0.041
40/20/100 0 0.071 0.069 0.117 0.014 0.013 0.031
0.01 0.080 0.078 0.132 0.014 0.014 0.034
0.05 0.100 0.098 0.160 0.016 0.015 0.039
40/20/200 0 0.011 0.011 0.007 0.014 0.013 0.021
0.01 0.065 0.063 0.109 0.013 0.013 0.030
0.05 0.098 0.096 0.158 0.016 0.015 0.039
40/40/100 0 0.019 0.019 0.001 0.016 0.015 0.023
0.01 0.031 0.030 0.062 0.013 0.012 0.025
0.05 0.086 0.085 0.141 0.015 0.015 0.036
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Table 6.37: Bias and MSE for the measures of heterogeneity with ‘moderate’ heterogeneity
and control group disease rates rB = {0.35, 0.45, 0.50, 0.55} based on 1000 simulations of
k trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated),
and odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.020 0.009 0.153 0.185 0.121 0.118
0.01 0.097 0.072 0.211 0.157 0.101 0.132
0.05 0.175 0.135 0.269 0.130 0.083 0.144
4/20/200 0 0.194 0.164 0.016 0.312 0.210 0.097
0.01 0.066 0.046 0.188 0.168 0.109 0.126
0.05 0.176 0.135 0.273 0.141 0.090 0.145
4/40/100 0 0.183 0.156 0.020 0.304 0.204 0.096
0.01 0.000 0.007 0.139 0.200 0.132 0.115
0.05 0.142 0.108 0.246 0.144 0.092 0.140
12/20/100 0 0.107 0.099 0.161 0.054 0.047 0.073
0.01 0.153 0.142 0.213 0.059 0.051 0.089
0.05 0.210 0.195 0.277 0.067 0.058 0.109
12/20/200 0 0.085 0.081 0.012 0.076 0.067 0.045
0.01 0.116 0.107 0.172 0.056 0.049 0.076
0.05 0.208 0.193 0.275 0.067 0.058 0.109
12/40/100 0 0.088 0.083 0.019 0.071 0.062 0.042
0.01 0.055 0.051 0.111 0.056 0.048 0.062
0.05 0.172 0.160 0.236 0.063 0.055 0.098
20/20/100 0 0.123 0.118 0.164 0.040 0.037 0.060
0.01 0.167 0.160 0.217 0.048 0.044 0.078
0.05 0.217 0.208 0.280 0.059 0.054 0.101
20/20/200 0 0.068 0.066 0.022 0.044 0.041 0.029
0.01 0.126 0.120 0.172 0.044 0.041 0.066
0.05 0.216 0.207 0.282 0.061 0.056 0.105
20/40/100 0 0.079 0.076 0.034 0.042 0.039 0.026
0.01 0.059 0.056 0.099 0.039 0.036 0.048
0.05 0.189 0.181 0.246 0.054 0.049 0.090
40/20/100 0 0.124 0.121 0.153 0.030 0.028 0.045
0.01 0.171 0.167 0.214 0.041 0.039 0.066
0.05 0.231 0.226 0.299 0.061 0.058 0.105
40/20/200 0 0.060 0.059 0.035 0.022 0.021 0.014
0.01 0.148 0.145 0.184 0.035 0.034 0.055
0.05 0.228 0.223 0.294 0.059 0.057 0.102
40/40/100 0 0.081 0.079 0.052 0.025 0.024 0.015
0.01 0.075 0.073 0.097 0.022 0.021 0.030
0.05 0.203 0.199 0.258 0.051 0.049 0.085
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Table 6.38: Bias and MSE for the measures of heterogeneity with ‘high’ heterogeneity
and control group disease rates rB = {0.35, 0.45, 0.50, 0.55} based on 1000 simulations of
k trials each with Nj clusters per group of size m, intracluster correlation ρ(truncated),
and odds ratio ψ = 0.7.
Bias MSE
k/Nj/m ρ Ha Ra I
2
a Ha Ra I
2
a
4/20/100 0 0.091 0.066 0.201 0.236 0.154 0.141
0.01 0.186 0.143 0.264 0.213 0.137 0.164
0.05 0.312 0.245 0.360 0.214 0.136 0.204
4/20/200 0 0.233 0.198 0.010 0.361 0.246 0.081
0.01 0.143 0.108 0.235 0.226 0.147 0.152
0.05 0.340 0.268 0.380 0.207 0.131 0.213
4/40/100 0 0.229 0.194 0.013 0.358 0.243 0.083
0.01 0.033 0.019 0.161 0.252 0.167 0.125
0.05 0.267 0.209 0.324 0.211 0.135 0.187
12/20/100 0 0.130 0.121 0.156 0.074 0.064 0.072
0.01 0.235 0.219 0.260 0.101 0.088 0.116
0.05 0.312 0.291 0.344 0.126 0.110 0.158
12/20/200 0 0.117 0.111 0.026 0.089 0.079 0.032
0.01 0.171 0.159 0.197 0.085 0.074 0.090
0.05 0.317 0.296 0.347 0.126 0.110 0.157
12/40/100 0 0.138 0.131 0.038 0.096 0.085 0.031
0.01 0.075 0.070 0.113 0.073 0.064 0.060
0.05 0.276 0.257 0.302 0.112 0.097 0.135
20/20/100 0 0.148 0.142 0.155 0.055 0.050 0.056
0.01 0.241 0.231 0.257 0.087 0.080 0.103
0.05 0.332 0.319 0.366 0.126 0.116 0.160
20/20/200 0 0.107 0.103 0.043 0.051 0.047 0.017
0.01 0.196 0.188 0.203 0.067 0.062 0.074
0.05 0.321 0.308 0.353 0.121 0.112 0.154
20/40/100 0 0.131 0.126 0.053 0.064 0.060 0.020
0.01 0.095 0.092 0.110 0.048 0.045 0.044
0.05 0.286 0.275 0.308 0.104 0.096 0.128
40/20/100 0 0.160 0.156 0.153 0.042 0.041 0.043
0.01 0.246 0.241 0.251 0.076 0.073 0.085
0.05 0.337 0.331 0.372 0.123 0.118 0.156
40/20/200 0 0.099 0.097 0.050 0.030 0.029 0.010
0.01 0.189 0.185 0.185 0.052 0.050 0.055
0.05 0.336 0.330 0.369 0.121 0.117 0.154
40/40/100 0 0.124 0.122 0.066 0.033 0.032 0.010
0.01 0.101 0.099 0.097 0.028 0.027 0.025
0.05 0.293 0.287 0.310 0.098 0.094 0.118
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Table 6.39: Confidence interval for Ha with ‘no’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 98.6( 1.4, 0.0)2.5 96.7( 3.3, 0.0)1.5 95.9( 4.1, 0.0)1.9 100( 0.0, 0.0)0.28
0.01 98.0( 2.0, 0.0)2.7 95.3( 4.7, 0.0)1.5 94.5( 5.5, 0.0)1.9 100( 0.0, 0.0)0.35
0.05 98.5( 1.5, 0.0)2.6 96.3( 3.7, 0.0)1.5 95.2( 4.8, 0.0)1.9 100( 0.0, 0.0)0.33
4/20/200 0 98.6( 1.4, 0.0)2.5 97.1( 2.9, 0.0)1.5 96.4( 3.6, 0.0)1.9 100( 0.0, 0.0)0.31
0.01 97.5( 2.5, 0.0)2.7 95.7( 4.3, 0.0)1.5 94.5( 5.5, 0.0)1.9 100( 0.0, 0.0)0.35
0.05 98.1( 1.9, 0.0)2.6 95.5( 4.5, 0.0)1.5 95.2( 4.8, 0.0)1.9 100( 0.0, 0.0)0.33
4/40/100 0 97.7( 2.3, 0.0)2.6 95.6( 4.4, 0.0)1.5 94.9( 5.1, 0.0)1.9 100( 0.0, 0.0)0.32
0.01 97.8( 2.2, 0.0)2.6 94.7( 5.3, 0.0)1.4 93.6( 6.4, 0.0)1.9 100( 0.0, 0.0)0.32
0.05 98.0( 2.0, 0.0)2.7 95.5( 4.5, 0.0)1.5 94.2( 5.8, 0.0)1.8 100( 0.0, 0.0)0.35
12/20/100 0 98.6( 1.4, 0.0)0.67 97.2( 2.7, 0.1)1.0 97.9( 2.1, 0.0)0.83 100( 0.0, 0.0)0.25
0.01 98.3( 1.7, 0.0)0.74 96.4( 3.6, 0.0)0.99 96.5( 3.5, 0.0)0.83 99.8( 0.2, 0.0)0.30
0.05 98.7( 1.3, 0.0)0.69 98.0( 2.0, 0.0)1.0 98.1( 1.9, 0.0)0.83 99.6( 0.4, 0.0)0.27
12/20/200 0 98.4( 1.6, 0.0)0.67 97.3( 2.5, 0.2)1.0 97.9( 2.1, 0.0)0.83 99.9( 0.1, 0.0)0.25
0.01 97.9( 2.1, 0.0)0.71 96.2( 3.8, 0.0)1.0 96.2( 3.8, 0.0)0.84 99.8( 0.2, 0.0)0.28
0.05 98.6( 1.4, 0.0)0.69 96.5( 3.4, 0.1)0.99 97.2( 2.8, 0.0)0.83 100( 0.0, 0.0)0.28
12/40/100 0 98.1( 1.9, 0.0)0.68 96.5( 3.3, 0.2)1.0 97.2( 2.8, 0.0)0.84 100( 0.0, 0.0)0.25
0.01 97.6( 2.4, 0.0)0.73 96.1( 3.8, 0.1)0.99 96.7( 3.3, 0.0)0.83 99.8( 0.2, 0.0)0.29
0.05 97.7( 2.3, 0.0)0.74 95.7( 4.1, 0.2)0.98 96.2( 3.8, 0.0)0.83 99.6( 0.4, 0.0)0.30
20/20/100 0 98.9( 1.1, 0.0)0.42 97.3( 1.7, 1.0)0.78 98.3( 1.7, 0.0)0.63 99.8( 0.2, 0.0)0.20
0.01 97.6( 2.4, 0.0)0.46 96.2( 3.2, 0.6)0.75 97.1( 2.9, 0.0)0.62 99.7( 0.3, 0.0)0.23
0.05 98.7( 1.3, 0.0)0.46 97.7( 2.3, 0.0)0.74 98.0( 2.0, 0.0)0.61 99.5( 0.5, 0.0)0.23
20/20/200 0 98.4( 1.6, 0.0)0.44 96.4( 2.3, 1.3)0.77 98.3( 1.7, 0.0)0.62 99.6( 0.4, 0.0)0.21
0.01 98.2( 1.8, 0.0)0.47 96.1( 3.2, 0.7)0.74 97.2( 2.8, 0.0)0.62 99.9( 0.1, 0.0)0.24
0.05 97.7( 2.3, 0.0)0.46 96.2( 3.4, 0.4)0.74 96.7( 3.3, 0.0)0.62 99.6( 0.4, 0.0)0.24
20/40/100 0 98.7( 1.3, 0.0)0.45 97.0( 2.1, 0.9)0.76 98.4( 1.6, 0.0)0.62 99.6( 0.4, 0.0)0.21
0.01 97.2( 2.8, 0.0)0.49 95.2( 4.1, 0.7)0.74 96.1( 3.9, 0.0)0.62 99.5( 0.5, 0.0)0.25
0.05 98.1( 1.9, 0.0)0.47 95.5( 3.8, 0.7)0.74 96.6( 3.4, 0.0)0.62 99.3( 0.7, 0.0)0.24
40/20/100 0 99.4( 0.6, 0.0)0.25 96.6( 1.0, 2.4)0.50 99.3( 0.7, 0.0)0.43 99.9( 0.1, 0.0)0.14
0.01 98.3( 1.7, 0.0)0.29 97.0( 2.5, 0.5)0.47 97.6( 2.4, 0.0)0.43 99.3( 0.7, 0.0)0.19
0.05 98.5( 1.5, 0.0)0.28 96.8( 2.4, 0.8)0.47 98.0( 2.0, 0.0)0.43 99.8( 0.2, 0.0)0.18
40/20/200 0 99.2( 0.8, 0.0)0.26 96.1( 1.2, 2.7)0.50 99.1( 0.9, 0.0)0.43 99.9( 0.1, 0.0)0.14
0.01 97.8( 2.2, 0.0)0.30 96.1( 3.1, 0.8)0.47 97.4( 2.6, 0.0)0.43 99.1( 0.9, 0.0)0.19
0.05 98.4( 1.6, 0.0)0.28 95.5( 3.1, 1.4)0.47 97.6( 2.4, 0.0)0.43 99.6( 0.4, 0.0)0.18
40/40/100 0 98.6( 1.4, 0.0)0.27 94.8( 2.4, 2.8)0.49 97.9( 2.1, 0.0)0.43 99.8( 0.2, 0.0)0.16
0.01 97.8( 2.2, 0.0)0.30 95.4( 3.4, 1.2)0.47 97.1( 2.9, 0.0)0.43 99.5( 0.5, 0.0)0.19
0.05 98.0( 2.0, 0.0)0.29 95.8( 3.0, 1.2)0.47 97.3( 2.7, 0.0)0.43 99.6( 0.4, 0.0)0.18
C m eans the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.40: Confidence interval for Ha with ‘low’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 94.5( 0.9, 4.6)2.9 97.4( 2.6, 0.0)1.6 94.2( 3.5, 2.3)1.9 51.5( 0.0,48.5)0.43
0.01 95.7( 0.7, 3.5)3.0 96.6( 3.4, 0.0)1.5 95.4( 3.4, 1.1)1.9 51.6( 0.0,48.4)0.45
0.05 96.2( 0.1, 3.7)2.7 98.1( 1.9, 0.0)1.5 96.6( 1.3, 2.1)1.9 46.4( 0.0,53.6)0.34
4/20/200 0 95.5( 2.6, 1.9)3.6 95.5( 4.5, 0.0)1.7 91.1( 7.2, 1.7)1.9 64.3( 0.0,35.7)0.65
0.01 97.4( 1.0, 1.6)3.2 95.6( 4.4, 0.0)1.5 93.3( 4.9, 1.8)1.8 57.4( 0.0,42.6)0.50
0.05 97.0( 0.2, 2.8)2.7 97.7( 2.3, 0.0)1.5 95.5( 2.3, 2.2)1.9 48.2( 0.0,51.8)0.36
4/40/100 0 94.9( 3.7, 1.4)3.7 94.2( 5.8, 0.0)1.7 89.4( 9.0, 1.5)1.9 68.0( 0.0,32.0)0.68
0.01 95.8( 1.4, 2.8)3.4 96.5( 3.5, 0.0)1.6 93.2( 4.9, 1.9)1.8 62.2( 0.0,37.8)0.54
0.05 94.9( 0.4, 4.7)2.8 97.3( 2.7, 0.0)1.5 95.5( 2.5, 2.0)1.9 48.4( 0.0,51.6)0.39
12/20/100 0 95.2( 0.7, 4.1)0.88 92.1( 1.1, 6.8)1.1 96.4( 1.0, 2.6)0.83 73.2( 0.1,26.7)0.37
0.01 96.6( 0.5, 2.9)0.85 92.4( 1.1, 6.5)1.0 96.8( 0.9, 2.3)0.83 69.7( 0.1,30.2)0.35
0.05 94.8( 0.0, 5.2)0.76 91.6( 0.3, 8.1)1.0 97.1( 0.0, 2.9)0.81 65.9( 0.0,34.1)0.30
12/20/200 0 94.8( 3.8, 1.4)1.1 94.1( 3.7, 2.2)1.1 93.8( 5.4, 0.8)0.85 86.2( 0.5,13.3)0.53
0.01 96.3( 0.8, 2.9)0.90 92.5( 1.9, 5.6)1.0 97.2( 1.2, 1.6)0.83 74.2( 0.0,25.8)0.39
0.05 94.8( 0.0, 5.2)0.76 91.1( 0.8, 8.1)1.0 96.6( 0.4, 3.0)0.82 65.9( 0.0,34.1)0.30
12/40/100 0 94.6( 3.8, 1.6)1.1 93.7( 3.3, 3.0)1.1 94.8( 3.9, 1.3)0.86 83.9( 0.6,15.5)0.50
0.01 95.0( 1.7, 3.3)0.98 91.3( 3.3, 5.4)1.0 95.3( 3.0, 1.7)0.84 79.7( 0.3,20.0)0.45
0.05 94.4( 0.3, 5.3)0.82 90.8( 1.6, 7.6)0.99 96.8( 0.7, 2.5)0.82 70.3( 0.1,29.6)0.34
20/20/100 0 94.6( 0.6, 4.8)0.62 89.9( 1.2, 8.9)0.76 96.6( 1.0, 2.4)0.62 76.6( 0.2,23.2)0.33
0.01 93.2( 0.2, 6.6)0.58 87.3( 1.3,11.4)0.72 98.1( 0.4, 1.5)0.63 71.9( 0.2,27.9)0.31
0.05 91.6( 0.0, 8.4)0.48 83.3( 0.4,16.3)0.74 96.6( 0.3, 3.1)0.61 63.3( 0.0,36.7)0.24
20/20/200 0 94.0( 4.3, 1.7)0.76 92.7( 2.9, 4.4)0.81 94.5( 3.7, 1.8)0.64 88.6( 0.5,10.9)0.44
0.01 94.8( 0.6, 4.6)0.60 88.8( 1.2,10.0)0.73 96.7( 0.8, 2.5)0.62 76.1( 0.1,23.8)0.32
0.05 91.7( 0.1, 8.2)0.50 83.1( 0.5,16.4)0.73 97.1( 0.2, 2.7)0.62 64.9( 0.0,35.1)0.26
20/40/100 0 92.8( 6.0, 1.2)0.78 92.4( 4.4, 3.2)0.79 92.5( 5.7, 1.8)0.65 89.1( 1.3, 9.6)0.46
0.01 95.2( 1.8, 3.0)0.68 89.2( 3.9, 6.9)0.73 95.0( 3.0, 2.0)0.63 83.1( 0.6,16.3)0.39
0.05 93.3( 0.1, 6.6)0.54 87.5( 0.7,11.8)0.72 96.6( 0.3, 3.1)0.62 68.5( 0.1,31.4)0.28
40/20/100 0 93.2( 0.7, 6.1)0.40 81.2( 0.7,18.1)0.50 96.2( 0.7, 3.1)0.43 74.7( 0.2,25.1)0.26
0.01 91.6( 0.2, 8.2)0.38 80.9( 0.5,18.6)0.47 96.2( 0.3, 3.5)0.43 74.0( 0.1,25.9)0.25
0.05 85.9( 0.0,14.1)0.31 72.6( 0.0,27.4)0.47 94.7( 0.0, 5.3)0.43 63.3( 0.0,36.7)0.20
40/20/200 0 94.5( 5.1, 0.4)0.53 93.8( 2.2, 4.0)0.54 94.7( 3.1, 2.2)0.46 92.9( 1.1, 6.0)0.37
0.01 92.0( 0.4, 7.6)0.40 81.6( 0.8,17.6)0.48 96.7( 0.5, 2.8)0.43 77.1( 0.1,22.8)0.27
0.05 87.0( 0.0,13.0)0.32 73.3( 0.4,26.3)0.47 97.1( 0.1, 2.8)0.43 62.5( 0.0,37.5)0.21
40/40/100 0 91.9( 7.4, 0.7)0.53 92.2( 4.1, 3.7)0.54 93.2( 5.3, 1.5)0.46 92.1( 2.1, 5.8)0.37
0.01 95.3( 1.0, 3.7)0.45 88.7( 1.3,10.0)0.49 96.3( 1.2, 2.5)0.44 85.7( 0.2,14.1)0.31
0.05 87.4( 0.0,12.6)0.34 74.4( 0.2,25.4)0.47 96.7( 0.1, 3.2)0.43 65.9( 0.0,34.1)0.22
C means the probability coverage. L and R de note tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.41: Confidence interval for Ha with ‘moderate’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 97.1( 0.7, 2.2)3.7 88.8( 2.1, 9.0)1.7 92.5( 3.3, 4.2)1.8 59.2( 0.0,40.8)0.65
0.01 96.5( 0.2, 3.3)3.3 83.1( 2.5,14.4)1.6 93.4( 2.0, 4.6)1.8 49.9( 0.0,50.1)0.53
0.05 95.4( 0.1, 4.5)2.9 83.0( 1.0,16.0)1.5 94.8( 0.7, 4.5)1.8 38.9( 0.0,61.1)0.37
4/20/200 0 96.6( 2.5, 0.9)4.5 91.5( 4.3, 4.2)1.9 86.8(10.1, 3.1)1.9 72.9( 0.0,27.1)0.94
0.01 96.1( 0.5, 3.4)3.4 86.5( 2.4,11.1)1.6 92.9( 2.5, 4.6)1.8 53.3( 0.0,46.7)0.57
0.05 95.5( 0.1, 4.4)2.9 81.7( 1.4,16.9)1.5 95.5( 0.9, 3.6)1.9 40.2( 0.0,59.8)0.40
4/40/100 0 96.2( 2.8, 1.0)4.6 91.5( 4.3, 4.1)1.9 87.6(10.0, 2.4)1.9 76.4( 0.0,23.6)0.99
0.01 96.8( 0.4, 2.8)3.8 88.0( 3.4, 8.6)1.7 92.1( 4.6, 3.3)1.8 59.6( 0.0,40.4)0.69
0.05 95.8( 0.1, 4.1)3.2 85.4( 1.4,13.2)1.5 95.0( 1.1, 3.9)1.8 46.0( 0.0,54.0)0.47
12/20/100 0 96.2( 0.9, 2.9)1.1 82.7( 1.4,15.9)1.1 93.7( 1.4, 4.9)0.85 73.5( 0.0,26.5)0.53
0.01 93.9( 0.1, 6.0)0.97 72.2( 1.3,26.5)1.0 94.4( 0.4, 5.2)0.84 62.0( 0.1,37.9)0.43
0.05 90.5( 0.0, 9.5)0.82 63.4( 0.2,36.4)1.0 92.7( 0.1, 7.2)0.81 49.4( 0.0,50.6)0.33
12/20/200 0 95.6( 4.1, 0.3)1.4 91.5( 3.9, 4.6)1.3 91.6( 6.4, 2.0)0.93 90.9( 0.6, 8.5)0.73
0.01 95.0( 0.3, 4.7)1.0 78.0( 1.4,20.6)1.1 94.4( 0.6, 5.0)0.85 69.1( 0.0,30.9)0.49
0.05 89.8( 0.0,10.2)0.79 61.0( 0.4,38.6)1.0 94.1( 0.1, 5.8)0.82 46.8( 0.0,53.2)0.32
12/40/100 0 95.4( 4.4, 0.2)1.4 91.0( 4.3, 4.7)1.2 90.2( 7.6, 2.2)0.94 90.7( 0.4, 8.9)0.75
0.01 96.2( 1.1, 2.7)1.2 83.4( 2.5,14.1)1.1 93.9( 2.5, 3.6)0.87 77.0( 0.2,22.8)0.58
0.05 91.7( 0.0, 8.3)0.91 67.6( 0.2,32.2)1.0 94.8( 0.2, 5.0)0.83 56.7( 0.0,43.3)0.39
20/20/100 0 93.6( 0.6, 5.8)0.79 82.0( 0.9,17.1)0.80 93.0( 0.6, 6.4)0.65 74.2( 0.3,25.5)0.46
0.01 88.8( 0.1,11.1)0.67 69.9( 0.6,29.5)0.74 91.3( 0.1, 8.6)0.63 59.2( 0.1,40.7)0.37
0.05 81.9( 0.0,18.1)0.53 52.7( 0.1,47.2)0.73 92.0( 0.0, 8.0)0.62 42.4( 0.0,57.6)0.28
20/20/200 0 93.9( 6.0, 0.1)1.0 93.7( 4.4, 1.9)0.89 92.0( 7.1, 0.9)0.72 94.8( 1.0, 4.2)0.66
0.01 92.7( 0.2, 7.1)0.74 76.5( 0.5,23.0)0.75 93.3( 0.3, 6.4)0.65 67.7( 0.1,32.2)0.43
0.05 81.6( 0.0,18.4)0.54 55.8( 0.1,44.1)0.73 91.1( 0.0, 8.9)0.62 44.3( 0.0,55.7)0.29
20/40/100 0 90.7( 9.3, 0.0)1.0 90.0( 7.7, 2.3)0.88 87.3(10.7, 2.0)0.73 92.5( 2.1, 5.4)0.67
0.01 97.1( 0.7, 2.2)0.85 86.4( 2.0,11.6)0.78 92.0( 1.5, 6.5)0.66 80.7( 0.0,19.3)0.51
0.05 86.6( 0.0,13.4)0.61 63.6( 0.3,36.1)0.73 92.3( 0.0, 7.7)0.62 52.7( 0.0,47.3)0.33
40/20/100 0 91.6( 0.0, 8.4)0.53 84.3( 0.0,15.7)0.55 75.7( 0.0,24.3)0.46 67.9( 0.0,32.1)0.37
0.01 83.2( 0.0,16.8)0.46 61.9( 0.0,38.1)0.49 62.7( 0.0,37.3)0.44 54.3( 0.0,45.7)0.31
0.05 58.2( 0.0,41.8)0.33 21.7( 0.0,78.3)0.48 32.2( 0.0,67.8)0.42 24.1( 0.0,75.9)0.21
40/20/200 0 92.3( 7.4, 0.3)0.68 95.7( 3.8, 0.5)0.60 92.6( 5.7, 1.7)0.51 94.6( 2.0, 3.4)0.50
0.01 89.5( 0.2,10.3)0.50 74.2( 0.4,25.4)0.51 71.7( 0.3,28.0)0.45 62.2( 0.2,37.6)0.35
0.05 62.2( 0.0,37.8)0.34 26.2( 0.0,73.8)0.47 36.8( 0.0,63.2)0.43 27.8( 0.0,72.2)0.23
40/40/100 0 90.1( 9.8, 0.1)0.70 93.7( 6.0, 0.3)0.58 89.7( 9.3, 1.0)0.51 93.9( 4.1, 2.0)0.51
0.01 96.5( 0.7, 2.8)0.59 93.7( 0.8, 5.5)0.53 87.9( 0.7,11.4)0.47 83.3( 0.3,16.4)0.42
0.05 74.4( 0.0,25.6)0.41 48.1( 0.0,51.9)0.48 53.8( 0.0,46.2)0.44 44.1( 0.0,55.9)0.27
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.42: Confidence interval for Ha with ‘high’ heterogeneity, control group disease
rates rA = {0.04, 0.07, 0.10, 0.13} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 97.8( 0.3, 1.9)4.1 73.8( 1.4,24.8)1.8 92.1( 2.1, 5.8)1.9 57.0( 0.0,43.0)0.78
0.01 96.6( 0.0, 3.4)3.5 64.7( 1.6,33.6)1.7 92.0( 1.4, 6.5)1.8 47.1( 0.0,52.9)0.60
0.05 96.6( 0.0, 3.4)3.1 58.6( 0.7,40.7)1.5 91.6( 0.5, 7.9)1.8 32.7( 0.0,67.3)0.42
4/20/200 0 96.4( 2.3, 1.3)5.3 85.8( 4.1,10.0)2.1 85.5(10.2, 4.2)2.0 77.8( 0.0,22.2)1.2
0.01 97.3( 0.0, 2.7)3.9 70.1( 1.2,28.7)1.7 92.5( 1.3, 6.2)1.9 53.3( 0.0,46.7)0.70
0.05 95.7( 0.0, 4.3)3.1 57.7( 1.0,41.3)1.5 92.6( 0.5, 6.9)1.8 34.5( 0.0,65.5)0.43
4/40/100 0 96.6( 2.7, 0.7)5.4 87.7( 4.2, 8.1)2.1 85.2(11.0, 3.7)2.0 81.1( 0.0,18.9)1.3
0.01 97.7( 0.8, 1.5)4.4 76.2( 2.7,21.1)1.8 89.8( 4.0, 6.2)1.9 62.3( 0.0,37.7)0.89
0.05 94.8( 0.0, 5.2)3.3 61.9( 0.9,37.2)1.6 92.5( 0.8, 6.7)1.8 40.7( 0.0,59.3)0.52
12/20/100 0 96.3( 0.1, 3.6)1.3 85.4( 0.4,14.2)1.2 91.6( 0.4, 8.0)0.88 69.2( 0.1,30.7)0.62
0.01 92.9( 0.0, 7.1)1.1 74.3( 0.5,25.2)1.1 89.8( 0.1,10.1)0.86 56.9( 0.0,43.1)0.52
0.05 84.0( 0.0,16.0)0.84 38.2( 0.0,61.8)1.0 86.5( 0.0,13.5)0.82 31.2( 0.0,68.8)0.34
12/20/200 0 95.0( 4.7, 0.3)1.6 92.5( 5.3, 2.2)1.3 89.4( 8.3, 2.3)1.0 91.2( 0.9, 7.9)0.91
0.01 94.6( 0.1, 5.3)1.2 78.8( 0.8,20.4)1.1 93.2( 0.2, 6.6)0.87 61.8( 0.1,38.1)0.57
0.05 82.6( 0.0,17.4)0.84 41.6( 0.1,58.3)1.0 87.9( 0.0,12.1)0.83 31.8( 0.0,68.2)0.35
12/40/100 0 94.7( 5.0, 0.3)1.7 93.5( 5.3, 1.2)1.3 88.9( 9.3, 1.8)1.0 94.3( 0.8, 4.9)0.95
0.01 97.7( 1.0, 1.3)1.4 88.7( 2.6, 8.7)1.2 91.5( 2.4, 6.1)0.92 78.9( 0.0,21.1)0.71
0.05 89.0( 0.0,11.0)0.97 61.6( 0.0,38.4)1.0 89.1( 0.0,10.9)0.83 44.8( 0.0,55.2)0.43
20/20/100 0 93.6( 0.2, 6.2)0.91 88.4( 0.4,11.2)0.87 79.6( 0.2,20.2)0.68 69.9( 0.0,30.1)0.54
0.01 87.1( 0.0,12.9)0.78 63.5( 0.3,36.2)0.76 65.6( 0.0,34.4)0.65 54.1( 0.0,45.9)0.45
0.05 67.1( 0.0,32.9)0.56 21.3( 0.0,78.7)0.74 34.0( 0.0,66.0)0.62 23.4( 0.0,76.6)0.29
20/20/200 0 92.4( 7.3, 0.3)1.2 94.0( 5.4, 0.6)0.92 87.9(10.2, 1.9)0.77 94.9( 1.3, 3.8)0.76
0.01 93.0( 0.1, 6.9)0.84 76.5( 0.8,22.7)0.78 73.4( 0.3,26.3)0.66 62.4( 0.0,37.6)0.51
0.05 71.7( 0.0,28.3)0.58 25.3( 0.0,74.7)0.72 38.8( 0.0,61.2)0.62 26.5( 0.0,73.5)0.31
20/40/100 0 91.9( 7.9, 0.2)1.2 92.8( 6.6, 0.6)0.91 88.1(10.2, 1.7)0.78 93.7( 2.0, 4.3)0.78
0.01 97.2( 0.4, 2.4)0.99 92.6( 1.1, 6.3)0.83 86.3( 0.9,12.8)0.70 80.0( 0.1,19.9)0.61
0.05 81.7( 0.0,18.3)0.68 40.3( 0.3,59.4)0.74 50.6( 0.0,49.4)0.63 36.5( 0.0,63.5)0.37
40/20/100 0 92.0( 0.0, 8.0)0.62 77.0( 0.0,23.0)0.58 73.7( 0.0,26.3)0.48 63.2( 0.0,36.8)0.44
0.01 73.4( 0.0,26.6)0.52 35.9( 0.0,64.1)0.51 47.0( 0.0,53.0)0.46 37.6( 0.0,62.4)0.36
0.05 34.5( 0.0,65.5)0.36 2.60( 0.0,97.4)0.48 13.0( 0.0,87.0)0.43 8.20( 0.0,91.8)0.23
40/20/200 0 87.5(12.5, 0.0)0.79 92.9( 7.1, 0.0)0.61 87.0(12.3, 0.7)0.54 94.0( 4.5, 1.5)0.55
0.01 84.7( 0.0,15.3)0.58 60.6( 0.0,39.4)0.53 66.2( 0.0,33.8)0.47 54.5( 0.0,45.5)0.42
0.05 40.0( 0.0,60.0)0.38 5.50( 0.0,94.5)0.48 14.9( 0.0,85.1)0.43 9.10( 0.0,90.9)0.25
40/40/100 0 87.8(12.1, 0.1)0.80 91.2( 8.8, 0.0)0.60 85.2(14.4, 0.4)0.54 93.3( 5.7, 1.0)0.56
0.01 95.8( 0.3, 3.9)0.67 89.8( 0.3, 9.9)0.55 87.5( 0.3,12.2)0.50 81.0( 0.0,19.0)0.49
0.05 58.0( 0.0,42.0)0.46 17.6( 0.0,82.4)0.49 31.1( 0.0,68.9)0.44 21.6( 0.0,78.4)0.31
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.43: Confidence interval for Ha with ‘no’ heterogeneity, control group disease
rates rB = {0.35, 0.45, 0.50, 0.55} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 98.4( 1.6, 0.0)2.3 96.7( 3.3, 0.0)1.5 95.9( 4.1, 0.0)1.9 100( 0.0, 0.0)0.28
0.01 97.0( 3.0, 0.0)2.5 94.3( 5.7, 0.0)1.4 93.9( 6.1, 0.0)1.9 100( 0.0, 0.0)0.35
0.05 97.4( 2.6, 0.0)2.4 93.9( 6.1, 0.0)1.4 93.2( 6.8, 0.0)1.9 100( 0.0, 0.0)0.33
4/20/200 0 98.2( 1.8, 0.0)2.4 95.8( 4.2, 0.0)1.5 95.6( 4.4, 0.0)1.9 100( 0.0, 0.0)0.31
0.01 97.0( 3.0, 0.0)2.5 95.0( 5.0, 0.0)1.5 94.4( 5.6, 0.0)1.9 100( 0.0, 0.0)0.35
0.05 97.2( 2.8, 0.0)2.5 93.7( 6.3, 0.0)1.4 92.4( 7.6, 0.0)1.9 100( 0.0, 0.0)0.36
4/40/100 0 98.1( 1.9, 0.0)2.4 96.1( 3.9, 0.0)1.5 95.6( 4.4, 0.0)1.9 100( 0.0, 0.0)0.31
0.01 97.3( 2.7, 0.0)2.5 94.5( 5.5, 0.0)1.4 93.5( 6.5, 0.0)1.9 100( 0.0, 0.0)0.36
0.05 97.0( 3.0, 0.0)2.5 94.5( 5.5, 0.0)1.4 93.5( 6.5, 0.0)1.9 100( 0.0, 0.0)0.33
12/20/100 0 99.1( 0.9, 0.0)0.63 97.6( 2.2, 0.2)1.0 98.4( 1.6, 0.0)0.83 99.9( 0.1, 0.0)0.25
0.01 96.4( 3.6, 0.0)0.68 94.6( 5.3, 0.1)0.99 95.1( 4.9, 0.0)0.83 99.8( 0.2, 0.0)0.29
0.05 96.4( 3.6, 0.0)0.66 95.4( 4.5, 0.1)0.99 95.6( 4.4, 0.0)0.84 99.6( 0.4, 0.0)0.28
12/20/200 0 99.3( 0.7, 0.0)0.64 98.4( 1.6, 0.0)1.0 98.6( 1.4, 0.0)0.82 100( 0.0, 0.0)0.23
0.01 97.1( 2.9, 0.0)0.71 95.0( 5.0, 0.0)0.97 95.9( 4.1, 0.0)0.84 99.7( 0.3, 0.0)0.31
0.05 97.3( 2.7, 0.0)0.67 95.9( 4.0, 0.1)0.99 96.3( 3.7, 0.0)0.82 99.4( 0.6, 0.0)0.29
12/40/100 0 98.0( 2.0, 0.0)0.68 96.4( 3.5, 0.1)1.0 96.6( 3.4, 0.0)0.83 99.6( 0.4, 0.0)0.26
0.01 97.5( 2.5, 0.0)0.70 95.2( 4.6, 0.2)0.99 95.9( 4.1, 0.0)0.83 99.4( 0.6, 0.0)0.29
0.05 97.2( 2.8, 0.0)0.68 95.2( 4.7, 0.1)0.99 95.8( 4.2, 0.0)0.83 99.3( 0.7, 0.0)0.29
20/20/100 0 98.1( 1.9, 0.0)0.42 96.5( 2.7, 0.8)0.78 97.7( 2.3, 0.0)0.62 99.5( 0.5, 0.0)0.20
0.01 96.2( 3.8, 0.0)0.48 93.7( 5.9, 0.4)0.73 94.9( 5.1, 0.0)0.62 98.9( 1.1, 0.0)0.26
0.05 96.8( 3.2, 0.0)0.45 94.8( 4.7, 0.5)0.73 95.7( 4.3, 0.0)0.62 99.0( 1.0, 0.0)0.25
20/20/200 0 98.8( 1.2, 0.0)0.46 96.7( 2.3, 1.0)0.77 98.2( 1.8, 0.0)0.62 99.7( 0.3, 0.0)0.21
0.01 97.4( 2.6, 0.0)0.47 95.6( 3.9, 0.5)0.73 96.6( 3.4, 0.0)0.63 99.8( 0.2, 0.0)0.25
0.05 97.7( 2.3, 0.0)0.44 96.0( 3.6, 0.4)0.74 97.2( 2.8, 0.0)0.62 99.4( 0.6, 0.0)0.23
20/40/100 0 97.8( 2.2, 0.0)0.47 95.4( 3.5, 1.1)0.76 97.0( 3.0, 0.0)0.63 99.6( 0.4, 0.0)0.22
0.01 97.5( 2.5, 0.0)0.48 95.8( 3.9, 0.3)0.73 96.6( 3.4, 0.0)0.62 99.7( 0.3, 0.0)0.25
0.05 96.4( 3.6, 0.0)0.45 95.0( 4.7, 0.3)0.74 95.7( 4.3, 0.0)0.62 98.7( 1.3, 0.0)0.24
40/20/100 0 98.7( 1.3, 0.0)0.26 96.3( 1.4, 2.3)0.50 98.7( 1.3, 0.0)0.44 99.4( 0.6, 0.0)0.14
0.01 97.3( 2.7, 0.0)0.30 95.0( 3.9, 1.1)0.47 96.7( 3.3, 0.0)0.43 99.0( 1.0, 0.0)0.19
0.05 96.8( 3.2, 0.0)0.29 94.7( 4.5, 0.8)0.47 96.2( 3.8, 0.0)0.43 99.3( 0.7, 0.0)0.20
40/20/200 0 98.7( 1.3, 0.0)0.30 96.1( 1.7, 2.2)0.50 98.6( 1.4, 0.0)0.43 99.7( 0.3, 0.0)0.15
0.01 97.1( 2.9, 0.0)0.30 94.8( 4.0, 1.2)0.47 96.7( 3.3, 0.0)0.43 98.8( 1.2, 0.0)0.19
0.05 97.5( 2.5, 0.0)0.28 95.2( 3.5, 1.3)0.47 96.7( 3.3, 0.0)0.43 99.2( 0.8, 0.0)0.18
40/40/100 0 98.6( 1.4, 0.0)0.32 95.6( 2.3, 2.1)0.49 98.3( 1.7, 0.0)0.43 99.6( 0.4, 0.0)0.16
0.01 97.7( 2.3, 0.0)0.33 96.0( 2.9, 1.1)0.47 97.5( 2.5, 0.0)0.43 99.2( 0.8, 0.0)0.20
0.05 97.2( 2.8, 0.0)0.28 95.1( 3.5, 1.4)0.47 97.0( 3.0, 0.0)0.43 98.5( 1.5, 0.0)0.18
C me ans the probability cove rage . L and R denote tail errors from le ft and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.44: Confidence interval for Ha with ‘low’ heterogeneity, control group disease
rates rB = {0.35, 0.45, 0.50, 0.55} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 96.4( 1.8, 1.8)2.9 96.9( 3.1, 0.0)1.6 94.6( 3.7, 1.7)1.8 56.2( 0.0,43.8)0.46
0.01 95.8( 0.4, 3.8)2.8 95.8( 4.2, 0.0)1.5 94.5( 3.7, 1.8)1.9 54.1( 0.0,45.9)0.45
0.05 94.7( 0.8, 4.5)2.5 95.9( 4.1, 0.0)1.5 95.2( 2.9, 1.9)1.9 46.5( 0.0,53.5)0.36
4/20/200 0 93.4( 4.6, 2.0)3.3 95.9( 4.1, 0.0)1.7 91.2( 7.2, 1.6)1.8 65.1( 0.0,34.9)0.59
0.01 95.3( 1.6, 3.1)2.9 95.9( 4.1, 0.0)1.5 94.6( 4.1, 1.3)1.8 55.9( 0.0,44.1)0.47
0.05 96.4( 1.0, 2.6)2.6 96.8( 3.2, 0.0)1.5 94.9( 2.6, 2.5)1.8 47.5( 0.0,52.5)0.37
4/40/100 0 91.8( 6.6, 1.6)3.4 95.5( 4.5, 0.0)1.7 91.0( 8.1, 0.9)1.8 67.6( 0.0,32.4)0.62
0.01 95.2( 2.7, 2.1)3.0 95.1( 4.9, 0.0)1.6 92.3( 6.0, 1.7)1.8 57.5( 0.0,42.5)0.51
0.05 95.9( 0.7, 3.4)2.6 96.5( 3.5, 0.0)1.5 94.9( 2.9, 2.2)1.9 49.3( 0.0,50.7)0.39
12/20/100 0 95.1( 1.6, 3.3)0.81 90.5( 1.6, 7.9)1.1 97.6( 1.3, 1.1)0.83 72.6( 0.0,27.4)0.37
0.01 94.0( 1.2, 4.8)0.79 90.5( 2.6, 6.9)0.99 96.0( 2.0, 2.0)0.83 71.3( 0.0,28.7)0.37
0.05 92.8( 0.7, 6.5)0.72 87.6( 2.3,10.1)0.98 96.9( 1.0, 2.1)0.83 64.5( 0.2,35.3)0.33
12/20/200 0 84.8(14.5, 0.7)0.98 92.2( 3.8, 4.0)1.1 93.5( 5.3, 1.2)0.86 81.7( 0.7,17.6)0.49
0.01 96.5( 0.9, 2.6)0.82 92.6( 2.4, 5.0)1.0 95.7( 1.5, 2.8)0.82 73.9( 0.3,25.8)0.38
0.05 92.1( 0.4, 7.5)0.71 87.7( 1.8,10.5)0.99 96.9( 0.9, 2.2)0.83 63.8( 0.1,36.1)0.32
12/40/100 0 83.4(16.0, 0.6)1.0 93.3( 3.5, 3.2)1.1 94.2( 4.7, 1.1)0.86 84.7( 0.3,15.0)0.53
0.01 95.3( 3.2, 1.5)0.88 91.5( 3.2, 5.3)1.0 95.2( 3.1, 1.7)0.84 78.0( 0.0,22.0)0.43
0.05 95.7( 0.4, 3.9)0.75 90.5( 1.5, 8.0)0.99 97.5( 0.5, 2.0)0.83 69.1( 0.0,30.9)0.34
20/20/100 0 95.3( 1.4, 3.3)0.57 87.8( 1.3,10.9)0.76 97.1( 1.0, 1.9)0.62 75.3( 0.1,24.6)0.32
0.01 94.8( 0.8, 4.4)0.56 88.2( 1.0,10.8)0.72 97.1( 0.8, 2.1)0.62 75.8( 0.0,24.2)0.33
0.05 92.3( 0.1, 7.6)0.49 83.9( 1.4,14.7)0.72 96.9( 0.5, 2.6)0.62 69.2( 0.0,30.8)0.28
20/20/200 0 81.1(18.5, 0.4)0.71 92.7( 3.2, 4.1)0.80 93.3( 5.3, 1.4)0.65 88.3( 0.9,10.8)0.44
0.01 93.8( 1.0, 5.2)0.59 89.5( 1.6, 8.9)0.72 96.6( 1.2, 2.2)0.62 78.9( 0.3,20.8)0.35
0.05 91.3( 0.3, 8.4)0.49 83.4( 1.3,15.3)0.72 97.0( 0.6, 2.4)0.62 68.3( 0.0,31.7)0.28
20/40/100 0 78.3(21.7, 0.0)0.74 92.9( 3.5, 3.6)0.79 93.8( 4.9, 1.3)0.65 90.2( 0.9, 8.9)0.47
0.01 94.4( 3.6, 2.0)0.64 90.0( 3.6, 6.4)0.73 94.3( 3.1, 2.6)0.63 83.3( 0.4,16.3)0.39
0.05 91.9( 0.6, 7.5)0.51 83.6( 1.3,15.1)0.73 96.4( 0.8, 2.8)0.62 69.0( 0.1,30.9)0.29
40/20/100 0 94.8( 1.0, 4.2)0.39 82.5( 0.6,16.9)0.50 96.6( 0.4, 3.0)0.44 77.4( 0.1,22.5)0.27
0.01 93.0( 0.3, 6.7)0.36 81.2( 0.3,18.5)0.47 96.9( 0.1, 3.0)0.43 74.4( 0.0,25.6)0.25
0.05 86.3( 0.0,13.7)0.31 72.8( 0.3,26.9)0.47 96.3( 0.1, 3.6)0.43 66.0( 0.0,34.0)0.22
40/20/200 0 70.2(29.8, 0.0)0.50 93.1( 2.8, 4.1)0.54 95.4( 3.5, 1.1)0.46 92.2( 1.1, 6.7)0.37
0.01 93.3( 0.6, 6.1)0.39 83.3( 1.3,15.4)0.48 96.3( 0.9, 2.8)0.44 78.5( 0.2,21.3)0.28
0.05 84.8( 0.1,15.1)0.32 72.5( 0.2,27.3)0.47 97.0( 0.1, 2.9)0.43 65.0( 0.0,35.0)0.22
40/40/100 0 67.6(32.4, 0.0)0.50 93.0( 3.0, 4.0)0.54 94.2( 4.3, 1.5)0.46 92.1( 1.1, 6.8)0.38
0.01 95.8( 2.6, 1.6)0.45 89.6( 1.6, 8.8)0.49 96.8( 1.1, 2.1)0.45 86.4( 0.3,13.3)0.33
0.05 87.7( 0.4,11.9)0.34 75.9( 0.8,23.3)0.47 96.6( 0.4, 3.0)0.43 70.8( 0.2,29.0)0.24
C means the probability coverage. L and R de note tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.45: Confidence interval for Ha with ‘moderate’ heterogeneity, control group disease
rates rB = {0.35, 0.45, 0.50, 0.55} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 95.6( 1.4, 3.0)3.4 88.5( 3.3, 8.2)1.7 92.5( 4.0, 3.5)1.8 57.4( 0.0,42.6)0.64
0.01 95.6( 0.3, 4.1)3.0 85.1( 3.0,11.9)1.6 95.5( 2.0, 2.5)1.9 47.5( 0.0,52.5)0.51
0.05 94.5( 0.1, 5.4)2.7 83.7( 1.6,14.7)1.5 95.6( 1.1, 3.3)1.9 40.4( 0.0,59.6)0.40
4/20/200 0 94.5( 4.6, 0.9)4.2 91.2( 5.4, 3.4)1.9 85.5(11.2, 3.3)1.9 74.0( 0.0,26.0)0.93
0.01 95.7( 0.4, 3.9)3.2 85.4( 3.8,10.8)1.6 92.4( 3.5, 4.1)1.9 51.1( 0.0,48.9)0.56
0.05 95.4( 0.3, 4.3)2.7 84.0( 2.4,13.6)1.5 94.3( 1.5, 4.2)1.8 39.2( 0.0,60.8)0.39
4/40/100 0 95.0( 4.0, 1.0)4.2 91.0( 5.8, 3.2)1.9 86.6(10.6, 2.8)1.9 74.1( 0.0,25.9)0.92
0.01 96.6( 1.7, 1.7)3.5 89.5( 3.6, 6.9)1.7 91.1( 4.9, 4.0)1.8 59.7( 0.0,40.3)0.66
0.05 94.5( 0.2, 5.3)2.8 84.8( 3.2,12.0)1.5 93.9( 2.0, 4.1)1.9 42.9( 0.0,57.1)0.45
12/20/100 0 95.4( 0.2, 4.4)0.97 79.6( 1.2,19.2)1.1 95.1( 0.9, 4.0)0.85 70.4( 0.1,29.5)0.50
0.01 93.7( 0.1, 6.2)0.88 71.7( 1.6,26.7)1.0 94.1( 0.9, 5.0)0.84 61.0( 0.0,39.0)0.43
0.05 86.0( 0.2,13.8)0.73 60.9( 0.5,38.6)0.99 93.1( 0.2, 6.7)0.82 48.7( 0.0,51.3)0.33
12/20/200 0 88.2(11.4, 0.4)1.3 90.3( 5.5, 4.2)1.2 88.6( 8.5, 2.9)0.93 89.5( 0.9, 9.6)0.75
0.01 94.7( 0.9, 4.4)0.95 77.2( 2.0,20.8)1.1 94.0( 1.5, 4.5)0.85 69.4( 0.0,30.6)0.49
0.05 88.0( 0.0,12.0)0.75 62.7( 0.6,36.7)0.99 93.5( 0.2, 6.3)0.83 50.8( 0.0,49.2)0.35
12/40/100 0 89.4(10.2, 0.4)1.3 90.6( 4.8, 4.6)1.2 90.1( 8.1, 1.8)0.94 90.1( 0.2, 9.7)0.76
0.01 96.0( 1.9, 2.1)1.1 83.2( 3.1,13.7)1.1 92.7( 2.8, 4.5)0.87 77.2( 0.2,22.6)0.58
0.05 90.7( 0.1, 9.2)0.82 66.9( 1.4,31.7)1.0 94.3( 0.4, 5.3)0.84 55.6( 0.0,44.4)0.40
20/20/100 0 94.6( 0.1, 5.3)0.70 82.4( 0.4,17.2)0.82 92.9( 0.2, 6.9)0.64 72.4( 0.0,27.6)0.44
0.01 89.2( 0.2,10.6)0.62 72.1( 0.5,27.4)0.74 91.9( 0.3, 7.8)0.63 62.5( 0.0,37.5)0.38
0.05 80.7( 0.0,19.3)0.52 57.0( 0.1,42.9)0.72 91.6( 0.0, 8.4)0.62 48.7( 0.0,51.3)0.31
20/20/200 0 84.7(15.0, 0.3)0.90 92.2( 5.1, 2.7)0.90 90.5( 7.9, 1.6)0.72 92.6( 1.5, 5.9)0.65
0.01 94.0( 0.5, 5.5)0.68 76.3( 1.5,22.2)0.74 92.8( 0.7, 6.5)0.64 70.0( 0.0,30.0)0.44
0.05 80.0( 0.0,20.0)0.52 53.4( 0.2,46.4)0.72 91.1( 0.0, 8.9)0.62 44.6( 0.0,55.4)0.30
20/40/100 0 86.7(13.0, 0.3)0.91 92.8( 4.6, 2.6)0.88 91.9( 7.3, 0.8)0.72 93.2( 1.4, 5.4)0.66
0.01 94.8( 2.5, 2.7)0.78 84.1( 3.0,12.9)0.77 93.5( 2.2, 4.3)0.67 79.9( 0.3,19.8)0.52
0.05 83.7( 0.1,16.2)0.57 65.1( 0.4,34.5)0.73 91.3( 0.1, 8.6)0.62 55.4( 0.0,44.6)0.34
40/20/100 0 90.8( 0.0, 9.2)0.49 85.5( 0.1,14.4)0.54 77.9( 0.0,22.1)0.46 72.9( 0.0,27.1)0.38
0.01 82.6( 0.0,17.4)0.43 65.0( 0.2,34.8)0.49 65.8( 0.0,34.2)0.45 58.1( 0.0,41.9)0.32
0.05 59.1( 0.0,40.9)0.33 27.6( 0.0,72.4)0.47 36.9( 0.0,63.1)0.43 32.0( 0.0,68.0)0.24
40/20/200 0 78.2(21.8, 0.0)0.60 94.7( 5.1, 0.2)0.59 89.8( 8.7, 1.5)0.51 95.5( 2.1, 2.4)0.52
0.01 90.9( 0.0, 9.1)0.47 77.1( 0.1,22.8)0.51 73.8( 0.0,26.2)0.45 65.5( 0.0,34.5)0.35
0.05 61.4( 0.1,38.5)0.34 30.1( 0.1,69.8)0.47 40.0( 0.1,59.9)0.43 33.3( 0.0,66.7)0.24
40/40/100 0 72.6(27.4, 0.0)0.61 93.0( 6.7, 0.3)0.58 88.2(11.0, 0.8)0.51 94.4( 3.8, 1.8)0.53
0.01 94.2( 2.8, 3.0)0.53 91.1( 1.4, 7.5)0.53 87.3( 0.8,11.9)0.47 83.7( 0.1,16.2)0.43
0.05 75.5( 0.0,24.5)0.39 46.0( 0.0,54.0)0.48 52.0( 0.0,48.0)0.43 44.7( 0.0,55.3)0.28
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Table 6.46: Confidence interval for Ha with ‘high’ heterogeneity, control group disease
rates rB = {0.35, 0.45, 0.50, 0.55} for MOVER, Q distribution, test-based, based on τ 2c ,
nonparametric bootstrap based on 1000 simulations of k trials each with Nj clusters per
group of size m, intracluster correlation ρ(truncated), and odds ratio ψ = 0.7
MOVER/ τ2c Q Test-Based NB
k/Nj/m ρ C(L,R)W C(L,R)W C(L,R)W C(L,R)W
4/20/100 0 97.0( 0.4, 2.6)3.7 76.0( 2.9,21.1)1.8 92.3( 3.1, 4.6)1.9 55.2( 0.0,44.8)0.74
0.01 95.3( 0.2, 4.5)3.3 67.7( 1.6,30.7)1.6 94.3( 1.0, 4.7)1.9 47.5( 0.0,52.5)0.61
0.05 93.7( 0.1, 6.2)2.7 58.1( 2.1,39.8)1.5 93.5( 0.7, 5.8)1.8 32.9( 0.0,67.1)0.42
4/20/200 0 96.4( 2.7, 0.9)4.8 88.6( 4.2, 7.2)2.1 86.1(10.7, 3.2)2.0 79.2( 0.0,20.8)1.2
0.01 96.2( 0.3, 3.5)3.5 71.3( 2.4,26.3)1.7 93.8( 2.0, 4.2)1.9 51.0( 0.0,49.0)0.67
0.05 93.3( 0.0, 6.7)2.6 56.7( 0.5,42.8)1.5 92.8( 0.4, 6.8)1.9 30.2( 0.0,69.8)0.38
4/40/100 0 96.6( 3.0, 0.4)4.8 86.8( 5.0, 8.2)2.1 87.0( 9.6, 3.4)2.0 78.5( 0.0,21.5)1.2
0.01 96.8( 0.9, 2.3)3.9 77.0( 4.5,18.5)1.8 91.6( 5.1, 3.3)1.9 62.0( 0.0,38.0)0.83
0.05 94.6( 0.1, 5.3)3.0 64.0( 1.7,34.3)1.6 92.8( 1.0, 6.2)1.8 39.1( 0.0,60.9)0.49
12/20/100 0 97.3( 0.1, 2.6)1.2 86.4( 1.2,12.4)1.2 91.9( 0.7, 7.4)0.89 72.4( 0.0,27.6)0.65
0.01 92.4( 0.0, 7.6)0.98 73.8( 0.6,25.6)1.1 89.1( 0.3,10.6)0.85 56.1( 0.0,43.9)0.51
0.05 82.2( 0.0,17.8)0.81 46.2( 0.4,53.4)0.99 88.7( 0.0,11.3)0.83 39.9( 0.0,60.1)0.39
12/20/200 0 93.4( 6.3, 0.3)1.5 92.9( 4.2, 2.9)1.3 89.7( 8.7, 1.6)1.0 92.2( 0.7, 7.1)0.92
0.01 94.0( 0.3, 5.7)1.1 80.3( 1.3,18.4)1.1 90.5( 0.8, 8.7)0.88 66.6( 0.1,33.3)0.60
0.05 82.1( 0.0,17.9)0.80 47.4( 0.1,52.5)0.99 89.2( 0.0,10.8)0.83 40.1( 0.0,59.9)0.38
12/40/100 0 92.2( 7.7, 0.1)1.5 91.7( 6.0, 2.3)1.3 88.0(10.7, 1.3)1.0 93.1( 0.6, 6.3)0.93
0.01 96.3( 0.6, 3.1)1.2 87.3( 2.4,10.3)1.1 92.8( 2.3, 4.9)0.92 78.0( 0.1,21.9)0.72
0.05 88.1( 0.0,11.9)0.89 63.0( 0.2,36.8)1.0 89.9( 0.0,10.1)0.84 46.8( 0.0,53.2)0.45
20/20/100 0 96.5( 0.1, 3.4)0.82 92.1( 0.3, 7.6)0.86 82.5( 0.1,17.4)0.68 70.8( 0.0,29.2)0.57
0.01 86.3( 0.0,13.7)0.70 62.7( 0.2,37.1)0.75 63.3( 0.1,36.6)0.65 53.1( 0.0,46.9)0.46
0.05 66.9( 0.0,33.1)0.54 26.0( 0.0,74.0)0.72 39.1( 0.0,60.9)0.62 28.0( 0.0,72.0)0.32
20/20/200 0 91.3( 8.7, 0.0)1.0 94.5( 5.2, 0.3)0.92 90.1( 8.8, 1.1)0.77 95.1( 1.6, 3.3)0.77
0.01 92.2( 0.1, 7.7)0.77 79.2( 0.2,20.6)0.78 74.9( 0.2,24.9)0.67 64.7( 0.0,35.3)0.51
0.05 68.3( 0.0,31.7)0.56 30.1( 0.1,69.8)0.72 42.3( 0.1,57.6)0.63 33.1( 0.0,66.9)0.34
20/40/100 0 88.8(11.1, 0.1)1.0 91.0( 8.5, 0.5)0.91 85.0(13.1, 1.9)0.78 93.5( 2.9, 3.6)0.79
0.01 97.1( 0.6, 2.3)0.87 92.2( 2.3, 5.5)0.83 86.2( 1.5,12.3)0.70 78.9( 0.2,20.9)0.62
0.05 76.5( 0.0,23.5)0.62 45.5( 0.1,54.4)0.74 53.8( 0.1,46.1)0.64 42.9( 0.0,57.1)0.39
40/20/100 0 91.8( 0.0, 8.2)0.56 79.5( 0.0,20.5)0.58 76.7( 0.0,23.3)0.48 66.7( 0.0,33.3)0.45
0.01 71.2( 0.0,28.8)0.49 41.0( 0.0,59.0)0.51 50.1( 0.0,49.9)0.46 42.6( 0.0,57.4)0.38
0.05 36.3( 0.0,63.7)0.36 7.70( 0.0,92.3)0.47 19.9( 0.0,80.1)0.44 14.8( 0.0,85.2)0.26
40/20/200 0 84.9(15.0, 0.1)0.68 92.7( 7.2, 0.1)0.61 87.0(12.4, 0.6)0.54 94.7( 4.2, 1.1)0.57
0.01 86.1( 0.0,13.9)0.54 62.9( 0.1,37.0)0.53 68.3( 0.0,31.7)0.47 58.2( 0.0,41.8)0.43
0.05 36.2( 0.0,63.8)0.37 8.00( 0.0,92.0)0.47 19.3( 0.0,80.7)0.43 13.9( 0.0,86.1)0.27
40/40/100 0 83.8(16.2, 0.0)0.69 91.0( 9.0, 0.0)0.60 85.0(14.9, 0.1)0.55 94.3( 5.2, 0.5)0.58
0.01 95.5( 0.2, 4.3)0.59 89.3( 0.5,10.2)0.55 87.6( 0.3,12.1)0.50 80.8( 0.0,19.2)0.49
0.05 54.1( 0.0,45.9)0.43 20.2( 0.0,79.8)0.49 33.2( 0.0,66.8)0.45 25.8( 0.0,74.2)0.32
C means the probability coverage. L and R denote tail errors from left and right in p ercent,
resp ectively. W denotes the average interval width.
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Chapter 7
Meta-analysis of practice-based
secondary prevention programs for
patients with heart disease risk
factors
7.1 Introduction
The aim of this chapter is to illustrate the analytic methods described in a meta-analysis
of four cluster randomization trials. These trials were conducted to compare two or
more interventions to reduce coronary heart disease (CHD) risk factors in primary care,
where the unit of randomization in each trial was at the practice level. The trials include
the Assessment of Implementation Strategies Trial (ASSIST) (Moher et al., 2001), the
Diabetes Care from Diagnosis study (Woodcock et al., 1999), the Hypertension Decision
Support study (Montgomery et al., 2000) and the Southampton Heart Integrated Care
Project (SHIP) (Jolly et al., 1999). The outline of this chapter is as follows: the four
trials are described in Section 7.2, and the methods of analysis and the results described
in Sections 7.3 and 7.4, respectively. Results are summarized and compared to related
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meta-analyses in Section 7.5.
7.2 Aspects of Study Data
Table 7.1: Description of studies.
Study Type of Intervention Type of
patients study design
ASSIST CHD Recall to a general stratified
(Moher et al., 2001) practitioner
Diabetes Care from Diagnosis Diabetes Trained practitioners stratified
(Woodcock et al., 1999) and nurses
Hypertension Decision Support Hypertension Decision support completely
(Montgomery et al., 2000) system + risk chart
SHIP MI+Angina Specialist cardiac stratified
(Jolly et al., 1999) liaison nurses
The four cluster randomization trials were included in a meta-analysis of intracluster
correlation coefficients involving 31 primary care cluster randomization trials (Adams
et al., 2004). All trials enrolled 10 or more practices and were conducted in English-
speaking countries or Northern Europe. The four studies were selected for the purposes
of conducting a meta-analysis to investigate secondary prevention programs for patients
with heart disease risk factors using the presence or absence of hypertension at one year
as the endpoint. Hypertension is defined as having systolic blood pressure exceeding
140 mm Hg, or having diastolic blood pressure exceeding 90 mm Hg (Chobanian et al.,
2003). These four trials were conducted in England with individual patient data available
with different study designs. For illustrative purposes, they were assumed completely
randomized.
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In ASSIST, the study objective was to compare three different interventions of care
delivery for secondary prevention of coronary heart disease (CHD) in primary care: audit
and feedback; recall to a general practitioner; and recall to a nurse clinic (Moher et al.,
2001). For our analyses, attention was limited to two intervention groups: audit and
feedback (control) vs. recall to a general practitioner (experimental). For the control
group, practices provided usual care, while for the experimental group, each practice
developed a disease register and recall system for regular review.
The Diabetes Care from Diagnosis study investigated the effects of patient-centered
training for general practitioners and nurses who cared for Type 2 diabetes patients who
were diagnosed over a 1 year period (Woodcock et al., 1999). General practitioners and
nurses in the experimental group received training sessions to recognize and practice
skills of patient-centered consulting, which were not provided to general practitioners and
nurses in the control group. At 6 and 12 months into patient recruitment, the nurses in
the experimental group met with the trainer for group support, and reviewed recruitment
with the research team. The nurses in the control group discussed the recruitment and
the use of British Diabetic Association materials with the research team.
The Hypertension Decision Support study was designed to evaluate a computer-based
clinical decision support system for patients with high blood pressure (Montgomery et al.,
2000). Medical practices were randomly assigned to a computer-based clinical decision
support system plus cardiovascular risk chart (which gives identical information about
risk); risk chart alone; or usual care (no information given about cardiovascular risk).
Again, attention was limited to two intervention groups: computer-based clinical decision
support system plus cardiovascular risk chart vs. usual care.
The SHIP was designed to assess the effectiveness of a program for coordinating and
supporting follow-up care in general practice among myocardial infraction (MI) or angina
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patients discharged from hospitals as compared to the usual care without any such support
(Jolly et al., 1999). More specifically, the experimental group was led by specialist cardiac
liaison nurses who contacted practices at the time of discharge to discuss future care and
to book the first follow-up visit.
Table 7.1 describes the study design for the four cluster randomization trials included
in the meta-analysis. Baseline characteristics of patients by intervention group for each
trial are given in Table 7.2. Most of the patients had either CHD or hypertension, except
for the one trial with diabetes patients. The number of practices was similar across the
intervention groups but somewhat different across trials. Mean age of the patients ranged
from 57 to 70 years. Specifically, the Diabetes Care from Diagnosis trial had the lowest
mean age and the Hypertension Decision Support trial had the highest mean age. Men
constituted more than 50% of the subjects in the ASSIST and the SHIP, while women
constituted more than 50% of the subjects in the other two trials.
7.3 Method of analysis
We performed analyses by using SAS 9.2 (SAS Institute, Inc, Cary, NC). Given the
individual patient data, the analysis for each trial was conducted using generalized es-
timating equation (GEE) to account for clustering by incorporating robust standard
errors using an exchangeable working correlation matrix for patients within the same
primary care practice. The methods of GEE were carried out with the procedure PROC
GENMOD. The summary odds ratios were computed by using both the fixed and random
effects models. The intracluster correlation coefficients for the four trials were calculated
using the ‘analysis of variance’ method (Donner and Klar, 2000, p9) with the procedure
PROC GLM, where negative values were truncated to zero. The approaches to addressing
heterogeneity included the adjusted Q statistic, the heterogeneity variance estimators with
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Table 7.2: Baseline characteristics of patients in intervention groups for each trial included
in the meta-analysis. Age is in years.
Experimental Control
ASSIST (Moher et al., 2001)
Practices 7 7
N 682 559
Mean age (SD) 66.2(5.4) 66.4(5.6)
Men (%) 457(67) 373(67)
Diabetes Care from Diagnosis (Woodcock et al., 1999)
Practices 20 20
N 142 108
Mean age (SD) 57.9(9.6) 57.3(9.6)
Men (%) 59(42) 43(40)
Hypertension Decision Support (Montgomery et al., 2000)
Practices 10 7
N 229 157
Mean age (SD) 70.6(5.5) 70.5(5.3)
Men (%) 106(46) 80(51)
SHIP (Jolly et al., 1999)
Practices 33 34
N 277 320
Mean age (SD) 63.2(10.1) 64.1(10.3)
Men (%) 189(68) 237(74)
corresponding confidence intervals and measures of heterogeneity, also with corresponding
confidence intervals (see Chapters 2-4). The complete list of the approaches is given in
Table 5.1. The DerSimonian and Laird estimator was used to estimate τ 2c unless otherwise
specified. Although some approaches performed better than others based on the simulation
results, all the approaches were applied to the meta-analysis for the purpose of illustration.
As part of a planned sensitivity analyses, the summary odds ratios, the adjusted Q statistic
and the adjusted I2 were recalculated for the meta-analysis excluding the Diabetes Care
intervention from the Diagnosis trial, which enrolled different type of patients as compared
to the other three trials.
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Study
Moher(2001)
Woodcock(1999)
Montgomery(2000)
Jolly(1999)
Fixed
Random
Adjusted Q
Adjusted I^2
Intervention
287/459
91/138
153/202
87/269
Control
249/392
63/107
104/130
111/305
OR
0.96
1.35
0.78
0.79
0.88
0.91
4.40
54%
(95% CI)
(0.71, 1.29)
(0.83, 2.20)
(0.44, 1.37)
(0.59, 1.04)
(0.75, 1.03)
(0.74, 1.12)
p=0.22
Risk of hypertension in trials evaluating secondary prevention programs
0.5 1.0 1.5 2.0 2.5
OR
Figure 7.1: Forest plot for the meta-analysis of practice-based secondary prevention
programs for patients with coronary heart disease risk factors.
7.4 Results
Three of the four trials reported a risk reduction for hypertension (experimental vs control);
however, the reduction in each trial was not statistically significant as the corresponding
confidence intervals included 1.0 (Figure 7.1). The summary odds ratios for hypertension
for the fixed and random effects model were 0.88 (95%CI, 0.75-1.03) and 0.91 (95%CI,
0.74-1.12), respectively, combining data from all four trials. The adjusted Q statistic was
5.43 (p = 0.14) and the adjusted I2 was 54%. The intracluster correlation cofficients were
0.003, -0.024, 0.013 and -0.028, corresponding to the ASSIST, the Diabetes Care from
Diagnosis study, the Hypertension Decision Support study and the SHIP, respectively.
The two negative values were truncated to zero.
The heterogeneity variance estimates ranged from τˆ 2c.ML = 0 to τˆ
2
c.MV = 0.033 (Table 7.3),
indicating a ‘small’ degree of heterogeneity. Although the point estimates of the overall
intervention effect did not differ greatly across the eight values of τ 2c , it is noted that the
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slight differences among the eight estimators led to fairly large differences among the
interval widths. This suggests that the choice of the estimator could lead to conflicting
conclusions regarding the true overall intervention effect. However, in this case, all eight
95% confidence intervals for the overall intervention effect included 1, indicating that the
reduction in the risk of having hypertension is not significant. The confidence intervals
for τ 2c obtained with the various approaches discussed earlier are also given in Table 7.4.
All the confidence intervals except the Sidik-Jonkman confidence interval includes zero,
suggesting that heterogeneity in the meta-analysis is not significant. It is also noted that
the precision tends to vary greatly across the different approaches.
Finally, the measures of heterogeneity were Ha = 1.47, Ra = 1.43 and I
2
a = 54%, indi-
cating a ‘moderate’ degree of heterogeneity based on the guideline described in Table
4.4. However, the ‘moderate’ degree of heterogeneity was not considered statistically
significant given that all the confidence intervals for H2a included 1 (for a ‘no’ degree of
heterogeneity) (Table 7.5).
For the meta-analysis of three cluster randomization trials omitting the Diabetes Care
from Diagnosis study, the adjusted Q statistic was 1.17 with p = 0.14 and the adjusted I2
was 0%. As a result, both summary odds ratios were identical, given by 0.84 (95%CI,
0.71-0.99), suggesting a statistically significant positive effect of secondary prevention
programs on reducing hypertension.
7.5 Summary
Overall, the secondary prevention programs showed a risk reduction of approximately
9%-12% in hypertension for patients with CHD risk factors at 1 year follow-up but the
reduction is not statistically significant. Clark et al. (2005) came to a different conclusion
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Table 7.3: Heterogeneity variance estimators and random effects summary odds ratios .
Estimator τˆ 2c OR(95% CI)
Variance component (VC) 0.020 0.91(0.82, 1.28)
DerSimonian and Laird (DL) 0.015 0.91(0.82, 1.25)
Two-step DL (DLVC) 0.016 0.91(0.82, 1.26)
Two-step DL (DL2) 0.016 0.91(0.82, 1.26)
Model error variance (MV) 0.033 0.92(0.80, 1.33)
Improved model error variance (MVVC) 0.019 0.91(0.82, 1.27)
Maximum likelihood (ML) 0.000 0.88(0.85, 1.17)
Restricted maximum likelihood (REML) 0.013 0.91(0.83, 1.24)
Table 7.4: Point estimates and confidence intervals for τ 2c .
Confidence interval τˆ 2c (95%CI)
Q profile τˆ 2c.DL = 0.015 (0.00, 0.85)
Biggerstaff-Tweedie τˆ 2c.DL = 0.015 (0.00, 1.31)
Profile likelihood (ML) τˆ 2c.ML = 0.000 (0.00, 0.17)
Profile likelihood (REML) τˆ 2c.RE = 0.013 (0.00, 1.47)
Wald-type (ML) τˆ 2c.ML = 0.000 (0.00, 0.03)
Wald-type (REML) τˆ 2c.RE = 0.013 (0.00, 0.08)
Sidik-Jonkman τˆ 2c.MV = 0.033 (0.01, 0.46)
Nonparametric bootstraps τˆ 2c.DL = 0.015 (0.00, 0.06)
that secondary prevention programs generally had a significant positive effect in processes
of care for all-cause mortality. Several factors may explain the difference. First, only four
trials were included in the meta-analysis, while the smallest meta-analysis reported by
Clark et al. (2005) included data from eight trials with the secondary prevention programs
solely exercise-based. Furthermore, the values of I2 reported in the meta-analyses by
Clark et al. (2005) were mostly zero as compared to 54% with our meta-analysis. Most of
all, our meta-analysis included the trial with diabetes patients, which are a different type
of patient, and had the opposite direction in intervention effect compared to the other
trials. The inclusion of this trial may be the source of heterogeneity for the results of the
sensitivity analysis excluding the trial with diabtetes patients showed that the adjusted I2
statistic was reduced to zero and the risk reduction for hypertension became statistically
significant. For illustrative purposes, the main analysis focused on the meta-anlaysis with
all four trials.
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Table 7.5: Confidence intervals for Ha.
Confidence interval for Ha = 1.47 (95%CI)
MOVER (1.00, 5.84)
Based on distribution of Qa (0.00, 2.15)
Test-based (0.79, 2.21)
Based on τ 2c (1.00, 5.31)
Nonparametric bootstraps (1.00, 1.86)
The adjusted Q statistic was not statistically significant, indicating no significant differ-
ences among the four estimated odds ratios. It is noted that the highest power of the
adjusted Q statistic for a meta-analysis with k = 4 is generally less than 30% (Table
6.3-6.6) unless the heterogeneity is considerably large (I2a ≥ 78%).
All the heterogeneity variance estimators suggest a ‘small’ degree of heterogeneity but at
a level considered not statistically significant with a 95% confidence interval including
0 (for a ‘no’ degree of heterogeneity). The results show that the overall intervention
effect is relatively insensitive to changes in τ 2c but these small changes may lead to fairly
large difference in confidence interval widths for the overall intervention effect (Sidik
and Jonkman, 2007; Viechtbauer, 2007a). In our example, all the heterogeneity variance
estimators came to a similar conclusion due to small values, but the two-step estimators
and the REML estimator performed better than the other estimators with relatively low
bias for k = 4. As for the confidence interval approaches for τ 2c , the Q profile confidence
interval generally performed relatively well, while other confidence intervals were either
overly liberal (Sidik-Jonkman and bootstraps) or overly conservative (Biggerstaff-Tweedie,
profile likelihood and Wald-type) (Table 6.19-6.22).
Finally, the measures of heterogeneity indicated that there was a ‘moderate’ degree of
heterogeneity but which was not statistically significant, with a 95% confidence interval
including 1.0 (for a ‘no’ degree of heterogeneity). Our simulation results in Chapter 6
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suggested that caution must be taken when interpreting the measures of heterogeneity for
a small number of trials (k = 4), which may result in a relatively large bias of approxi-
mately 0.15 (Table 6.35 to 6.38). Similarly, the test-based confidence interval and the
confidence interval based on the distribution of the Q statistic performed relatively well
for k = 4 based on our simulation results shown in the previous chapter (Table 6.43-6.46).
Overall, there is no substantial heterogeneity was found applying the proposed approaches.
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Chapter 8
Conclusions
8.1 Introduction
The primary objective of this thesis was to to develop and evaluation methods that
identify and quantify heterogeneity in a meta-analysis of cluster randomization trials
assuming a fixed effects model. The possible approaches included the adjusted Q statistic,
heterogeneity variance estimators with their corresponding confidence intervals and finally
measures of heterogeneity with their corresponding confidence intervals. The discussion
was limited to completely randomized cluster randomized trials having binary outcomes
measured by the odds ratio comparing an experimental to a control intervention. The
aim of this final chapter is to summarize main results in Section 8.2, identify potential
limitations and propose areas of future research in Section 8.3.
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8.2 Summary
8.2.1 Key findings
The different forms of the Q statistic were compared for testing heterogeneity in a
meta-analysis of cluster randomization trials: the unadjusted Q statistic, the adjusted Q
statistic with truncated ANOVA-based ρ, and the adjusted Q statistic omitting truncation.
It was clearly seen that the unadjusted Q statistic resulted in severely inflated Type I
error for clustered data. For example, the observed Type I error was close to 100% at
ρ = 0.05 for all the parameter combinations with k ≥ 12. In contrast, the adjusted Q
statistic with truncated ρ showed generally satisfactory Type I error, except for ρ = 0
where the Type I error was overly conservative. On the other hand, the adjusted Q
statistic omitting truncation of ρ maintained Type I error at nominal level throughout all
parameter combinations.
Although the adjusted Q statistic is simple to calculate and has satisfactory Type I error,
its power raises a concern because it depends heavily on the number of trials. In this
case, power analysis before conducting the meta-analysis of cluster randomization trials
is useful to ensure the validity of the test. Our results showed that the power calculated
using the derived formula was similar to the power obtained from the simulation for all the
parameter combinations investigated. An increase in the power of the adjusted Q statistic
may be obtained by increasing the number of trials, overall sample size per trial (i.e.
n×m), or degree of heterogeneity. However, the power reduces dramatically for a small
increase in the values of the intracluster correlation coefficient. In addition, for a fixed
sample size, the power of the adjusted Q statistic is greater for a large number of small
clusters than for a small number of large clusters. Based on the results, a meta-analysis
with at least 12 trials for ρ = 0 and 40 trials for ρ = 0.01 is sufficiently large to detect
‘high’ heterogeneity in order to achieve a desired power of approximately 80%.
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Eight heterogeneity variance estimators adjusted for clustering were compared, including
the four noniterative estimators VC, DL, MV and MVVC; the two two-step estimators
DLVC and DL2 and finally the two iterative estimators ML and REML. The simulation
results indicated that the MVVC estimator for ‘no’ to ‘low’ heterogeneity and the DLVC
estimator for ‘moderate’ to ‘high’ heterogeneity had the lowest bias as compared to other
estimators, followed by the ML and REML estimators. These results are consistent with
the conclusion presented by Viechtbauer (2007a) and also complement their findings,
which focused on the meta-analysis of individually randomized trials, with no considera-
tion of the two-step estimators.
We also compared the eight confidence intervals for the adjusted heterogeneity variance
estimators. These included the Q profile (QP), Biggerstaff-Tweedie (BT), ML profile like-
lihood (pML), REML profile likelihood (pRE), ML Wald-type (wML), REML Wald-type
(wRE), Sidik and Jonkman (SJ) and nonparametric bootstraps (NB) confidence intervals,
where only the Sidik and Jonkman confidence interval had a closed-form solution. The
simulation results showed that the Q profile confidence interval had relatively satisfactory
performance in terms of coverage, tail errors and interval width at least for ‘low’ to ‘high’
heterogeneity with small meta-analyses of large trials. According to Viechtbauer (2007a)
based on the meta-analysis of individually randomized trials, the large coverage above
the nominal for the Q profile confidence interval at τ 2c = 0 may be resulted of having the
asymptotic distribution used to construct the confidence interval other than the expected
chi-square distribution with one degree of freedom. Other confidence interval approaches
were either overly conservative (BT, pML, pRE, wML, wRE) or overly liberal (SJ and NB).
The adjusted measures of heterogeneity were Ha, Ra and I
2
a . The simulation results
showed that the adjusted statistics were generally an accurate indicator of the degree of
heterogeneity with a relatively large number of trials. However, the adjusted statistics
had a relatively large bias of 0.15 when the number of trials was small, compromising
139
their interpretation.
It was also useful to compare the confidence intervals of the Ha statistic including the
MOVER, the confidence interval based on the Q distribution, the test-based confidence
interval, the confidence interval based on τ 2c and the nonparametric bootstraps confidence
interval. According to the simulation results, it appears that the within study variance
(the denominator for MOVER) had little impact on the MOVER given that the within
study variance was relatively small as compared to the between study variance (the
numerator for MOVER). Also, given that the Q profile approach was used for constructing
the confidence interval for the denominator of MOVER and the confidence interval based
on τ 2c , they had similar performance. For ‘low’ to ‘high’ heterogeneity, the MOVER
consistently maintained a nominal coverage level for small meta-analyses of large trials.
Nevertheless, the confidence interval based on the Q distribution is preferred for ‘no’
heterogeneity.
8.2.2 Recommendations
It is apparent that the adjusted Q statistic is a reasonable choice for testing the hetero-
geneity of intervention effects obtained from cluster randomization trials given that the
unadjusted Q statistic produces highly inflated Type I errors. However, it is known that
the power of the adjusted Q statistic depends on the number of trials. This was shown by
a derived algebraic formula for its power. As for the heterogeneity variance estimators,
the REML estimator with consistently relatively low bias is recommended. Although this
procedure requires an iterative scheme, several noniterative approaches are also available
that show reasonable performance: the MVVC estimator for ‘no’ to ‘low’ and the two-step
estimator DLVC for ‘moderate’ to ‘high’ heterogeneity. The REML profile likelihood can
be used to construct the confidence interval of the REML estimator and the Q profile
can be used to construct confidence intervals for the two-step estimator DLVC or the
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MVVC estimator given relatively small meta-analyses with large trials. The measures of
heterogeneity appear to be a consistent indicator of the degree of heterogeneity when the
number of trials is relatively large. However, caution must be taken in interpreting the
results with a small number of trials. In this case, confidence interval construction may
be informative. For ’no‘ heterogeneity, the confidence interval based on the Q distribution
is recommended. Otherwise, the MOVER approach, which had the similar performance
as the profile Q confidence interval, is a reasonable choice to construct the confidence
interval for Ha or I
2
a given relatively small meta-analyses with large trials.
8.2.3 Practical issues
Meta-analysts must often select methods based on the form of the available data. Accord-
ing to Whitehead (2002), available data may be classified in three forms for individually
randomized trials. A similar analogy will be applied to extend the forms of available data
in the context of cluster randomized trials.
First, an estimate of the intervention effect for each trial and its corresponding standard
error are the minimum information needed to apply the proposed approaches to assessing
heterogeneity in the meta-analysis of cluster randomization trials. When the adjusted
variance is not provided, the intraclass correlation coefficient and an average cluster size
for each trial are needed to compute the inflation factor (IF) to account for clustering.
According to Ivers et al. (2011), only 18% of the 300 manuscripts that they reviewed
reported an estimated intracluster correlation coefficient. In this case, the missing intra-
class correlation coefficient may be imputed by a common intraclass correlation coefficient
extracted from other published papers reporting similar trials, although the risks of bias
using this strategy is well-known. Also, in this form, the meta-analysis is limited to
combine the studies with the same type of effect measures. For instance, a study with
the mean difference as the measure of effect cannot be used in the meta-analysis limited
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to binary outcomes.
The second form of available data consists of summary statistics for each intervention
group, enabling a choice to be made between several different measures of the intervention
effect. For binary data, one way is to record the number of events (Aijk) and the cluster size
for each cluster (mijl), which are sufficient for computing the odds ratio and the standard
error (Equation 2.4) for each trial. Another approach is to record the disease rates (Pij)
for the control and experimental group, the average cluster size per intervention (mij) and
the intraclass correlation coefficient. A summary of this notation can be found in Table 2.2.
The third form consists of individual patient data, allowing any measures of the interven-
tion effect and method of estimation. In addition, if all the studies provide individual
patient data, a more thorough analysis can be undertaken by employing a statistical
modeling approach.
8.3 Limitations and future research
First, the focus of the thesis is limited to the meta-analysis of completely randomized
cluster randomization trials. In practice, meta-analysts may encounter the challenge of
combining cluster randomization trials using different designs, such as the stratified design
or the matched-pair design. The approaches described here may be easily extended to
meta-analyses of stratified cluster randomization trials by treating each stratum as a
separate trial in the meta-analysis. As for the matched-pair designs, it will not be feasible
to routinely calculate the intracluster correlation coefficient where the between-cluster
variation is confounded with the intervention effect (Klar and Donner, 1997). Thus, one
could conduct the meta-analyses separately for the completely randomized and for the
matched-pair designs using standard techniques (Donner and Klar, 2002). Alternatively,
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there is the option of ignoring the stratification for the stratified design or breaking the
matches for the matched-pair design (Donner et al., 2007). However, this may lead to a
loss in power if the stratification/matching is effective.
Second, the approaches presented here were developed specifically for the case of two
intervention groups. However, many trials contain more than two intervention groups.
For instance, two of the four cluster randomization trials in our example (ASSIST and
SHIP) had three intervention groups but the third intervention group was discarded for
the proposes of analysis. However, the approaches discussed may usefully be extended
to incorporate the meta-analysis of cluster randomization trials with more than two
intervention groups. A list of approaches for including multiple intervention groups
from a given trial may be found in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins and Green, 2008, Chapter 16).
Third, the binary outcome is assumed approximately normal on the log odds ratio scale.
We would therefore expect that the conclusions for the binary outcomes found in this
thesis might also be applied to normally distributed continuous outcome data, that yield
standardized mean differences. However, the performance of these methods have not yet
been determined for outcomes which do not follow approximately a normal distribution.
Further study would be required to draw firm conclusions regarding continuous outcomes
in the meta-analysis of cluster randomization trials, or to make recommendations for
non-normally distributed effect measures.
Fourth, the proposed approaches are based on the assumption of fixed within study vari-
ances, where sampling errors in these variances are ignored. This issue arises particularly
when the trials are small. Otherwise, it appears that this assumption would have little
impact on the results (Bohning et al., 2002; Hardy and Thompson, 1996). For instance,
the simulation results were similar when treating the within study variance as fixed when
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applying the MOVER approach, as compared to the confidence interval based on τ 2c
approach where the estimated within study variance was used. Also assuming a constant
within study variance among trials in a meta-analysis tends to overestimate the statistical
power of the adjusted Q statistic with varying within study variances. Similar results
were found in a simulation study by Hardy and Thompson (1998).
Fifth, the assumption of a common intracluster correlation coefficient was used across
all trials considered, by averaging the estimates as computed from the separate trials.
This approach becomes less efficient when there is a substantial difference among the
estimates of intracluster correlation coefficient across trials. In this case, a separate es-
timate of intracluster correlation coefficient for each trial may be used (Donner et al., 2001).
Sixth, the simulation study is limited to the data generated under a fixed effects model.
Some researchers (Sidik and Jonkman, 2005; Viechtbauer, 2007a) generated data under
the random effects assumption to allow more variability in intervention effects. It is
expected that the decision to model as fixed effects in our study may result in greater
statistical power; whereas the random effects model tends to lead to a loss in power.
Seventh, the simulation results presented are necessarily limited in scope in order to
understand the performance of the approaches under simple scenarios.
For example, attention was restricted to an equal number of clusters with an equal number
of subjects per intervention group. However, there is often considerable variation in both
the number of clusters and cluster sizes in practice. An equal number of clusters per
intervention group generally leads to an increase in efficiency as compared to unequal
allocation (Donner and Klar, 2000, p.59). In the case of unequal cluster sizes, if the
cluster size is replaced by its average, a slight underestimation in power would be expected.
Another option is to use a more conservative approach by replacing the cluster size by its
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maximum to provide some protection for statistical power (Donner and Klar, 2000, p.57).
The conclusion drawn here based on simulation results for trials with 20 or 40 clusters
may not apply to trials with a fairly small number of clusters (10 or less) since the large
sample approximation underlying these approaches may be questionable (Donner and
Klar, 2000, p.100). Further study may be helpful to broaden our findings to more general
settings by generating data under the random effects assumptions and considering unequal
allocation with unbalanced cluster size.
Eighth, we recognize that the focus of this thesis has been on analytic methods used to
identify the degree of heterogeneity. Thus, when substantial heterogeneity is detected, fur-
ther study would be required to apply subgroup analysis or meta-regression to investigate
the source of heterogeneity in a meta-analysis of cluster randomization trials (Higgins
et al., 2002b; Rotondi and Khobzia, 2010).
Finally, the discussion is limited to the meta-analysis of only cluster randomization
trials. However, meta-analysts may encounter the challenge of combining the results from
both individually randomized and cluster randomized trials. In this case, the proposed
approaches can be easily applied by setting the values of intracluster correlation coefficient
equal to zero for the individually randomized trials (Darlington and Donner, 2007).
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Appendix A
Derivation of Q statistic
Let θ1, . . . , θk be the log odd ratios from k trials which are considered to be a random
sample from a normal distribution of trials with mean θ and within study variance
σ2j = w
−1
j for trial j, j = 1, . . . , k. Then the likelihood function is
L(θ) =
k∏
j=1
(
wj
2pi
)1/2
e−(1/2)wj(θj−θ)
2
and the log likelihood function is
lnL(θ) = −k
2
ln2pi +
1
2
k∑
j=1
lnwj − 1
2
k∑
j=1
wj(θj − θ)2
The Q statistic (Cochran, 1954) tests the null hypothesis: Ho : θ1 = θ2 = . . . = θk = θ
versus the alternative HA: at least one trial had a truly different intervention effect as
compared to the other trials, where θ denotes the common intervention effect. To calculate
the likelihood ratio test (LRT) denoted by λ(θ), the maximum likelihood estimator (MLE)
of θ under Ho and HA must be determined by solving
dlnL(θ)
dθ
=
k∑
j=1
wj(θj − θ) = 0
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Therefore, the MLE under Ho is θo and the MLE under HA is
θˆ =
∑k
j=1wj θˆj∑k
j=1wj
(A.1)
Then, the likelihood ratio test is
λ(θ) =
L(θo|θ)
L(θˆ|θ)
=
∏k
j=1
(
wj
2pi
)1/2
e−(1/2)wj(θj−θo)
2
∏k
j=1
(
wj
2pi
)1/2
e−(1/2)wj(θj−θˆ)2
= e−
1
2
∑k
j=1
wj{(θj−θo)2−(θj−θˆ)2}
The likelihood ratio test can be further simplified by noting that
k∑
j=1
wj{(θj − θo)2 − (θj − θˆ)2}
=
k∑
j=1
wj(θˆ − θo){(θj − θo) + (θj − θˆ)}
=
k∑
j=1
wj(θj − θo)
∑k
j=1wjθj − θo
∑k
j=1wj∑k
j=1wj
+ (θˆ − θo)
∑k
j=1wjθj
∑k
j=1wj −
∑k
j=1wj
∑k
j=1wjθj∑k
j=1wj
=
{∑kj=1wj(θj − θo)}2∑k
j=1wj
=
(
∑k
j=1wjθj)
2 − 2∑kj=1wjθj∑kj=1wjθo + (∑kj=1wjθo)2∑k
j=1wj
=
(
∑k
j=1wj θˆ)
2 − 2∑kj=1wj θˆ∑kj=1wjθo + (∑kj=1wjθo)2∑k
j=1wj
=
(
∑k
j=1wj)
2(θˆ2 − 2θˆθo + θ2o)∑k
j=1wj
=
k∑
j=1
wj(θo − θˆ)2
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Therefore, the likelihood ratio is given by
λ(θ) = e−
1
2
∑k
j=1
wj(θo−θˆ)2
Given one free parameter under Ho and k free parameters under HA, the degrees of freedom
are k−1. The null hypothesis is rejected if −2logλ(θ) = ∑kj=1wj(θo− θˆ)2 ≥ χk−1,α, where
θˆ is the MLE under HA as given in Equation A.1. Under Ho, −2logλ(θ) = ∑kj=1wj(θj−θˆ)2,
known as the Q statistic asymptotically follows a chi square distribution with k−1 degrees
of freedom (see Casella and Berger (2002, Theorem 10.3.3)).
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Appendix B
Intracluster correlation coefficient
(ANOVA estimator)
A suitable and convenient estimator of ρ is the analysis of variance (ANOVA) estima-
tor(Snedecor and Cochran, 1980). This method was originally used for continuous data
but is also suitable for binary data (Fleiss, 1981). Let Scj and Swj be the unbiased vari-
ance estimators between and within clusters in trial j, respectively. Given Scj = MSW ,
Swj = (MSCj−MSWj)/moj and m¯Aij = ∑nijl=1m2ijl/Mij , the analysis of variance estimator
of intracluster correlation coefficient in trial j is given by
ρˆj =
Scj
Scj + Swj
=
MSCj −MSWj
MSCj + (moj − 1)MSWj (B.1)
where
MSCj =
2∑
i=1
nij∑
l=1
mijl(Pˆijl − Pˆij)2/(Nj − 2)
MSWj =
2∑
i=1
nij∑
l=1
mijlPˆijl(1− Pˆijl)/(Mj −Nj)
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and
moj =
[
Mj −
2∑
i=1
m¯Aij
]
/(Nj − 2)
where MSCj and MSWj are the pooled mean square errors between and within clusters
in trial j, respectively. The analysis of variance (ANOVA) estimator is a consistent but
not unbiased estimate of the intracluster correlation coefficient. It can also result in a
negative value, indicating greater variation among individuals in the same cluster than
among different clusters. In practice, negative values are generally regarded as implausible
for cluster randomization trials; therefore, a negative estimated value of ρj is customary
set equal to zero.
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Appendix C
Variance component approach
Given the unweighted mean θ¯ =
∑k
j=1 θˆj/k, the usual sample variance of θˆj may be
expressed as
S2θ =
1
k − 1
k∑
j=1
(θˆj − θ¯)2
Then the expected value of S2θ in terms of variance components is
E[S2θ ] =
1
k − 1[
k∑
j=1
E(θj − θ)2 −
k∑
j=1
E(θ¯ − θ)2]
=
1
k − 1[
k∑
j=1
var(θj)− kvar(θ¯)]
=
1
k − 1[
k∑
j=1
(σ2jc + τ
2)−
∑k
j=1(σ
2
jc + τ
2)
k
]
=
∑k
j=1 σ
2
jc
k
+ τ 2
Then σ2jc may be estimated using σˆ
2
jc in equation (2.4).
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Appendix D
ML approach
Under a random effects model, the marginal distribution of the estimated intervention
effect θˆj for a meta-analysis of k cluster randomized trials follows a normal distribution
with mean θ and variance σˆ2jc + τ
2
c . Given wˆ
∗
jc = 1/(σˆ
2
jc + τ
2
c ), the likelihood function is
given by
L(θ, τ 2c ) =
k∏
j=1
(
wˆ∗jc
2pi
)1/2
e−(1/2)wˆ
∗
jc(θˆj−θ)2
and the log likelihood function is
lnL(θ, τ 2c ) = −
k
2
ln2pi +
1
2
k∑
j=1
lnwˆ∗jc −
1
2
k∑
j=1
wˆ∗jc(θˆj − θ)2
First, by setting the first derivative of the log likelihood function lnL(θ, τ 2c ) to zero in
respect to θ, the maximum likelihood estimate of θ is given by
θˆc =
∑k
j=1 wˆ
∗
jcθˆj∑k
j=1 wˆ
∗
jc
(D.1)
Next, the first derivative of lnL(θ, τ 2c ) in respect to τ
2
c is
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dlnL(θ)
dτ 2c
= −1
2
k∑
j=1
wˆ∗jc +
1
2
k∑
j=1
(wˆ∗jc)
2(θˆj − θ)2 (D.2)
Then, by setting (D.2) to zero and substituting θ by θˆc in (D.1), we have
k∑
j=1
(wˆ∗jc)
2(σˆ2jc + τ
2
c ) =
k∑
j=1
(wˆ∗jc)
2(θˆj − θˆc)2 (D.3)
By rearranging equation (D.3), the maximum likelihood estimate of τ 2c is obtained as
τˆ 2c.ML =
∑k
j=1 wˆ
2
jc.ML{(θˆj − θˆc.ML)2 − σˆ2jc}∑k
j=1 wˆ
2
jc.ML
(D.4)
where θˆc.ML =
∑k
j=1 wˆjc.MLθˆj/
∑k
j=1 wˆjc.ML and wˆjc.ML = 1/(σˆ
2
jc + τˆ
2
c.ML). The estimate of
τ 2c.ML is obtained iteratively with an initial value of τˆ
2
c.ML = 0. At each iteration, a positive
value of τˆ 2c.ML is assured by setting the negative value equal to zero until convergence is
reached.
Furthermore, the Wald-type confidence intervals for τˆ 2c.ML are constructed from the
sampling variance calculated from the inverse of the Fisher information. The Fisher
information IML can be computed by taking the negative of the second derivative of
lnL(θ, τ 2c ) in respect to τ
2
c as follows:
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IML = −d
2lnL(θ)
(dτ 2c )
2
= −1
2
k∑
j=1
(wˆ∗jc)
2 +
k∑
j=1
(wˆ∗jc)
3(θˆj − θˆc)2
=
1
2
k∑
j=1
(wˆ∗jc)
2 (D.5)
which can be simplified by replacing the second term in equation (D.5) with the equality
found in equation (D.3). Further, replacing wˆ∗jc in equation (D.5) by wˆjc.ML, the sampling
variance for τˆ 2c.ML (i.e. the inverse of IML) is then obtained by
ˆvar(τˆ 2c.ML) = 2
 k∑
j=1
wˆ2jc.ML
−1
The 95 percent Wald-type confidence interval is calculated as τˆ 2c.ML ± 1.96
√
ˆvar(τˆ 2c.ML)
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Appendix E
REML approach
For the restricted maximum likelihood estimator, the log likelihood function
lnLR(θ) = −k
2
ln2pi +
1
2
k∑
j=1
lnwˆ∗jc −
1
2
ln
k∑
j=1
wˆ∗jc −
1
2
k∑
j=1
wˆ∗jc(θˆj − θ)2
The restricted maximum likelihood estimate of θ remains at the same as the maximum
likelihood estimate of θ in D.1. The first derivative of lnLR(θ) in respect to τ
2
c is given by
dlnLR(θ)
dτ 2c
= −1
2
k∑
j=1
wˆ∗jc +
1
2
∑k
j=1(wˆ
∗
jc)
2∑k
j=1 wˆ
∗
jc
+
1
2
k∑
j=1
(wˆ∗jc)
2(θˆj − θ)2 (E.1)
By setting equation (E.1) to zero and substituting θ by θˆ∗c in equation (D.1), we have
k∑
j=1
(wˆ∗jc)
2(σˆ2jc + τ
2
c ) =
∑k
j=1(wˆ
∗
jc)
2∑k
j=1 wˆ
∗
jc
+
k∑
j=1
(wˆ∗jc)
2(θˆj − θˆc)2 (E.2)
By rearranging equation (E.2), the restricted maximum likelihood estimate of τ 2c is
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obtained as
τˆ 2c.RE =
∑k
j=1 wˆ
2
jc.RE{(θˆj − θˆc.RE)2 + 1/
∑k
j=1 wˆjc.RE − σˆ2jc}∑k
j=1 wˆ
2
jc.RE
(E.3)
where wˆjc.RE = 1/(σˆ
2
jc + τˆ
2
c.RE) and θˆc.RE =
∑k
j=1 wˆjc.RE θˆj/
∑k
j=1 wˆjc.RE. τˆ
2
c.RE is obtained
iteratively with an initial value of zero. At each iteration, a negative value is truncated at
zero until convergence is reached.
Furthermore, we can calculate the Fisher information to construct the Wald-type confi-
dence intervals. The Fisher information IRE for the REML estimate can be obtained by
taking the negative of the second derivative of lnLR(θ) in respect to τ
2
c after simplifying
using the equality in equation (D.3), it is given by
IRE = −d
2lnL(θ)
(dτ 2c )
2
= −1
2
k∑
j=1
(wˆ∗jc)
2 +
∑k
j=1(wˆ
∗
jc)
3∑k
j=1 wˆ
∗
jc
− 1
2
(∑k
j=1(wˆ
∗
jc)
2∑k
j=1 wˆ
∗
jc
)2
+
k∑
j=1
(wˆ∗jc)
3(θˆj − θˆc)2
=
1
2
k∑
j=1
(wˆ∗jc)
2 +
∑k
j=1(wˆ
∗
jc)
3∑k
j=1 wˆ
∗
jc
− 1
2
(∑k
j=1(wˆ
∗
jc)
2∑k
j=1 wˆ
∗
jc
)2
(E.4)
Replacing wˆ∗jc in equation (E.4) by wˆjc.RE , the sampling variance is then the inverse of
the Fisher information, given by
ˆvar(τˆ 2c.RE) = 2
 k∑
j=1
wˆ2jc.RE − 2
∑k
j=1 wˆ
3
jc.RE∑k
j=1 wˆjc.RE
+
(∑k
j=1 wˆ
2
jc.RE∑k
j=1 wˆjc.RE
)2−1
The 95 per cent Wald-type confidence interval is given by τˆ 2c.RE ± 1.96
√
ˆvar(τˆ 2c.RE).
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